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ABSTRACT 
The ability to image endogenous neurotransmitter release will vastly increase our understanding of a 
variety of neuropsychiatric disorders.  Current published work in this field is mainly limited to 
measuring dopamine release in vivo.  Recently, there have been increasing efforts to enable imaging the 
release of other neurotransmitters such as serotonin, opioid peptides and GABA. The changes in 
binding observed during endogenous release studies are generally assumed to take place at the cell 
surface by competition of radioligand with a neurotransmitter molecule. This has been termed The 
Occupancy Model.  However, an Internalisation Hypothesis has been proposed given that many 
positron emission tomography (PET) ligand target proteins are susceptible to agonist induced 
endocytosis. 
In this thesis, studies are presented which investigate further the Internalisation Hypothesis and the 
influence these processes may have on imaging release of other neurotransmitters, such as opioid 
peptides.  In vitro radioligand binding studies are presented investigating the effect of different buffers, 
representative of conditions experienced by a receptor following endocytosis, on the binding of three 
D2/3 receptor PET ligands. A decreased ability to bind, driven by a reduction in affinity, was observed 
in sub-cellular environments compared with those found at the cell surface. The contribution of each 
cellular compartment to overall striatal binding was also determined. The majority (~65%) of the total 
striatal signal was shown to result from membrane bound D2/3 receptors, a small (~30%) contribution 
was derived from the microsomal D2/3 receptors, and the cytosolic fraction contributes negligibly to the 
overall signal. The potential of imaging endogenous opioid peptide release using an experimental 
pharmacological challenge was investigated. The effects of cellular environments on two radioligands 
known to label opioid receptors in vivo were characterised and the affinity of a range of endogenous 
opioid peptides at [
11
C]carfentanil and [
3
H]diprenorphine labelled sites determined. [
11
C]Carfentanil 
and [
3
H]diprenorphines sensitivity to endogenous opioid peptide release by acute amphetamine 
challenge was explored following radioligand injection in rodents, microdissection and uptake 
assessment, ex vivo autoradiography and sub-cellular fractionation combined with in vitro radioligand 
binding. The effects of acute amphetamine challenge on opioid receptor trafficking in the striatum and 
hypothalamus was investigated using dual labelling fluorescence confocal microscopy. These studies 
demonstrate that [
11
C]carfentanil maybe more sensitive than [
3
H]diprenorphine to endogenous opioid 
peptide release following acute amphetamine challenge. The reduction in [
11
C]carfentanil binding 
observed in the hypothalamus was accompanied by increased association of µ receptors with EEA-1, 
an early endosomal marker. Collectively, these data suggest an agonist-induced internalisation process 
may contribute to the observed signal change with these PET ligands in vivo. Lastly, the effects of 
different cellular environments on the binding parameters of three distinct protein targets was 
investigated; namely the GABAA ionotropic receptor, the serotonin transporter and the D1 G-protein 
coupled receptor. These data demonstrate that the effects of different cellular environments are both 
protein target and radioligand specific and that the effects of agonist induced internalisation on 
radioligand binding is not specific to D2/3 G-protein coupled receptors, but multiple PET radioligand 
protein targets. 
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CHAPTER 1 
Introduction 
 
1.1.  Positron Emission Tomography 
Positron Emission Tomography (PET) allows for non-invasive imaging of radioligand 
target molecule biodistribution and density, assessment of local tissue metabolism 
(using [
18
F]FDG), blood flow (using [
18
O]H2O) and disease progression or treatment 
efficacy (Cunningham et al., 2005, Matthews et al., 2012).  
 
Briefly, radioactive decay of compounds labelled with a positron emitter results in 
emission of a neutron and a positron. This positron, then interacts with local electrons 
(in tissues, for example), resulting in immediate annihilation and the production of 
two gamma rays in opposite directions at 180
o
 to each other, which are detected by a 
ring of detectors embedded in the PET camera. Detection of pairs of gamma rays 
(coincidence detection) allows for determination of the source of the initial 
annihilation event. Following coincidence detection of all annihilation events at all 
angles within the frame of the PET camera, image reconstruction is possible and a 
map of tissue radioactive localisation can be generated. Typically, PET images are 
reconstructed and aligned to a corresponding subject CT or MRI image. Following 
this, kinetic modelling allows for extraction of image derived data. 
 
1.1.2.  Derivation of In Vivo Binding Parameters  
Conventional methods for determining in vivo binding parameters were originally 
proposed by Mintun et al (1984). Fractional rate constants (defining delivery of free 
radiotracer to central binding sites and efflux of free radioligand from brain (Figure 
1.0.)) were used to define binding potential (BP). 
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Figure 1.0. Tissue Compartmental Model. 
Figure describing transfer of radioligand from peripheral blood to specifically bound central 
receptor sites. k5 and k6 are rarely determinable, as such data is often fit according to a two 
tissue compartmental model. 
 
Using the above microparameters, BP, equivalent to Bmax/KD, can be estimated 
assuming the following relationships: 
    
    
  
    
  
  
  
 
Equivalent to: 
    
       [      ]
    
   
                      [           ]
     
 
 
The equation above also demonstrates the relationship between PET tracer kinetics 
and in vitro radioligand binding kinetics. BP can be further expressed relative to the 
free fraction of radioligand in plasma (fp) and uptake in a nondisplaceable 
compartment (fND). However, due to the difficulty in estimating accurate individual 
rate constants and the inherent variability of this process, BP is now more frequently 
estimated using a series of macroparameters (volumes of distributions) derived from 
tissue response functions (area under tissue (or blood/plasma) time activity curves; 
Innis et al.,  2007): 
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Since the in vivo binding parameter BP is equivalent to Bmax/KD, alterations in either 
Bmax or KD may underpin the change in BP observed following administration of a 
challenge or in a disease state.  
 
1.2.  Imaging Endogenous Release with PET 
1.2.1.  The Occupancy Model  
The Occupancy Model illustrates the interaction between a radioligand, its receptor 
target and the endogenous ligand for that target. Using this model to describe PET 
data, radioligand binding is proposed to change proportionally to the amount of 
endogenous ligand present, on a competitive basis. Therefore, increase of endogenous 
neurotransmitter reduces radioligand binding proportional to the amount released. 
Conversely, depletion of radioligand binding increases radioligand binding, since 
more target sites are unoccupied by radioligand (Figure 1.1.).   
 
 
Figure 1.1.  The Occupancy Model 
Radioligand binding is depicted as changing proportional to endogenous dopamine levels. 
 
Typically, enhancement of neurotransmitter levels can take place either by 
physiological or pharmacological challenge. Physiological challenges, such as pain, 
cognitive or motor tasks can be implemented where an increase in transmission and 
activation in a known neurocircuit leads to increased neurotransmitter release. 
Pharmacologically, neurotransmitter re-uptake blockers, such as amphetamine, can be 
used to increase synaptic neurotransmitter levels. Alternatively, neurotransmitters can 
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be depleted by blockade of synthesising enzymes pharmacologically, or by dietary 
depletion of amino acid precursors required for neurotransmitter synthesis. 
 
1.2.2.  The Gold Standard, Imaging Dopamine Release 
The dopamine D2/3 receptor system has been extensively characterised using 
pharmacological challenge imaging paradigms to measure dopamine release. 
Currently the most widely used ligand for D2/3 receptor mapping and measuring acute 
fluctuations in dopamine concentrations is [
11
C]raclopride (Ginovart, 2005). However 
other tracers such as [
123
I]IBZM, [
11
C]NPA and [
11
C]PhNO have also proven to be 
useful tools for probing the dopaminergic neurotransmitter system (Shotbolt et al., 
2012, Kaasinen et al., 2000, Heinz et al., 1998). These imaging paradigms have vastly 
increased our understanding of the dopaminergic systems role in disease states such as 
schizophrenia (Laruelle et al. 1997), substance misuse and addiction (Volkow et al. 
2003). 
Administration of dopamine transporter blockers such as amphetamine and 
methylphenidate have been shown to increase circulating dopamine levels in the 
rodent and the primate striatum using in vivo microdialysis techniques (Laruelle et al., 
1997, Butcher et al., 1991, Butcher et al., 1988). Further to this, reserpine and 
α-methyl-p-tyrosine pre-treatment has been shown to reduce both basal and 
amphetamine induced increases dopamine levels (Butcher et al., 1991, Butcher et al., 
1988) by inhibiting vesicular packaging of monoamines and dopamine synthesis 
respectively (Figure 1.2).  
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Figure 1.2.  Mechanism of action of dopamine enhancers and depleters such as 
amphetamine and reserpine. 
Dopamine is synthesised from tyrosine (TYR) via DOPA formation by tyrosine hydroxylase. 
Following this, dopamine is packaged into vesicles for release at the synapse by VMAT. The 
dopamine transporter acts to remove dopamine from the synaptic cleft, back into the cell. 
Amphetamine both, blocks DAT and VMAT, inhibiting re-uptake causing dopamine 
concentrations outside the cell to increase and inhibiting vesicular packaging causing 
cytosolic dopamine levels to rise, respectively. This increase in cytosolic dopamine causes 
reversal of DAT and dopamine is actively pumped from the cell (reviewed in (Sulzer et al., 
2005)). Reserpine also blocks VMAT, but instead of being pumped out by DAT, as reserpine 
does not also bind to DAT, the dopamine is degraded and synaptic dopamine levels deplete. 
α-methyl-p-tyrosine, inhibits tyrosine hydroxylase (blue cross), reducing DOPA and therefore 
dopamine synthesis, depleting synaptic dopamine levels. 
 
Together these treatments when combined with PET imaging allow for investigation 
of both basal occupation of dopamine receptors by dopamine and pre-synaptic 
integrity in the striatum, by depletion and augmentation of endogenous dopamine 
levels respectively.  
 
The effect of endogenous dopamine modulation on D2/3 receptor radioligand binding 
has been investigated using a variety of ex vivo and in vivo techniques. Additionally, 
to further characterise the signals observed, microdialysis experiments have also been 
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conducted, to assess the duration and extent of dopamine release on changes in PET 
binding observed.  
 
Typical paradigms would involve a single bolus administration of radioligand 
followed by acquisition of baseline levels of D2/3 receptor binding (BPND Baseline). 
Subsequently, the pharmacological challenge is applied, the radioligand is 
re-administered and another set of D2/3 binding parameters are acquired 
(BPND Post-challenge). The change in binding, from scan one to scan two is proportional to 
the amount of dopamine modulation: 
 
∆BPND = ((BPND Baseline - BPND Post-challenge) / BPND Baseline)  
∆BPND: Change in binding potential defined by uptake in the non-displaceable compartment 
 
Alternatively, both pre- and post-challenge levels of D2/3 receptor density can be 
acquired during a single scan with constant infusion of radioligand. Ideally, to 
substantiate any changes in binding from scan 1 to scan 2 test re-test variability would 
also be determined to ensure any changes observed are greater than the variability 
between scans.  
 
1.2.2.1.  Imaging dopamine release with [
11
C]raclopride and other benzamide 
ligands 
Initial dopamine enhancement and depletion studies conducted ex vivo with 
[
3
H]raclopride were in accordance with the occupancy model, i.e. uptake increased 
following depletion of dopamine and decreased following enhancement of dopamine 
(Ross and Jackson, 1989); (Young et al., 1991).  
In vivo microPET imaging studies in the rat have shown raclopride displacement 
following amphetamine administration mirrors the endogenous dopamine release in 
the striatum, using the cerebellum as a reference region for non-displaceable binding 
(Hume et al., 1992, Houston et al., 2004, Le Masurier et al., 2004). Changes in 
[
11
C]raclopride binding proportional to the modulation of dopamine have been 
observed in other pre-clinical species where further division of striatal regions is 
possible, due to larger brain volume and better camera resolution. In the Gottingen 
mini-pig, intravenous amphetamine has been shown to decrease [
11
C]raclopride 
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binding throughout the striatal sub-divisions (Lind et al., 2005). Furthermore, in the 
primate brain, both increases and decreases in [
11
C]raclopride uptake have been 
observed following reserpine and dopamine transport blocker (GBR12909) 
pre-treatment, respectively (Ginovart et al., 1997, Tsukada et al., 1999). A direct 
correlation has been observed between peak dopamine increase following various 
doses of amphetamine and peak dopamine levels in microdialysate samples and 
reductions in [
123
I]IBZM binding (Laruelle et al., 1997). Additionally, 
α-methyl-p-tyrosine, attenuated the reductions in [123I]IBZM binding caused by 
amphetamine (Laruelle et al., 1997). Interestingly, Ginovart et al (1997) show that the 
changes observed in monkey brain with reserpine pre-treatment are affinity driven, 
with a decrease KD
apparent
 following treatment. This study also demonstrated that, 
assuming reserpine pre-treatment caused complete depletion of synaptic dopamine, at 
baseline, 34-36% of D2/3 receptors labelled with [
11
C]raclopride are occupied by 
endogenous dopamine (Ginovart et al., 1997).  
 
Decreases in [
11
C]raclopride binding in the human brain has most notably been 
documented by Volkow et al. (1994). Intravenous methylphenidate (0.25 and 
0.5 mg/kg) in 14 healthy male individuals resulted in significant reductions in uptake 
in the basal ganglia (Volkow et al., 1994). The changes in binding were related to age, 
with older participants exhibiting a lower ∆Bmax/KD and baseline measures of anxiety 
and mood (Volkow et al., 1994). Since this work, various groups have implemented a 
variety of pharmacological (for example, amphetamine (both oral (Cardenas et al., 
2004) and intravenous), cocaine (Cox et al., 2009), and ketamine (Vollenweider et al., 
2000)) and non-pharmacological challenges (for example, the placebo effect (Boileau 
et al., 2007), sustained painful stimuli caused by saline injected into the left masseter 
muscle (Scott et al., 2007) and video-game playing (Koepp et al., 1998a)).  
 
All of these studies demonstrate the robustness and the translational nature of in vivo 
competition imaging with [
11
C]raclopride. However, certain caveats (to be highlighted 
later), suggest that although robust and reproducible, the cellular basis underpinning 
the changes in signals observed in these studies might require further investigation, 
outside the occupancy model. Further to this, [
11
C]raclopride is unable to image extra-
striatal dopamine release. It is thought that greater sensitivity to small changes in 
extrastriatal dopamine levels may be more readily detected with high affinity 
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antagonist radioligands such as [
11
C]FLB-457 and [
18
F]fallypride, or agonist 
radioligands such as [
11
C]PhNO and [
11
C]NPA. For agonist radioligands the total 
receptor population labelled is, in theory, susceptible to changes in dopamine 
concentration. Whereas with antagonist ligands only a fraction of the total binding 
sites labelled are, since both g-protein coupled and uncoupled receptors will also be 
labelled.  
 
1.2.2.2.  Imaging dopamine release with agonist radioligands - [
11
C]PhNO and 
[
11
C]NPA 
Initial ex vivo binding studies performed with the agonist radioligand [
11
C]PhNO 
suggest that pre-treatment with amphetamine thirty minutes prior to radioligand 
dosing dose-dependently reduces the striatum:cerebellum ratio. A maximum 
reduction of 38 % was observed following intravenous amphetamine (4 mg/kg) 
(Wilson et al., 2005). Both reserpine and α-methyl-p-tyrosine pre-treatment 24- and 1 
hour prior to radioligand injection respectively, increased [
11
C]PhNO 
striatum:cerebellum ratios (Wilson et al., 2005). Additionally, amphetamine 
pre-treatment (10 mg/kg) resulted in a 57% reduction in mouse striatum:cerebellum 
uptake ratio of the D2/3 receptor agonist radioligand [
3
H]NPA (Kohler et al., 1981). In 
vivo competition imaging with [
11
C]PhNO in the cat shows the following rank order 
of sensitivity to displacement by dopamine following amphetamine treatment: 
[
11
C]PhNO > [
11
C]NPA > [
11
C]raclopride.  
 
[
11
C]NPA and [
11
C]PhNO have been assessed for their susceptibility for displacement 
by dopamine enhancement in the primate brain. Amphetamine administered as a bolus 
injection, five minutes prior to [
11
C]PhNO injection resulted in a 44 % (brainstem) 
and 67 % (ventral striatum) reduction in specific regional uptake (Narendran et al., 
2006). Administration of the same dose of amphetamine lead to a significant 
reduction of [
11
C]NPA binding in the striatum (~43 %) and the globus pallidum 
(~28 %) (Narendran et al., 2007). Again, these data are in agreement with the 
occupancy model and a reduction in binding following dopamine release and further 
suggest that agonist ligands may indeed be more susceptible than antagonist ligands in 
the primate brain. Importantly, the same rank order of sensitivities to dopamine 
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release is noted in primate that was observed in the cat: [
11
C]PhNO > [
11
C]NPA > 
[
11
C]raclopride.  
 
In healthy human subjects pre-treatment with oral amphetamine (average 0.42 mg/kg) 
caused a significant reduction in caudate (13 %), putamen (21 %) and ventral striatum 
(25 %) [
11
C]PhNO binding was observed (Willeit et al., 2008). Direct comparison of 
[
11
C]PhNO and [
11
C]raclopride has been made within the same subject following 
administration of oral amphetamine. Shotbolt et al (2012) report significant 
reductions in binding with both tracers in all regions of interest (Shotbolt et al., 2012). 
The magnitude of change post-amphetamine was greater with [
11
C]PhNO in all shared 
regions of interest (Caudate, putamen, thalamus, ventral striatum and globus pallidus). 
Reductions in binding were also observed for [
11
C]PhNO in the hypothalamus (28 %) 
and substantia nigra/ventral tegmental area (27 %) (Shotbolt et al., 2012). Within 
study comparison of [
11
C]NPA and [
11
C]raclopride demonstrate that the effect size of 
amphetamine pre-treatment was significantly greater in all regions of interest for 
[
11
C]NPA (Narendran et al., 2010).  
 
Together these studies all build upon the various pre-clinical studies described, 
showing that agonist tracers are possibly more sensitive to modulation of endogenous 
dopamine levels, and [
11
C]PhNO maybe more sensitive than [
11
C]NPA (at least in the 
ventral striatum). It has been suggested that the increased sensitivity of agonist tracers 
such as [
11
C]NPA and [
11
C]PhNO may be due to increased D3 receptor affinity 
(particularly with PhNO) compared with that of [
11
C]raclopride. The data reviewed 
here, suggest, that [
11
C]NPA and [
11
C]PhNO do seem more sensitive than antagonist 
ligands. However this is perhaps due to their agonist pharmacology rather than their 
D3 receptor selectivity. For example, no change in [
11
C]PhNO binding was observed 
in globus pallidus by Willeit et al (2008), where D3 receptors predominate. Further to 
this, the signal changes in caudate and putamen, where D2 receptors predominate are 
comparable between [
11
C]NPA and [
11
C]PhNO but are greater than [
11
C]raclopride.  
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1.2.3.  Questioning the Occupancy Model 
Various lines of evidence suggest that a simple direct competition model might not 
describe sufficiently the data obtained from endogenous release studies. Some of 
these lines of evidence are described below. 
 
1.2.3.1.  Paradoxical findings with spiperone and n-methyl spiperone  
Ex vivo binding studies conducted with [
3
H]spiperone and [
3
H]n-methyl spiperone 
frequently show no change, or paradoxical changes in binding to those expected 
following modulation of endogenous dopamine levels. For example, no change in 
[
3
H]spiperone KD and Bmax values were observed by Sun et al (2003) following 
amphetamine pre-treatment in the rat striatum. Conversely, an increase in intracellular 
[
3
H]spiperone binding was observed (Sun et al., 2003). This intracellular trapping of 
[
3
H]spiperone has previously been reported (Chugani et al., 1988). Microdissection 
studies with [
3
H]spiperone demonstrate significant increases in uptake in the striatum, 
hippocampus and frontal cortex following administration of amphetamine and 
methylphenidate. Further to this, reserpine decreased uptake in the 
striatum/hippocampus (Bischoff et al., 1991), generating findings that are paradoxical 
to the occupancy model. The effects of dopamine modulation on [
3
H]spiperone 
binding in the rat using micro-PET to our knowledge, has not been assessed, however 
this has been investigated in the non-human primate brain. Bolus and constant 
infusion of amphetamine has been shown to have no effect on striatal and cortical 
binding of [
11
C]n-methyl spiperone or even increase association of [
11
C] n-methyl 
spiperone to striatal receptors (Hartvig et al., 1997). This lack of effect on primate 
striatal [
11
C]n-methyl spiperone binding has also been observed following treatment 
with ketamine, which has also been shown to cause dopamine release (Kobayashi et 
al., 1995).  
 
This paradoxical behaviour of  [
11
C]n-methyl spiperone and [
3
H]spiperone with 
respect to the occupancy model, its potential intracellular trapping following 
amphetamine treatment and its unfavourable binding kinetics have more than likely 
hindered its use for investigating dopamine release in the human subjects. These data 
also demonstrate that despite being pharmacologically similar to raclopride (i.e. an 
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antagonist), spiperone represents a within receptor system disparity with respect to the 
ability to image dopamine release with D2/3 receptor in vivo radioligand binding. 
 
1.2.3.2.  Non-competitive binding studies - In vivo scatchard 
In PET, binding potentials (BP) are used as an indicator of the ability of the 
radioligand to bind to its target. When neurotransmitter release is induced, BPs are 
normally observed to decrease as a result of a decrease in available free receptors for 
the radioligand due to binding of the endogenous ligand and hence a decreased BP is 
observed. BP values are the equivalent of Bmax/KD and as such can be presented 
without the relative contribution of the KD and the Bmax being known in vivo.  
 
Competitive binding interactions are described by Scatchard analysis, where in the 
presence of a competing ligand, the apparent affinity (KD) of the radioligand is 
reduced but the total receptor reserve (or Bmax) remains constant. An example where 
this has been carried out in vivo can be seen in Ginovart et al (2004). Here, repeated 
radioligand injections were conducted with different specific activities in the presence 
or absence of amphetamine challenge (Ginovart et al., 2004). It was shown that the 
binding of [
11
C]raclopride in the presence of amphetamine was affected in a 
uncompetitive manor i.e. whilst overall BP. decreased, KD increased (representing a 
decrease in affinity of receptors for [
11
C]raclopride) and Bmax reduced (indicating that 
there was a decreased number of binding sites available for raclopride (Ginovart et al., 
2004).  
 
The changing Bmax and KD values demonstrated by Ginovart et al (2004), show that 
uncompetitive interactions are occurring between the D2/3 receptor radiotracer and the 
competing endogenous ligand. Specifically, changes in receptor density (decreases in 
Bmax after amphetamine) suggest the induction of dopamine release decreases the 
number of receptors available to be bound by [
11
C]raclopride as well the affinity of 
D2/3 receptor for [
11
C]raclopride. Together these findings suggest that in addition to 
the cellular mechanisms proposed by the Occupancy Model other processes are 
contributing to the reductions in binding observed during endogenous release studies. 
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1.2.3.3.  Differential centrifugation studies and paradoxical binding changes 
Ex vivo studies combining differential centrifugation and in vitro radioligand binding 
have provided some results that oppose the classic occupancy model. For example, 
administration of amphetamine combined with ex vivo homogenate binding to 
determine receptor density and radioligand affinities have demonstrated a decrease in 
[
11
C]raclopride to be observed in vivo possibly caused by a change in receptor density 
rather than receptor affinity (Sun et al., 2003). Furthermore, these studies demonstrate 
there is a reduction in cell surface binding of [
3
H]raclopride and [
3
H]spiperone but an 
increase in receptor binding of [
3
H]spiperone only in the endosomal fraction post-
amphetamine treatment (Sun et al., 2003).  
 
Autoradiography studies conducted following stimulation of D2/3 receptor (by either 
agonist administration or electrical stimulation of the nigrostriatal pathway) show 
increased uptake of [
3
H]spiperone, consistent with an increase in uptake following 
agonist induced internalisation of D2/3 receptor. Furthermore, a reduction in 
[
3
H]spiperone binding is observed following pre-treatment of animals with reserpine, 
indicating that accumulation of [
3
H]spiperone occurs in a dopamine dependent 
manner (Chugani et al., 1988).  
 
These studies further reinforce the paradoxical behaviour of [
3
H]spiperone with 
respect to endogenous competition protocols. Furthermore, these also studies 
highlight the importance that cellular trafficking of receptors may have on the change 
in binding observed with D2/2 receptor radioligands. 
 
1.2.3.4.  Temporal discrepancies between dopamine release and ΔBP. 
To further investigate the change in signals observed during in vivo competition 
imaging studies, microdialysis has been employed to relate the change in PET signal 
with the change in dopamine levels. Typically, dopamine levels are related to the 
change in PET signal observed. However, it has been noted that the duration of the 
change in dopamine levels post-challenge are short lived compared with the duration 
of change in PET signal. Together, this suggests that dopamine exerts a sustained or 
longer lasting effect on D2/3 receptor binding than simple direct competition of the 
radioligand. In addition a ceiling effect has been described with respect to the 
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magnitude of dopamine release and the change in binding post-challenge when 
compared with base-line levels. 
 
For example, Laruelle et al (1997) observe a maximum of 1824% increase above 
baseline of dopamine microdialysate concentration from the primate brain 
post-amphetamine administration. These values returned to baseline by 120 minutes. 
The changes in dopamine occurred in a dose dependent manner and were related to 
similar changes in D2/3 SPECT measurements. However, D2/3 receptor binding was 
still significantly reduced up to 240 minutes post amphetamine (Laruelle et al., 1997), 
by which time, dopamine levels had returned to baseline. Further to this, studies in 
male baboons show that full recovery of baseline [
11
C]raclopride BP was not observed 
until 48 hours post-amphetamine administration (Narendran et al., 2007). Similar 
findings have also been observed with the agonist radioligand [
11
C]NPA (Narendran 
et al., 2007).  
 
The data from dual microdialysis-PET studies clearly demonstrate a relationship 
between dopamine release and change in D2/3 receptor PET signal. However 
temporally, later cellular processes may be contributing to the signal change in BP 
observed with D2/3 receptor radioligands, since dopamine is required to initiate the 
change in BP, but not necessary to sustain the reduced BP over time.  
 
Collectively, the findings presented here indicate that the signal change observed 
following endogenous dopamine release cannot solely be explained by The 
Occupancy Model. Furthermore, various lines of evidence, suggest that cellular 
processes such as receptor internalisation following agonist exposure might also be 
contributing to the signal changes observed in vivo.  
 
1.2.4.  The Internalisation Hypothesis 
An internalisation hypothesis has been proposed to contribute to the reductions in 
binding observed in vivo with D2/3 receptor radioligands following enhancement of 
endogenous dopamine (Laruelle, 2000a). Following an increase in endogenous 
agonist concentration, a reduction in radioligand binding is observed due to 
sequestration of target receptor to intracellular compartments. Once in these 
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compartments, the ability of the radioligand to bind is thought to be reduced 
compared with the receptor is present at the cell surface (Figure 1.3).  
 
 
Figure 1.3.  The Internalisation Hypothesis 
Cellular trafficking of receptors (in grey) following modulation of endogenous 
neurotransmitter levels is depicted. 
 
Following depletion of endogenous neurotransmitter concentrations, trafficking of 
receptors from intracellular pools to the cell surface increases the number of 
membrane bound receptors able to bind, leading to an overall increase binding (Figure 
1.3). It is likely that a combination of both the Occupancy Model and the 
Internalisation Hypothesis are contributing to the signal changes observed during in 
vivo competition imaging studies. Therefore, various groups have attempted to further 
investigate this hypothesis, with the hope that a better understanding of the cellular 
processes under pinning the signal changes with D2/3 receptor radioligands may 
facilitate the translation of this type of in vivo competition imaging to other receptor 
systems.  
 
1.2.4.1.  Changes in binding observed with D2/3 receptor radioligands in a receptor 
internalisation deficient mouse 
Skinbjerg et al (2009) demonstrated that internalisation of D2/3 receptors occurs via 
recruitment of β-arrestin 2 to the intracellular domains of the receptor. Specifically, 
down regulation of D2 receptor immunofluorescence was observed in tissue sections 
following pre-treatment with either dopamine or the D2/3 receptor agonist, 
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methyl-NPA, consistent with agonist induced internalisation of D2/3 receptor 
(Skinbjerg et al., 2009). However, this was not observed in β-arrestin 2 homozygous 
knock out animals (Skinbjerg et al., 2009). Skinbjerg et al (2010) also demonstrate 
that despite comparable reductions in [
11
C]MNPA and [
18
F]fallypride binding 
following amphetamine treatment at 30 minutes, β-arrestin 2 knock out animals 
baseline levels of radioligand binding had returned 4 hours post-amphetamine 
whereas wild type radioligand binding was still reduced (Skinbjerg et al., 2010). 
 
1.2.4.2.  Influence of quinpirole treatment on D2/3 ligand binding 
The effects of receptor translocation from the cell surface to intracellular 
compartments on D2/3 receptor ligand affinity have previously been assessed (Guo et 
al., 2010b). Guo et al (2010) demonstrated in a whole cell system, that when 
compared with their affinity at the plasma membrane, a range of D2/3 receptor ligands 
have lower affinity following treatment with quinpirole (a prototypical exogenousD2 
receptor agonist) . However, subtle changes in receptor density were not determined 
in these studies, which may also have contributed to the changes in binding observed 
in vivo. Furthermore, D2 receptor internalisation was quinpirole induced, rather than 
dopamine. The extent and duration of D2 receptor internalisation may be agonist 
dependent. Despite this, these data indicate that D2 receptor affinity for a variety of 
compounds is reduced post-internalisation into subcellular compartments. 
Additionally, these studies reinforce the hypothesis that agonist induced 
internalisation following dopamine release in vivo may contribute to the signal 
changes observed during endogenous release studies.  
 
 
These studies indicate that agonist induced internalisation of D2/3 receptors in a 
β-arrestin 2 dependent manner maybe contributing to the reduction in binding 
observed in vivo with D2/3 receptor radioligands. Furthermore, these findings also 
suggest that further characterisation of the temporal nature of D2/3 receptor 
internalisation in whole tissues may be required to better understand the changes 
observed with D2/3 receptor radioligands.  
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1.3.  Agonist Induced Internalisation 
As discussed above, various lines of evidence suggest that receptor trafficking may 
also be contributing to the changes in radioligand binding that are observed following 
perturbations in endogenous dopamine levels. An agonist-induced internalisation 
hypothesis has therefore been proposed. 
 
 
Four routes or types of receptor internalisation have previously been proposed by 
Wileman et al (1985). These include: 
 
1. Receptors recycling and lysosomal ligand degradation 
2. Receptor and ligand recycling 
3. Ligand and receptor lysosomal degradation 
4. Receptors degradation and ligand recycling to the plasma membrane 
(Wileman et al., 1985) 
 
Following receptor agonist binding and subsequent G-protein receptor kinase (GRK) 
activation, phosphorylation of intracellular proteins such as β-arrestin takes place 
(Figure 1.4.).  The receptor ligand complex is trafficked towards early endosomal 
compartments in clathrin coated pits. β-Arrestins serve as adapters, which can link the 
receptors to various proteins of the endocytic machinery like clathrin and clathrin 
adaptor protein (AP2) (Reiter and Lefkowitz, 2006). These clathrin coated pits are 
snipped from the plasma membrane by accessory proteins such as dynamin (Figure 
1.4.). Active pumping of hydrogen ions takes place within the endosomal membrane 
to acidify the vesicle compartment. In addition to this, changes in the levels of other 
monovalent ions such as potassium and sodium takes places as the receptor-ligand 
complex moves to the intracellular compartment. In the endosome receptors can 
become dephosphorylated by G-protein coupled receptor phosphorylases and recycled 
back to the plasma membrane; re-sensitised for subsequent ligand binding. 
Alternatively, the complex can be retained within the endosomal vesicles and targeted 
for lysosomal degradation (Ferguson, 2001). It is thought that β-arrestin mediated 
G-protein coupled receptor ubiquitination may determine whether receptors are 
internalised for desensitisation and recycling to the plasma membrane or trafficking to 
the lysosomal fraction and degeneration (Reiter and Lefkowitz, 2006; Figure 1.4.).  
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Figure 1.4.  Schematic of Agonist Induced Internalisation 
 
1.4.  Receptor Systems 
The studies presented here will focus mainly on the D2/3 and opioid receptor systems. 
These receptors, their PET imaging ligands and some of the knowledge regarding 
their membrane trafficking will be introduced in the following sections.  
 
1.4.1.  D2/3 receptors 
1.4.1.1.  Structure, Expression, Function, Pharmacology 
Both D2 and D3 receptors are seven trans-membrane spanning Gi-protein coupled 
receptors. The cellular signalling of D2 has been extensively reviewed by Beaulieu 
and Gainetdinov (2011). In summary, activation of striatal D2 receptors can be 
divided into both fast (0 and 30 minutes after agonist binding) and slow signalling (30 
to 120 minutes after agonist binding). Fast receptor signalling involves rapid 
Gi G-protein inhibition of adenylate cyclase and cell cAMP levels. Resulting in 
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modulation of target protein function such as, ionotropic glutamate and GABA 
receptors (Beaulieu and Gainetdinov, 2011) and inhibition of Ca
2+ 
channels and 
inwardly rectifying potassium channels, thereby preventing neurotransmitter release 
and causing a shift in membrane potentials (Beaulieu and Gainetdinov, 2011). Slow 
D2 receptor signalling involves recruitment of intracellular proteins to the receptor, 
initiating receptor internalisation processes and longer lasting cell signalling 
(Beaulieu et al., 2007, Beaulieu and Gainetdinov, 2011). 
 
Northern blot analysis of D2 receptor cDNA shows high levels of expression in the 
anterior and posterior basal ganglia and the pituitary. No expression was observed in 
the cerebellum (Bunzow et al., 1988). In agreement, in vitro binding showed high 
levels of D2 receptor in the rat striatum, nucleus accumbens, olfactory tubercle and 
very low levels in the cerebellum (Kohler et al., 1985) (further reviewed in 
(Cumming, 2011)).  
 
D2 and D3 receptors share 52% amino acid sequence homology, however, when only 
the transmembrane region is considered, this reaches 75%. Therefore, both D2 and D3 
receptors share similar pharmacology regarding binding affinities of some classical 
antagonist neuroleptics and typical agonist compounds.  
 
Initial histochemical studies suggest discrete localisations of D3 receptor cDNA is 
found in regions of limbic projections such as the islands of calleja and the 
hypothalamus (Landwehrmeyer et al., 1993, Sokoloff et al., 1990). In human 
forebrain, high expression was observed in the nucleus accumbens and globus 
pallidus (Gurevich and Joyce, 1999). Additionally, 6-OHDA lesion of the medial 
forebrain bundle, suggest D3 is additionally expressed along with D2 as an 
autoreceptor on dopaminergic neurons projecting from A9 and A10 of the VTA, 
functioning as part of the mesocorticolimbic dopaminergic system (Sokoloff et al., 
1990). 
 
The dopaminergic mesocorticolimbic system projects from the ventral tegmental area 
to the nucleus accumbens and the caudate putamen in the ventral and dorsal striatum 
respectively (Sesack et al., 1994). Discrete D2 receptor immunoreactivity has been 
observed along these axonal projections and terminals. Intense staining has also been 
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observed at the dendrites of these neurons within the VTA and substantia nigra 
(Sesack et al., 1994). D2 receptor immunoreactivity has been seen at the dendrites of 
GABAergic medium spiny neurons, adjacent to tyrosine hydroxylase positive (and 
relatively D2 receptor negative) axon terminals in the caudate (Delle Donne et al., 
1996, Sesack et al., 1994). D2 receptors have also been observed on tyrosine 
hydroxylase negative cells, such as those positive for choline acetyltransferase, 
enkephalin and substance P positive cells (Le Moine et al., 1990, Surmeier et al., 
1996). Furthermore, D2 receptors have been identified on corticostriatal neuron 
terminals in the striatum, acting as heteroreceptors, regulating glutamate release 
(Sesack et al., 1994).  
 
1.4.1.2.  Internalisation of D2/3  
Down-regulation, desensitisation and internalisation of D2/3 receptors have been 
described. Itokawa et al (1996) have shown that following incubation with 10 µM 
dopamine, intact CHO cells stably expressing both D2
long 
and D2
short
 receptors show a 
significant decrease in [
3
H]sulpiride labelled sites by 20 minutes (Itokawa et al., 
1996). This decrease in binding was both pharmacologically reversed by treatment 
with a D2 receptor antagonist and physically reversed by washing off the dopamine. 
Goggi et al (2007) show dopamine induced D2 receptor internalisation was blocked 
by phenylarsine oxide and high molarity sucrose solutions (both known to block 
clathrin mediated endocytosis specifically) (Goggi et al., 2007). Recycling 
experiments suggest that following exposure to 10 µM dopamine, 50 % of 
internalised receptors had recycled back to the cell surface by 30 minutes (Vickery 
and von Zastrow, 1999). The trafficking of D2 receptors has been shown to be GRK2 
or GRK5 (Ito et al., 1999) and Rab5 dependent (Iwata et al., 1999). Other intracellular 
proteins have also been implicated in D2 receptor sequestration such as protein kinase 
C and β-arrestin. (Namkung and Sibley, 2004, Macey et al., 2004).  
 
The cellular localisation of D2 receptor has been described in tissues using subcellular 
fractionation of rat cortex combined with semi-quantitative Western blotting to show 
that D2 receptors are mainly associated with the plasma membrane. However, D2 
receptor immunoreactivity was also observed in microsomal membrane fractions 
(Voulalas et al., 2011). D2 receptor silver-gold grains have been observed at readily 
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endocytosing plasma membranes of the primate cortex (Paspalas et al., 2006). 
Paspalas et al (2006) show within a single dendrite, approximately 12.6 % of total D2 
receptor immunoreactivity was associated with clathrin coated vesicles and 16 % 
were associated with endoplasmic vesicles. These findings demonstrate in tissues, 
where intact cellular architecture and endogenous sub-cellular machinery is present, 
that D2 receptors undergo constitutive recycling from the cell surface to the endocytic 
machinery and that at any point, in the absence of stimulation D2 receptors maybe 
present in the intracellular compartments on the cell.  
 
1.4.1.3.  Imaging D2/3 
As previously highlighted, a variety of PET and SPECT ligands have been developed 
for imaging D2 and D3 receptors. Since there is a current lack of D2 or D3 receptor 
compounds with sufficient sub-type selectivity and their localisation in the ventral and 
dorsal striatum partially overlap (especially given the spatial resolution of PET) the 
majority of the D2 or D3 receptor ligands implemented to date are referred to as mixed 
D2/3 imaging agents.  
 
1.4.2.  The Opioid Receptor System 
The opioid receptor family primarily consists of three seven trans-membrane spanning 
G-protein coupled receptors, µ, δ and κ. These are all activated following the release 
of endogenous opioid peptides and are negatively coupled to the Gi G-proteins. 
Stimulation of all opioid receptors leads to activation of inwardly rectifying potassium 
channels (Chen and Yu, 1994) and inhibition of N-type calcium channels (North et 
al., 1987, Seward et al., 1991). Together these effects result in depression of neuronal 
excitability and decreased neurotransmitter release. The opioid receptor-like (ORL1) 
or nociceptin receptor has also been identified, along with its endogenous peptide 
agonist nociceptin (Meunier et al., 1995). The nociceptin receptor however, is not 
hypothesised to be bound by any of the radioligands mentioned throughout the studies 
present in this thesis (Mollereau et al., 1994, Bunzow et al., 1994), therefore, will not 
be extensively reviewed here. 
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Opioid receptors are approximately 60 % identical in their amino acid sequence, the 
most conserved regions being found at the plasma membrane spanning portions of 
transmembrane helices 2, 3 and 7 (Waldhoer et al., 2004). These transmembrane 
helices form part of the deeper binding pocket for all opioid receptor ligands and 
confer shared affinities for compounds such as naltrexone (Waldhoer et al., 2004). 
Extracellular loops are more divergent amongst μ, δ and κ receptors allowing for 
peptide and ligand selectivity profiles (Waldhoer et al., 2004). 
 
1.4.2.1.  µ Receptor Central Distribution and Function 
High expression of µ receptors are observed in the basolateral nucleus of the 
amygdala, locus coeruleus, the superficial layers of the colliculi and striatal patches of 
the caudate putamen. Moderate levels of expression are observed in layers three and 
one of the frontal, parietal and temporal cortex and large granular cells of the 
hippocampal formation (Mansour et al., 1994, Mansour et al., 1988, Mansour et al., 
1995, Tempel and Zukin, 1987, Sharif and Hughes, 1989).  
 
µ receptor agonists are associated with a variety of physiological effects including 
potent analgesia and euphoria. Side effects include constipation and respiratory 
depression following higher doses, and tolerance or dependence associated with 
repeated use. The euphoria, reinforcing effects and resultant rapid development of 
tolerance and dependence of opiate agonist use has led to their widespread focus 
within addiction research. Mice lacking the µ receptor demonstrate significant 
reductions in the anti-nociceptive effects of morphine dosing.  
 
 
1.4.2.1.1.  µ Receptor Internalisation 
Keith et al (1998) examined a range of µ receptor agonists for their ability to induce 
receptor internalisation and inhibition of forskolin stimulated cAMP levels. Thirty 
minute exposure of 293-SF-MOR cells stably expressing epitope tagged µ receptor to 
met-enkephalin and β-endorphin demonstrates that following exposure, µ receptors 
translocate from the cell membrane to the cytoplasm toward brightly stained 
endocytic vesicles (Keith et al., 1998). Comparable levels of internalisation were 
observed for the endogenous agonist β-endorphin and the exogenous agonist 
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methadone (~27 % and ~25 %) (Keith et al., 1998). Significantly greater levels of 
internalisation were observed with etonitazene and dihydroetorphine (~53 % and 
~50 %), whereas little to no internalisation was observed following exposure to 
morphine (~5 %) (Keith et al., 1998). Interestingly, despite the lack of internalisation 
of µ receptors following various concentrations of morphine, morphine was 
equipotent to DAMGO with respect to inhibition of cAMP (Keith et al., 1998). 
Similar levels of G-protein activation by morphine and DAMGO were also observed 
(Burford et al., 1998). Morphine’s cell surface and sub-cellular signalling has 
subsequently been shown by many to be distinct from the majority of other µ receptor 
agonists. In addition to studies in cell systems, trafficking of µ receptors ex vivo using 
immunohistochemical techniques and tissue preparations have shown that both the 
agonist specific and temporal characteristics of endocytosis seen in cell systems are 
still observed (reviewed in (Wang et al., 2008, von Zastrow, 2010)) and both peptide 
and non-peptide agonists lead to accumulation of µ receptors to clathrin coated 
vesicles (Wang et al., 2008)(reviewed in (von Zastrow, 2010)).  
 
1.4.2.2.  δ Receptor Central Distribution and Function 
Compared with µ receptors, δ receptor expression and binding is more homogenous 
throughout the caudate, putamen and accumbens. Wang and Pickel (2001) examined 
the sub-cellular distribution of δ receptors within the striatum. In dendritic spines 
(75 %) and terminals (50 %), the majority of δ receptors identified were pre-synaptic 
(on neurons projecting from the cortex) and cytoplasmically located (Wang and 
Pickel, 2001). Cytoplasmic receptors were either associated with membranes of 
synaptic vesicles or spine microtubule apparatus. This suggests a role for δ receptors 
in regulating the release of neurotransmitters and in modulation of long term-adaptive 
changes in neuronal processes along the corticostriatal pathway. In the hippocampus, 
δ receptor expression is observed throughout the CA3-1 pyramidal cell layer. 
Moderate levels of expression are also observed in layers two to three and five to six 
of the frontal, parietal and insular cortex and medulla and pons (Mansour et al., 1994, 
Mansour et al., 1988, Mansour et al., 1995, Tempel and Zukin, 1987, Sharif and 
Hughes, 1989).  
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Behavioural studies in δ receptor homozygous knock out animals show no change in 
nociceptive thresholds in the hot plate or tail flick tests compared with wild type 
littermates (Filliol et al., 2000). When δ receptor synthetic peptide agonists (DPDPE 
or deltorphin II) are administered intrathecally, blunted analgesic responses are 
observed. Whereas when these peptides are administered intracerebroventricularly 
potent analgesia was elicited, these responses were blocked by naltrexone, suggesting 
that the analgesia is opioid in origin. Supraspinal analgesia in δ receptor knockout 
animals is also observed with the non-peptide δ receptor agonist BW37U86 (Zhu et 
al., 1999).  A decrease in the number of visits to open arms of the elevated plus maze 
and less time spent in the aversive side of the light-dark box test is also observed in δ 
receptor knockout animals (Filliol et al., 2000). Together these data suggest that δ 
receptors may act physiologically to control anxiety symptoms. Furthermore, an 
increased immobility time is observed in knock out animals compared with wild type 
littermates also suggesting δ receptor may have a role in presentation of depressive-
like symptoms (Filliol et al., 2000). 
 
1.4.2.2.1.  δ Receptor Internalisation 
Increases in membrane bound δ receptor expression in dorsal horn neurons are 
observed following peripheral administration of pro-inflammatory agents such as 
complete Freud’s adjuvant (Cahill et al., 2003, Iadarola et al., 1988, Ruda et al., 
1988). These data suggest that increased release of opioid peptides in the dorsal horn 
may lead to up-regulation of δ receptor synthesis and increase membrane trafficking. 
Bao et al (2003) suggest that following δ receptor insertion, an increased rate of 
endocytosis of newly inserted receptors is observed (Bao et al., 2003). Outside the 
spinal cord, decreases in plasma membrane δ receptor levels have been demonstrated 
following acute exposure of isolated hippocampal neurons with the exogenous agonist 
SNC80 (Pradhan et al., 2009).  
 
1.4.2.3.  κ Receptor Central Distribution and Function  
Significant species differences in expression of κ receptors have been described 
(Robson et al., 1985). In the rat the greatest abundance is observed throughout the 
striatum, the ventral tegmental area and the substantia nigra and various nuclei of the 
thalamus. In the accumbens and caudate putamen κ receptors have been shown to 
associate pre-synaptically, being intracellularly embedded in membranes of synaptic 
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vesicles and at axon terminals, regulating neurotransmitter (opioid and non-opioid) 
release (Meshul and McGinty, 2000). Moderate levels have also been seen in the 
periaqueductal grey, suprachiasmatic nucleus, paraventricular nucleus and layers five 
and six of the parietal, temporal and occipital cortex (Mansour et al., 1994, Mansour 
et al., 1988, Mansour et al., 1995, Tempel and Zukin, 1987, Sharif and Hughes, 1989).  
 
In vivo, κ receptor agonists have been shown to exhibit an inhibitory effect on 
dopaminergic mesolimbic and nigrostriatal pathways. Animals lacking the κ receptor 
have been suggested to perform better than their wild type litter mates in tasks 
requiring spatial learning (the spatial Morris water maze) and reference/working 
memory (the eight arm radial maze task) (Jamot et al., 2003). These findings suggest 
that in comparison to μ receptors, κ receptors may not facilitate hippocampal based 
learning. κ receptor agonists are potent peripheral analgesics thought to have a better 
side effect profile than morphine because of lower of dependence and tolerance 
potential. However, brain penetrant κ receptor agonist result in dysphoria and 
sedation. For example, the naturally occurring κ receptor agonist, Salvinorin A, 
isolated from the leaves of the Salvia divinorum plant, results in powerful 
hallucinations, and can sometimes be reported as dysphoric (Prisinzano, 2005). 
 
1.4.2.3.1.  κ Receptor Internalisation 
Studies conducted with the human form of the κ receptor transfected into recombinant 
cell lines demonstrate that κ receptor undergoes robust and rapid translocation to 
cytoplasmic vesicles in a clathrin dependent manner (reviewed in (Liu-Chen, 2004)). 
However, cell systems where the rat and mouse κ receptor has been selectively 
expressed suggest that these isoforms do not endocytose as robustly as the human 
isoform when exposed to exogenous agonists (Liu-Chen, 2004). Increased 
cytoplasmic κ receptor immunoreactivity has, been demonstrated in ex vivo slices 
taken from rats following treatment with the exogenous agonist U50488 (Reyes et al., 
2010). An increase in total tissue immunoreactivity was also observed by Reyes et al 
(2010). Together, these data suggest that both changes in receptor translocation and 
expression may occur with κ receptors following agonist treatment.  
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1.4.2.4.  The Endogenous Opioid Peptides 
Four main classes of endogenous opioid peptides have been shown to activate µ, δ 
and κ receptors. Each have varying affinities and efficacies at the opioid receptor 
proteins and are released from neurons in distinct patterns throughout the brain and 
spinal cord. 
 
1.4.2.4.1.  The Enkephalins 
Enkephalin peptides are produced from both Pro-enkephalin A and Pro-enkephalin B 
(also termed pro-dynorphin) selective for both μ and δ receptors (Costa et al., 1987).  
Cleavage is generally carried out by the metallopeptidase enkephalin convertase E 
(Fricker and Snyder, 1982). From a single molecule of pro-enkephalin A, six met-
enkephalin molecules are produced (four unflanked met-enkephalin, one met-
enkephalin-arg-gly-leu molecule and one met-enkephalin-arg-phe molecule) and one 
leu-enkephalin (Figure 1.5.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.  Biosynthesis scheme of met- and leu-enkephalin molecules from 
pro-enkephalin A 
Figure adapted from Lynch and Snyder, 1986. R = Arginine, G = Glycine, L = Lysine, 
F = Phenylalanine. 
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Processing of Pro-enkephalin B can lead to the production of dynorphin 1-8, or to 
three molecules of leu-enkephalin following more extensive cleavage at all dibasic 
amino acid sites (Lynch and Snyder, 1986) (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6.  Biosynthesis of leu-enkephalin and dynorphin 1-8 from pro-enkephalin B. 
 
In the rodent brain, enkephalin positive neuron fibres have been identified throughout 
the caudate and nucleus accumbens (Cuello, 1983). Enkephalin terminal projections 
are observed with both enkephalin positive and negative neurons (McCollum et al., 
2012). Pathways extend from the caudate to the globus pallidus where intense 
enkephalin positive immunoreactivity is observed (Cuello and Paxinos, 1978). Some 
of these neurons have further processes that extend to the substantia nigra. 
Hippocampal and hypothalamic enkephalin positive cells have also been identified 
(Cuello, 1983). 
 
Following release of enkephalins from pre-synaptic stores, enzymatic breakdown can 
occur via Enkephalinase, a dipeptidylcarboxypeptidase strongly associated with the 
degradation of enkephalin peptides (Schwartz et al., 1981). At the cellular level, 
Enkephalinase is primarily membrane bound with a brain distribution synonymous to 
that of enkephalin peptides (Schwartz et al., 1981).  
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1.4.2.4.2.  Pro-Opioimelanocortin (POMC) and β-endorphin 
Pro-opiomelanocortin (POMC) is a biologically inactive protein which, following 
enzymatic cleavage, gives rise to a number of biologically important molecules, such 
as β-endorphin 1-31 (Frederickson and Geary, 1982). β-endorphin 1-31 is a μ receptor 
selective peptide. Further processing of β-endorphin 1-31, leads to the generation of 
β-endorphin 1-27 and 1-26, both of which are inactive (see Figure 1.7.) (Loh, 1992).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.  Biosynthesis of β-endorphin from POMC. 
 
Dense POMC positive neuron perikarya have been noted in the anterior and 
intermediate lobe of the pituitary. Intense cytoplasmic POMC staining is also 
observed in the arcuate nucleus of the hypothalamus. Both of these regions extend 
axons throughout the brain, innervating a variety of neuronal structures (Kineman et 
al., 1989, Khachaturian et al., 1984). Rostral projections from the arcuate nucleus 
extend to the nucleus accumbens, the head of the caudate and putamen and medial 
thalamic nuclei. Lateral and caudal projections from the pituitary extend to the medial 
and central amygdala nuclei and the ventral tegmental area, substantia nigra and raphe 
nucleus, respectively. The hippocampus and cerebellum are devoid of POMC 
immunoreactivity in both pig and rhesus brain (Kineman et al., 1989, Khachaturian et 
al., 1984).  
 
 
       
       
    
POMC 
Pro γ-MSH ACTH β-Lipotropin 
   γ-MSH   α-MSH   β-MSH β-Endorphin 1-31 
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1.4.2.4.3.  Dynorphin 
Dynorphin-A and –B are biologically active peptides produced from 
Preprodynorphin, the release of which from pre-synaptic nerve terminals, results in 
activation of κ receptors. Typically enzymatic cleavage of Preprodynorphin peptides 
from the carboxy terminus leads to the production of dynorphin-A, -B and α-neo 
endorphin (reviewed in (Simonato and Romualdi, 1996)). However, cleavage at 
mono-basic arginine residues can lead to the production of dynorphin 1-32, dynorphin 
B 1-13 and dynorphin A 1-8 ((Simonato and Romualdi, 1996); Figure 1.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8.  Biosynthesis of Dynorphin peptides from Preprodynorphin. 
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In post-mortem human samples, dense dynorphin 1-13 immunoreactivity was 
observed in the substantia nigra, anterior and posterior hypothalamus, caudate 
nuclease and putamen (Gramsch et al., 1982). Moderate staining was seen in the 
globus, hippocampus and amygdala (Gramsch et al., 1982). Dynorphin-B 
immune-positive cell bodies have been identified in the central nucleus of amygdala 
and the paraventricular and supraoptic nucleus of hypothalamus, the latter being 
co-localised with dynorphin-A in magnocellular neurons (Weber and Barchas, 1983).   
. 
 
1.4.2.4.4.  Endomorphin 
Endomorphin-1 and -2 are µ receptor peptide agonists with high receptor affinity 
(1 nM and 1.5 nM, respectively (Hackler et al., 1997)). Endomorphin-1 positive 
neuronal fibres have been observed in the frontal cortex, both the shell and core of the 
nucleus accumbens, the amygdala, dorsal raphe thalamus and ventromedial, pre-optic 
area and arcuate nucleus of the hypothalamus (Martin-Schild et al., 1999, Fichna et 
al., 2007). Spinal cord endomorphin-1 immunoreactivity is sparse compared with that 
of endomorphin-2 (Martin-Schild et al., 1999). Endomorphin-2 immunoreactivity has 
been shown to co-localise with µ receptors and substance P in both primary afferents 
and intrinsic neurons of the dorsal horn (reviewed in (Zadina, 2002)). In the brain 
endomorphin-2 peptides have been identified in the periaqueductal grey, locus 
coeruleus and hypothalamus where cell bodies project to the substantia nigra, ventral 
tegmental area and amygdala (reviewed in (Fichna et al., 2007)).  
 
 
1.4.2.5.  Imaging the opioid receptor system 
A variety of radioligands that are structurally related to the endogenous opioid 
peptides have been developed for in vitro imaging of opioid receptor sites, in addition 
to radiolabelled synthetic molecules (Table 1.1).  
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Table 1.1.  Opioid receptor selective radioligands 
 
Radioligand 
Labelled 
Receptor 
Affinity (nM) Reference 
[
3
H]DAMGO
1/#
 µ 
3.46
*
 
0.28
$ 
(Onogi et al., 1995) 
(Chen et al., 1991) 
[
3
H]DPDPE
2/# δ 7.73* (Kieffer et al., 1992) 
[
3
H]DTLET
3/#
 δ 1.4* (Kieffer et al., 1992) 
[
3
H]Dynorphin A 1-8
# Κ 0.66$ (Gillan et al., 1985) 
[
3
H]Dynorphin A 1-9
# Κ 0.066$ (Gillan et al., 1985) 
[
3
H]Bremazocine Κ 0.25$ 
(Gillan et al., 1985) 
(Lahti et al., 1985) 
[
3
H]Etorphine µ 0.60
$ 
(Simon et al., 1973) 
[
3
H]Naltrindole δ 
0.056
$ 
0.037
$ 
(Fang et al., 1994) 
(Yamamura et al., 
1992) 
[
3
H]U69593 Κ 2.9-4.8$/& (Lahti et al., 1985) 
1
[D-Ala, MePhe
4
, Gly(ol)
5
]enkephalin, 
2
cyclic[D-penicillamine
2
, 
D-penicillamine
5
]enkephalin, 
3
Tyr-D-Thr-Gly-Phe-Leu-Thr, 
*
KD value from saturation 
studies in cells, 
$
KD value from saturation studies in tissue homogenates, 
#
Radiolabelled 
peptide ligand, 
&
2.9 nM guinea pig, 3.9 nM rat, 4.8nM mouse 
 
Many of the peptide-related radioligands have low brain bioavailability when dosed 
peripherally due to rapid metabolism and poor blood brain barrier penetration. 
Subsequently, none of the opioid receptor peptide-like compounds have been 
developed as PET radioligands. 
 
Currently, in vivo PET imaging agents are available for the all three main opioid 
receptor sub-types using non-selective ligands such as [
11
C]diprenorphine (µ, δ and κ 
receptor antagonist), partially selective ligands such as [
18
F]cyclo-foxy (µ and κ 
receptor antagonist) and receptor selective radioligands such as [
11
C]carfentanil (µ 
receptor agonist), [
11
C]methyl-naltrindole (δ receptor antagonist) and [11C]GR103545 
(κ receptor agonist). Using these radioligands the opioid receptor systems 
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involvement in a variety of neurological and psychiatric conditions has been 
investigated, these and other studies are further reviewed in (Henriksen and Willoch, 
2008, la Fougere et al., 2009, Hammers and Lingford-Hughes, 2006).  
 
1.4.2.5.1.  Imaging endogenous opioid peptide release 
The ability to image endogenous opioid peptide release would allow further 
characterisation of the role of the opioid receptor system in both physiological and 
pathological situations. Furthermore, the mechanism of action of established and 
novel pharmaceuticals can be more extensively investigated along with the interaction 
of other neurotransmitter systems with the opioidergic system. The sensitivity of both 
[
11
C/
3
H]diprenorphine and [
11
C]carfentanil to endogenous opioid peptide release has 
been demonstrated in various physiological paradigms. However a pharmacological 
challenge, such as that present for imaging dopamine release with PET, remains to be 
formally evaluated in preclinical models. 
 
1.4.2.5.1.1.  [
11
C]Diprenorphine 
Diprenorphine is a high affinity non-selective opioid receptor ligand, acting as a µ 
receptor antagonist and a κ/δ receptor partial agonist (Lewis and Husbands, 2004). 
Various pre-clinical studies with [
3
H]diprenorphine suggest that this ligand is 
susceptible to endogenous release of opioid peptides. Potassium induced 
depolarisation of hippocampal slices prior to incubation with radioligand significantly 
reduced the amount of [
3
H]spelling bound throughout the hippocampus (Neumaier 
and Chavkin, 1989). The decrease in autoradiographical binding was calcium 
dependent (indicating the requirement of pre-synaptic release) and was diminished 
following exclusion of peptidase inhibitors. Behavioural stress paradigms such as the 
cold water swim and prolonged foot shock test have also been assessed with respect 
their ability to cause endogenous opioid peptide release and decrease 
[
3
H]diprenrophine binding. Following stress exposure and intravenous injection of 
[
3
H]diprenrophine, reductions in binding were observed in the medulla, midbrain, 
thalamus, caudate and various limbic structures (Seeger et al., 1984). These findings 
are also observed using ex vivo autroradiography (Seeger et al., 1984). Consistent 
with decreases in [
3
H]diprenorphine binding following behavioural stimulation, whole 
brain homogenate radioligand binding assays have been performed in mice following 
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treatment with enkephalin degrading enzyme inhibitors. Ruiz-Gayo et al (1992) report 
a maximum of 30 % reduction in whole brain binding was observed following 
treatment with enkephalin degrading inhibitor RB101. This reduction in binding was 
further potentiated by the warm water swim test (Ruiz-Gayo et al., 1992).  
 
In vivo imaging studies in epilepsy patients suggest that [
11
C]diprenorphine binding is 
sensitive to changes in endogenous opioid peptides immediately following or during 
an epileptic event. For example, Hammers et al (2007) observe an increase in 
[
11
C]diprenorphine binding in the temporal pole of patients following spontaneous 
seizures (Hammers et al., 2007). Changes in binding were on the same side of the 
brain as the seizure focus and were inversely related to the time since the last seizure 
event (Hammers et al., 2007). Furthermore, Koepp et al (1998) observe significant 
differences in [
11
C]diprenorphine binding between healthy controls and patients with 
reading induced epilepsy (Koepp et al., 1998b). Following radiotracer administration, 
subjects were asked to read aloud a passage of scientific text. In healthy controls an 
increase in [
11
C]diprenorphine binding was observed in the parietal-temporo-occipital 
cortex, whereas in patients a decrease in binding was demonstrated (Koepp et al., 
1998b). Koepp et al (1998) suggest that in healthy controls the increase in binding 
during the reading task is consistent with a reduction in endogenous opioid peptide 
release during cognitive activation (Koepp et al., 1998b). Whereas, the reduction in 
binding observed in patients during a reading induced seizure is consistent with 
release of endogenous peptides following high-frequency stimulation. Koepp et al 
(1998) consider altered receptor affinity for [
11
C]diprenorphine following endogenous 
peptide release ((Koepp et al., 1998b), further highlighted in (Hammers and Lingford-
Hughes, 2006)). 
 
Studies investigating pain neurocircuitry in humans have also suggested that 
diprenorphine may be sensitive to endogenous opioid peptide release. Application of 
moderate painful heat stimulation to the right volar forearm was associated with 
increased levels of unpleasantness and decreased [
18
F]fluodiprenorphine binding in 
the anterior cingulate, bilaterally in the prefrontal and insular cortex and thalamus and 
ipsilateral in the nucleus accumbens and amygdala (Sprenger et al., 2006). Sprenger et 
al (2006) suggest that release of endogenous opioid peptides lead to the decreases in 
binding observed (Sprenger et al., 2006).   
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1.4.2.5.1.2.  [
11
C]Carfentanil 
Carfentanil is a highly potent fentanyl analogue with sub-nanomolar affinity at the µ 
receptor (0.025 - 0.42 nM; (Frost et al., 1985, Yeadon and Kitchen, 1988, Titeler et 
al., 1989, Maguire et al., 1992)). Autoradiography studies have demonstrated high 
levels of binding in the patches of the rat striatum, accumbens, cingulate cortex, 
substantia nigra, various thalamic nuclei (particularly the ventral medial), the 
amygdala and the colliculi (Fitzgerald and Teitler, 1993). Following incorporation of 
carbon-11 and injection into the mouse and rat, high uptake is observed in the 
striatum, thalamus, hypothalamus, and cortex, with the lowest levels of binding being 
seen in the cerebellum (Jewett and Kilbourn, 2004, Saji et al., 1992).  
  
Physiological challenge PET studies have demonstrated that [
11
C]carfentanil is 
susceptible to endogenous release of opioid peptides. For example, following 
application of capsaicin, decreased thalamic binding contralateral to the hand that the 
cream is administered to is observed. These decreases in binding are associated with 
self-reports of pain intensity (Bencherif et al., 2002). Additionally, significant 
decreases in [
11
C]carfentanil binding have been observed in the accumbens and insula 
following infusion of hypertonic saline into muscle tissues (Scott et al. 2007b). In this 
study Scott et al (2007), demonstrated that the binding of [
11
C]carfentanil returns to 
baseline levels 75 minutes post-administration of saline into the muscle. Similar 
findings have also seen with the D2/3 receptor radioligand [
11
C]raclopride. These data 
suggest that compared with pharmacological manipulation of neurotransmitter 
concentrations, physiological challenges lead to reductions in binding potentials that 
may be more proportional to duration and magnitudes of transmitter release. In 
addition these data indicate that different cellular processes may contribute to the 
changes in BP seen following different challenge paradigms.  
 
Together these studies indicate that various physiological challenges can lead to 
reductions in both [
11
C]diprenorphine and  [
11
C]carfentanil binding following release 
of endogenous opioid peptides. However, the cellular mechanisms underlying these 
signal changes are not clear. Furthermore, a suitable pharmacological challenge for 
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imaging opioid peptide release is yet to be robustly characterised. In order to gain 
better understanding of the opioid receptor system in both physiological and 
pathological transmission, the effects of opioid peptide release on receptor affinities, 
availabilities and trafficking should be determined. This information may also aid the 
translation of novel neurotransmitter release paradigms to other receptor systems. 
 
The information that has been summarised in the previous sections demonstrate that 
despite being robust and reproducible, the cellular mechanisms underpinning the 
signal changes observed following dopamine release with D2/3 receptor radioligands 
are not completely understood. An agonist induced internalisation hypothesis has 
been proposed to contribute to the changes observed. The effects of PET protein 
target translocation to sub-cellular compartments on radioligand binding parameters 
warrants further investigation. Furthermore, the literature presented also suggests that 
both the non-selective opioid receptor antagonist, radioligand [
11
C]diprenorphine and 
the selective μ receptor agonist radioligand, [11C]carfentanil may sensitive to 
physiological release of endogenous opioid peptides. However, these radioligands 
have not been directly compared with respect to their sensitivity to amphetamine 
induced opioid peptide release. Finally, the effects of opioid receptor translocation on 
radioligand binding have not been extensively investigated previously.  
 
 
 
The studies performed in this thesis aim to: 
1. Investigate the effect receptor internalisation may have on binding signals 
observed during in vivo competition binding studies with D2/3 receptor 
radioligands.   
2. Characterise the cellular composition of the binding signals observed for three 
widely implemented D2/3 receptor radioligands in physiologically relevant 
tissues and assay conditions.   
3. Translate the methodologies initially characterised with the D2/3 system to 
other receptor systems, via assessment of the ability of a novel 
pharmacological challenge to cause endogenous opioid peptide release and 
alter radioligand binding. The effects of receptor translocation as a result of 
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pharmacological challenge, was assessed using both in vitro and ex vivo 
radioligand binding and immunofluorescence techniques. 
4. Determine the effects of protein translocation from the cell surface to 
sub-cellular compartments using three commonly used PET radioligands for 
target proteins distinct from G-proteins (i.e. transporters and ion channels), in 
order to extend my hypothesis beyond G-protein coupled 
receptor - radioligand interactions.  
 
 
Fundamentally, these data will highlight the importance that trafficking of PET 
radioligand protein targets may have on the signals observed during in vivo imaging 
studies. The methodologies utilised will be applicable to multiple protein targets, 
outside those investigated in this thesis. The data produced will inform future 
radioligand development programs and further the understanding of data produced 
from existing PET radioligands. 
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CHAPTER 2 
General Methods 
2.1.  Introduction 
A series of general tissue preparation and radioligand binding methods are 
implemented throughout the chapters presented in this thesis.  These methods are 
outlined below.  Specific details relating to radioligand and protein concentrations, 
compounds used for defining specific binding and incubation periods will be detailed 
within the text of the relevant chapter. 
 
2.2.  Methods 
2.2.1.  Tissue homogenate preparation for radioligand binding 
Brain tissue was isolated.  Wet weight tissue was weighed and homogenised in 10x 
weight/volume (w/v) sucrose buffer (0.32 mM Sucrose, 5 mM Tris HCl, 1 mM MgCl2 
pH 7.4, 4 °C) and centrifuged at 32,000 g (20 minutes, 4 °C).  The supernatant was 
removed and the pellet washed twice by centrifugation (32,000 g, 20 minutes, 4 °C) in 
Tris buffer (50 mM Tris-Base, 1 mM MgCl2, pH7.4, 4 °C).  For generation of 
membrane pellets for [
3
H]Ro154513 binding, the pellets were washed a further 4 
times by centrifugation (32,000 g, 20 minutes, 4 °C)  in Tris buffer to remove any 
endogenous GABA (according to (Bowery et al., 1983)).  For all membrane 
preparations, the final pellets were re-suspended in Tris buffer to approximately 
10 mg/ml. 
 
2.2.2.  Saturation radioligand binding studies in different physiological 
environments  
Membranes were thawed and diluted to the desired concentration (µg membrane 
protein/well) in each of the three relevant physiological buffers and incubated (37 
o
C) 
with a range of radioligand concentrations: 
 
 
Chapter 2: General Methods 
 
~ 38 ~ 
 
1. Extracellular: Extra: 50 mM Tris HCl, 140 mM NaCl, 5 mM KCl, 1.5 mM MgCl2, 
1.5 mM CaCl2, pH 7.4, 37 
o
C,  
2. Intracellular: Intra: 50 mM Tris HCl, 10 mM NaCl, 140 mM KCl, 0.5 mM 
MgCl2, pH 7.0, 37 
o
C and  
3. Endosomal: Endo: 20 mM MES, 10 mM NaCl, 140 mM KCl, 0.5 mM MgCl2, 
0.003 mM CaCl2, pH 6.0, 37 
o
C  
(Murphy et al., 1984, Somjen, 2004, Alberts et al., 2002, Grabe and Oster, 2001, 
Gerasimenko et al., 1998, Gekle et al., 1999, Faundez and Hartzell, 2004, Christensen et al., 
2002, Brinley, 1980) 
  
The specific binding component was determined using an excess of unlabelled 
compound. The concentrations of radioligands used and the identity and 
concentrations of the compounds used to determine the specific binding component 
are detailed in the relevant chapters. Assays were terminated via filtration through 
Whatman GF/B filters followed by 4 x 1 ml washes with ice-cold Wash buffer 
(50 mM Tris HCl, pH 7.4, 4 
o
C).  Filters were transferred to scintillation vials and 
scintillation fluid added (3 ml/vial; Packard Ultima Gold MV) and bound 
radioactivity determined on a Packard Tricarb liquid scintillation counter.  For 
[
11
C]carfentanil, filter bound radioactivity was determined using a γ-counter. The 
specifically bound radioactivity was decay corrected to the time of radioligand 
addition to the assay wells.  Whatman GF/B filters were pre-incubated in 
polyethylenimine (PEI; 0.05%, 60 minutes) prior to filtration.  
 
2.2.3.  Sub-cellular fractionation procedure 
The various fractions generated in these studies and their contents are (Figure 2.1.): 
 
1. P1: nuclear and cell debris fraction, 
2. P2: plasma membrane and mitochondrial pellet, 
3. P3endo: microsomal pellet diluted in endosomal buffer and 
4. S3: cytosolic fraction.  
 
Tissues were thawed over ice and then were suspended in 10x w/v sucrose buffer 
(0.32 mM Sucrose, 5 mM Tris HCl, 1 mM MgCl2 pH 7.4, 4 °C) and homogenised 
using a Teflon glass homogeniser (20 strokes, on ice).  
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Step 1: Homogenisation,  
             Spin 1,000 g,  
            10 minutes  
            (x2 washes) 
Step 2: Spin 17,000 g, 
             20 minutes 
            (x2 washes) 
Step 3: Spin 100,000 g 
             90 minutes 
S3 Generated 
S1 
P1 
S2 P2 
P3 
 
Figure 2.1.  Fractionation Procedure 
All centrifugation steps were conducted at 4 °C. Wash steps were conducted under the same 
centrifugation conditions as fraction generation.  All wash steps and re-suspensions were 
conducted in Tris buffer (50 mM Tris-Base, 1 mM MgCl2, pH 7.4, 4 °C).  All wash 
supernatants were combined with the original supernatant from that particular step for further 
centrifugation.  
 
The membrane fraction, P2, was re-suspended in Tris buffer.  The supernatant from 
P3, S3, was collected as the cytosolic fraction. The microsomal fraction, P3, was 
re-suspended in endosomal buffer (P3endo; Endo: 20 mM MES, 10 mM NaCl, 
140 mM KCl, 0.5 mM MgCl2, 0.003 mM CaCl2, pH 6.0, 37 
o
C).  Samples of the cell 
S3 
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fractions (250 µl of each) were assessed for protein content and the remainder 
aliquoted and stored at -80 
o
C for use in subsequent radioligand binding studies. 
 
2.2.4.  Cell fraction radioligand binding 
Radioligand binding studies were performed from independent fractionation 
procedures.  
Studies were performed using fixed, saturating concentrations of all radioligands 
(concentration detailed in the relevant chapter). The specific binding component was 
determined using an excess of unlabelled compound (nature and concentration 
detailed in the relevant chapter).  For each replicate, fractionation samples from P2, 
P3endo and S3 were diluted to the same protein concentration.  Protein concentrations 
were determined by the colorimetric method using bicinchoninic acid assay (see 
section 2.2.5.).  P3 fractions were diluted in endosomal (P3endo) buffer.  Following 
radioligand addition, assays were incubated at 37 
o
C for specific time periods.  Assays 
were terminated via filtration through Whatman GF/B filters followed by 4 x 1 ml 
washes with ice-cold Wash buffer (50 mM Tris HCl, pH 7.4, 4 
o
C).  Filters were 
transferred to scintillation vials and scintillation fluid added (3 ml/vial; Packard 
Ultima Gold MV) and bound radioactivity determined on a Packard Tricarb liquid 
scintillation counter.  For [
11
C]carfentanil, filter bound radioactivity was determined 
using a γ-counter, and specifically bound radioactivity was decay corrected to the 
time of radioligand addition to the assay wells.  Whatman GF/B filters were 
pre-incubated in polyethylenimine (PEI; 0.05%, 60 minutes) prior to filtration.  
 
2.2.5.  Protein Assay 
Protein concentrations for all determinations were made by the colorimetric method 
using bicinchoninic acid assay at 562 nm (Thermo Scientific Pierce BCA Protein 
Assay Kit) (Smith et al., 1985). 
 
2.2.6.  Data Analysis 
All data were analysed using GraphPad Prism 5.0.  One- and Two-way ANOVA were 
performed using SigmaStat 3.0.  Student’s t-tests were performed using GraphPad 
Chapter 2: General Methods 
 
~ 41 ~ 
 
Prism 5.0.  Bmax values in pmol/g tissue (nM) were generated according to Equation 1 
(where it is assumed that 1 ml of homogenised wet weight tissue is equivalent to 1 g 
in weight).  In vitro binding potentials (BP) were generated using Equation 2.  
Relative Specific Activity (RSA) values were generated using Equation 3 (Laduron, 
1977). Kon association values were determined using Equation 4. Kinetic KD values 
were determined using Equation 5. Uptake values were determined using Equation 6. 
 
Equation 1.  Bmax in pmol/g tissue determination (where pmol/g is equivalent to nM);   
 
 
    
  
                 
               
 
 
Where     
  is the maximum number of binding sites expressed in pmol/g tissue equivalent 
to nM;       is the maximum number of binding sites expressed in fmol/mg of protein; 
“Mass tissue” in assay in g; and “Protein content” in g/ml.   
 
Equation 2.  In vitro BP determination;  
 
 
     
    
 
  
 
 
Where      is the in vitro binding potential (unit less);     
  is the maximum number of 
binding sites expressed in pmol/g tissue equivalent to nM and    is the equilibrium 
dissociation constant in nM. 
 
Equation 3.  Relative specific activity (RSA) determination; 
 
 
    
                               
                      
 
 
Where     is the relative specific activity in each fraction; “% Specific binding per fraction” 
is the percentage of total specific binding of the radioligand in the fraction and “% Protein per 
fraction” is the percentage of the total protein in the fraction. 
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Equation 4.  kon determination 
 
 
    
           
             
 
 
Where     is the rate constant of the association of radioligand and receptor in M
-1
.min
-1
; 
     is the observed rate constant for the association of radioligand and receptor in min
-1
; 
     is the rate constant for the dissociation of radioligand and receptor in min
-1
 and 
[radioligand] is the concentration of radioligand in M. 
 
Equation 5.  Kinetic KD determination 
 
 
   
    
   
 
 
Where    is the equilibrium dissociation constant in M;      is the rate constant for the 
dissociation of radioligand and receptor in min
-1
 and     is the rate constant of the association 
of radioligand and receptor in M
-1
.min
-1. 
 
 
Equation 6.  Uptake Value determination 
 
        
                      
                                     
 
 
Where, radioactivity in tissue is determined from the number of counts from the tissue and 
converted to Becquerels/mg of tissue and radioactivity injected per body weight is the number 
of Becquerels injected per gram of body weight.  
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CHAPTER 3 
The Effects of Different Cellular Environments on D2/3 Receptor 
Binding 
3.1.  Introduction 
The literature reviewed in chapter 1 highlights the robust and reproducible change in 
binding observed following amphetamine administration with D2/3 radioligands. 
However, different radioligands labelling the same receptor have also been shown to 
be differentially sensitive to the same apparent amount of pre-synaptic dopamine 
release. For example [
11
C]spiperone, [
11
C]raclopride and [
11
C]PhNO display differing 
sensitivities to manipulations in endogenous dopamine (Shotbolt et al., 2012, Hartvig 
et al., 1997). Various confounders to the traditional occupancy model have also been 
demonstrated, for example: 
 
 
 Lack of sensitivity or paradoxical behaviour of spiperone to modulations of 
endogenous dopamine levels 
 Temporal discrepancies between the binding signal change observed and the 
surge in dopamine post-challenge, and the ceiling effects relating to reductions in 
binding 
 Derivation of both receptor affinity and receptor availability changes 
post-amphetamine challenge using in vivo scatchard analysis 
 Blunted duration of binding signal changes in a β-arrestin knock-out (i.e. 
internalisation deficient) mouse model 
 
Receptor internalisation has previously been hypothesised to play a role in the signal 
changes observed (Laruelle, 2000b).  Importantly, the D2 and D3 receptor proteins are 
known to internalise following exposure to either endogenous or exogenous agonists.  
A significant decrease in [
3
H]sulpiride-labelled D2-sites are observed 20 minutes 
following incubation with  dopamine (10 µM) in intact CHO cells stably expressing 
D2 receptors (Itokawa et al., 1996).  Furthermore, reductions in [
3
H]sulpiride binding 
has also been observed in cells stably expressing D3 receptors following incubation 
with dopamine (Kim et al., 2001).  Since the proposal of the internalisation 
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hypothesis, various studies have been made to further explore this theory.  For 
example, differential centrifugation of rat brain homogenates following amphetamine 
pre-treatment demonstrated an increase in [
3
H]spiperone labelled  D2/3 receptors in 
microsomal cell fractions (Sun et al., 2003). Additionally, a reduction in membrane 
bound [
3
H]raclopride labelled sites were also observed with no compensatory 
increases in microsomal binding following amphetamine pre-treatment (Sun et al., 
2003), further highlighting the disparities between radioligands labelling the same 
molecular target.  
 
In vivo imaging using the β-arrestin 3 knock-out mouse, demonstrates the same 
reduction in [
11
C]MNPA and [
18
F]fallypride 30 minutes following amphetamine 
administration as wild type animals (Skinbjerg et al., 2010).  Further in vivo imaging 
of these animals 4 hours post-amphetamine, binding remains reduced in wild-type 
animals whereas in the β-arrestin 3 knock-out mice, striatal uptake had returned to 
baseline levels (Skinbjerg et al., 2010). Recent evidence also shows that 
internalisation of dopamine receptors leads to a decrease in affinity of D2/3 ligands in 
the intracellular compartment of recombinant cell lines. It is thought that these affinity 
changes would translate to a decrease in observed BP in vivo (Guo et al. 2010). 
However, a lack of correlation was found in cells between the individual ligands 
affinity shift in the intracellular environment and the changes in BP observed in vivo.  
 
Both subtle changes in receptor affinity and availability in sub-cellular compartments 
following receptor internalisation may contribute to changes observed in the total PET 
binding signal following a pharmacological challenge. Changes in in vivo receptor 
availability cannot be determined in cell systems, and as such have not been fully 
investigated. In the following sections we investigate the effects of agonist-induced 
internalisation on D2/3 receptor binding parameters in tissue homogenates in order to 
further investigate the internalisation hypothesis.  
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3.2.  Aims  
In order to further investigate changes in D2/3 receptor radioligand binding parameters 
following agonist-induced internalisation: 
 
 The effects of different cellular environments (extracellular, intracellular and 
endosomal), representative of the internalisation pathway, on the binding 
characteristics (affinity, receptor availability and in vitro binding potentials) for 
three commonly utilised D2/3 PET radioligands will be investigated in rodent 
tissue homogenates using in vitro radioligand binding assays 
 
Binding in tissue homogenates may allow determination of changes in both receptor 
density and affinity in sub-cellular conditions, which will be more representative of 
the cellular processes occurring following a pharmacological challenge in vivo. 
Ultimately, this will further our understanding of how agonist-induced receptor 
internalisation effects the observed alterations in binding signals with D2/3 receptor 
PET ligands in vivo. 
 
The contribution of sub-cellular D2/3 receptor reserves to tissue radioligand binding 
has not been fully investigated with specific D2/3-receptor PET ligands, e.g. 
[
3
H]raclopride, [
3
H]spiperone and [
3
H]PhNO.  Therefore, any involvement of the 
specific target protein in these sub-cellular compartments to the overall observed PET 
signal will increase our understanding of the cellular mechanisms involved in 
endogenous release studies with these particular radioligands. Therefore: 
 The relative amount of total binding associated with the membrane, microsomal 
and cytosolic fractions from striatal tissue with the D2/3 ligands, [
3
H]raclopride, 
[
3
H]spiperone and [
3
H]PhNO, using sub-cellular fractionation procedures and in 
vitro radioligand binding techniques will be determined 
 Data from this study will be expressed as a function of total fraction binding : 
total fraction protein levels, namely relative specific activity (RSA) values, which 
to our knowledge has never been reported with these D2/3 PET ligands 
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3.3.  Methods 
3.3.1.  Membrane Preparation 
Membranes were prepared using the methods outlined in Section 2.1. using striatal 
tissue isolated from male Sprague Dawley rats (~250 g; Table 3.1. for tissue details). 
The final pellets were re-suspended in Tris buffer to approximately 10 mg/ml. 
 
3.3.2.  Sub-cellular Fractionation 
The sub-cellular fractionation procedure was conducted using the methods 
highlighted in Sections 2.2.3. (Figure 2.1; Table 3.2.). The fractionation procedure 
was conducted on three independent pig striatal preparations for [
3
H]raclopride and 
[
3
H]PhNO. Two independent preparations were used for [
3
H]spiperone binding. The 
translation from rat to pig tissue was made based on evidence presented in section 
8.1.1.. Here rat and pig D2/3 radioligand receptor binding parameters are shown to be 
altered in a similar manor following exposure to the different cellular environments 
investigated throughout this thesis i.e. lower in vitro BP values in the endosomal 
environment compared with the extracellular are affinity driven. Furthermore, use of 
pig striatum allowed for reductions in animals numbers.  
 
3.3.3.  Radioligand Binding Assay 
3.3.3.1.  Tissue Saturation Studies 
Specific details relating to protein, radioligand concentrations and compound used to 
define the specific binding component can be found in Table 3.1. All assays were 
conducted using the methods outlined in Section 2.2. Specific radioligand assay 
conditions are outlined below (Table 3.1.). 
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Table 3.1.  Radioligand binding assay conditions for each radioligand implemented 
 
Radioligand
 
(Target) 
Concentration 
Range 
(nM) 
Incubation 
(mins) 
Compound 
for specific 
binding 
definition 
(µM) 
Tissue
 
Protein 
concentration 
per well (µg)) 
[
3
H]Raclopride
# 
(D2/3) 
0.003 - 30 60 
Haloperidol 
(1) 
Striatum 200 
[
3
H]PhNO
* 
(D2/3) 
0.001 - 10 60 
Haloperidol 
(1) 
Striatum 200 
[
3
H]Spiperone
#
 
(D2/3) 
0.001 - 10 60 
Haloperidol 
(1) 
Striatum 200 
 
* denotes agonist ligand # denotes antagonist ligand. 
 
3.3.3.2.  Kinetic Assays 
Rat striatal P2 homogenates were thawed and diluted to the desired concentration (µg 
membrane protein/well) in both extracellular and endosomal buffers. For association 
experiments, [
3
H]spiperone (1 nM), [
3
H]raclopride (2 nM) or [
3
H](+)PhNO (1 nM) 
were added at 22 time points (ranging from 1 – 100 minutes) to wells containing 
400 µl protein and 50 µl assay buffer. For dissociation studies, protein and 
[
3
H]spiperone (1 nM), [
3
H]raclopride (2 nM) or [
3
H](+)PhNO (1 nM) were added to 
the assay plate and allowed to associate at 37 
o
C for 100 minutes. Following this, 
haloperidol (1 µM) was added to wells in order to initiate the dissociation.  
Haloperidol was added at 22 different time-points ranging from 101 to 200 minutes 
(i.e. following the association phase).  All time points were terminated simultaneously 
at 100/200 minutes via filtration through Whatman GF/B filters followed by 4 x 1 ml 
washes with ice-cold Wash buffer (50 mM Tris HCl, pH 7.4, 4 
o
C).  
 
3.3.3.3.  Sub-cellular Fraction Studies 
Radioligand binding assays in cell fractions were performed as noted in Section 2.2.4. 
Specific details regarding assay conditions for each radioligand are noted below 
(Table 3.2.)  
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Table 3.2.  Radioligand binding assay conditions for each fractionation study 
 
Tissue 
Source 
(Fraction) 
Protein 
concentration 
per well (µg)) 
Radioligand 
(concentration 
nM) 
Compound 
for specific 
binding 
definition 
(µM) 
Incubation 
(min) 
Pig Striatum 
(P2, P3endo, S3) 
200 
[
3
H]Raclopride
 
(20) 
Haloperidol 
(1) 
60 
Pig Striatum 
(P2, P3endo, S3) 
200 
[
3
H]PhNO
 
(5) 
Haloperidol 
(1) 
60 
Pig Striatum 
(P2, P3endo, S3) 
200 
[
3
H]Spiperone 
(5) 
Haloperidol 
(1) 
60 
 
Determination of protein concentration and data analysis were conducted as outlined 
in Sections 2.5 and 2.6. Bmax values in pmol/g of protein (or nM) were generated using 
Equation 1; in vitro binding potentials were generated using Equation 2; and RSA 
values were generated using Equation 3 (see Section 2.2.6).  Kon values were 
determined using Equation 4 and the kinetic KD values determined using Equation 5 
(see below): 
 
Equation 4.  kon determination 
 
 
    
           
             
 
 
Where     is the rate constant of the association of radioligand and receptor in M
-1
.min
-1
; 
     is the observed rate constant for the association of radioligand and receptor in min
-1
; 
     is the rate constant for the dissociation of radioligand and receptor in min
-1
 and 
[radioligand] is the concentration of radioligand in M. 
 
Equation 5.  Kinetic KD determination 
 
 
   
    
   
 
 
Where    is the equilibrium dissociation constant in M;      is the rate constant for the 
dissociation of radioligand and receptor in min
-1
 and     is the rate constant of the association 
of radioligand and receptor in M
-1
.min
-1. 
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3.3.  Results  
3.3.1.  Saturation studies 
3.3.1.1.  [
3
H]Raclopride 
The affinity for [
3
H]raclopride in the endosomal environment was significantly lower 
(9.45 ± 3.60 nM) compared with the extracellular (2.01 ± 0.16 nM, p < 0.01). The 
affinity for [
3
H]raclopride was not significantly altered in the intracellular condition 
(4.34 ± 0.82 nM) compared with either the extracellular or endosomal environments. 
No significant differences in receptor availability were observed when comparing any 
of the cellular environments tested (Table 3.3. and Figure 3.1.). 
 
Table 3.3.  KD and Bmax values for [
3
H]raclopride in the three cellular environments 
 
 
KD (nM) and Bmax (fmol/mg protein) values for [
3
H]raclopride in rat striatum (n = 4, 
mean ± s.e.mean) in the three ionic environments (Extra, Intra and Endo). One-way ANOVA 
with Tukey post-test were performed using SigmaStat 3.0. 
**
p < 0.01 represent comparison of 
intracellular or endosomal to the extracellular condition. ANOVA results: KD F(2,8) = 4.44, 
p = 0.05; Bmax F(2,8) = 0.31, p = 0.74. 
 
[
3
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Figure 3.1.  Saturation curves of [
3
H]raclopride using rat striatal tissues in the three 
cellular environments.  
Results are expressed as the mean ± s.e.mean from four independent observations, each 
performed in triplicate. 
Condition KD (nM) Bmax (fmol/mg protein) 
Extra 2.01 ± 0.16 368 ± 80
 
Intra 4.34 ± 0.82 381 ± 86 
Endo 9.45 ± 3.60
** 
292 ± 68 
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3.3.1.2.  [
3
H]PhNO 
D2/3 affinity for [
3
H]PhNO in the endosomal condition was significantly lower 
(10.32 ± 2.70 nM) compared with the extracellular (0.56 ± 0.13 nM; p  < 0.01). No 
significant differences in affinity were observed in the intracellular environment 
(0.34 ± 0.05 nM) compared with the extracellular. No significant differences in 
receptor availability were observed when comparing any of the cellular environments 
tested (see Table 3.4. and Figure 3.2.). The data for obtained in the endosomal 
condition did not reach plateau. In order to prevent potential ligand depletion and self-
block at much higher radioligand concentrations GraphPad was allowed to extrapolate 
both affinity and availability values. Therefore, the values presented here, are likely 
underestimations of the decrease in affinity observed in this condition for [
3
H]PhNO. 
 
Table 3.4.  KD and Bmax values for [
3
H]PhNO in the three cellular environments 
 
KD (nM) and Bmax (fmol/mg protein) values for [
3
H]PhNO in rat striatal homogenates (n = 4, 
mean ± s.e.mean) in the three ionic environments (Extra, Intra and Endo). One-way ANOVA 
with Tukey post-test were performed using SigmaStat 3.0. 
*
p < 0.01 represent comparison 
endosomal with the extracellular condition. 
#
p < 0.01 represent comparison endosomal with 
the intracellular condition. ANOVA results: KD F(2,9) = 12.96, p = 0.002; Bmax F(2,9) = 1.04, 
p = 0.39. 
[3H]PhNO
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Figure 3.2.  Saturation curves of [
3
H]PhNO using rat striatal homogenates in the three 
cellular environments (Extra, Intra and Endo).  
Results are expressed as the mean ± s.e.mean from four independent observations, each 
performed in triplicate. 
Condition KD (nM) Bmax (fmol/mg protein) 
Extra 0.56 ± 0.13 130 ± 21
 
Intra 0.34 ± 0.05
 
169 ± 32 
Endo 10.32 ± 2.70
*/# 
103 ± 41 
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3.3.1.3.  [
3
H]Spiperone 
No significant differences in affinity were observed for [
3
H]spiperone between the 
endosomal  or intracellular (0.11 ± 0.08 nM) environment (0.36 ± 0.15 nM) compared 
with the extracellular (0.09 ± 0.01 nM). Additionally, no significant differences in 
receptor availability were observed when comparing any of the cellular environments 
tested (Table 3.5. and Figure 3.3.). 
 
Table 3.5.  KD and Bmax values for [
3
H]spiperone in the three cellular environments 
 
 
KD (nM) and Bmax (fmol/mg protein and pmol/g tissue) values for [
3
H]spiperone in rat striatal 
homogenates (n = 4, mean ± s.e.mean) in the three ionic environments (Extra, Intra and 
Endo). One-way ANOVA with Tukey post-test were performed using SigmaStat 3.0. 
ANOVA KD F(2,9) = 2.77; p = 0.12; Bmax F(2,9) = 1.15, p = 0.36. 
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Figure 3.3.  Saturation curves of [
3
H]spiperone using rat striatal homogenates in the 
three cellular environments.  
Results are expressed as the mean ± s.e.mean from four independent observations, each 
performed in triplicate. 
Condition KD (nM) Bmax (fmol/mg protein) 
Extra 0.09 ± 0.01 265 ± 39
 
Intra 0.11 ± 0.08 349 ± 35 
Endo 0.36 ± 0.15
 
278 ± 51 
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3.3.1.4.  In vitro BP values 
When both changes in affinity and receptor availability are taken into consideration 
with one output variable via the generation of in vitro BP values (Equation 2, Section 
2.2.6), in vitro BP in the endosomal was significantly lowered for all three 
radioligands when comparing extracellular with endosomal (Table 3.6., p  < 0.05). 
The lower binding observed in the endosomal condition was driven by a reduction in 
affinity rather than in receptor availability, since no change in Bmax (fmol/g or nM) 
was observed with any ligand tested. The following rank order in decrease in in vitro 
BP from extracellular to endosomal was observed (Table 3.6.):  
 
[
3
H]PhNO > [
3
H]raclopride > [
3
H]spiperone  
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Table 3.6.  Bmax (nM), in vitro BP and reduction in in vitro BP observed in the endosomal 
condition compared to the extracellular condition values for each radioligand in the 
three cellular environments 
 
Radioligand Bmax (nM
$
) In vitro BP 
% Change From 
Extracellular In 
vitro BP 
 
       [
3
H]Raclopride 
   
·     Extra 13.8 ± 0.8 6.93 ± 0.08 100 
·     Intra 12.9 ± 0.7 3.24 ± 0.31 47 
·     Endo 9.1 ± 0.5 1.22 ± 0.34
*
 18
 
[
3
H]PhNO    
·     Extra 7.2 ± 0.2 14.53 ± 4.09 100 
·     Intra 8.2 ± 0.5 25.39 ± 5.68 174 
·     Endo 6.1 ± 1.6 0.62 ± 0.08
**
 4
 
[
3
H]Spiperone    
·     Extra 15.2 ± 0.5 179.5 ± 28.14 100 
·     Intra 18.6 ± 1.6 168.1 ± 10.86 93 
·     Endo 18.3 ± 1.9 68.43 ± 14.16
**
 38
 
 
Values for [
3
H]raclopride, [
3
H]spiperone and [
3
H]PhNO in rat striatal tissue (n = 4, 
mean ± s.e.mean) in the three ionic environments (Extra, Intra and Endo). One-way ANOVA 
with Tukey post-test were performed using SigmaStat 3.0.  
*
p < 0.05, 
**
p < 0.01 represent 
comparison of intracellular or endosomal to the extracellular condition. Bmax (nM) calculated 
using Equation 3. 
$
Assumes 1g of tissue equivalent to 1ml; and therefore pmol/g tissue is 
equivalent to nM. ANOVA results [
3
H]raclopride F(2,6) = 6.31, p = 0.034; [
3
H]PhNO 
F(2,9) = 19.78, p < 0.001; [
3
H]spiperone F(2,9) = 14.42, p = 0.002. 
 
3.4.2.  Kinetic Studies 
A slightly faster association (0.40 ± 0.15 min
-1
 to 0.18 ± 0.02 min
-1
) and slower 
dissociation rate (0.05 ± 0.01 min
-1
 to 0.08 ± 0.03 min
-1
) was observed in the 
extracellular compared with the endosomal environment for [
3
H]spiperone (Table 
3.7.), however, this was not significant, and when converted into kinetic KD values, a 
small but non-significant change in affinity, comparable with those observed in 
saturation studies, was observed in the endosomal environment compared with the 
extracellular (Table 3.7.). 
 
[
3
H]Raclopride and [
3
H]PhNO kinetic KD values obtained in the extracellular 
environment were comparable with those derived from saturation studies 
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([
3
H]raclopride = 2.01 ± 0.16 nM (saturation) versus 1.05 ± 0.45nM (kinetic); 
[
3
H]PhNO = 0.56 ± 0.13 nM (saturation) versus 0.73 ±  0.12 nM (kinetic)). In the 
endosomal environment, koff rates for [
3
H]raclopride, and accurate kob values for 
[
3
H]PhNO were undeterminable, with full inhibition of binding and association 
plateau not able to be achieved at 6 hours post assay initiation (Table 3.7.).  
 
Table 3.7.  Kinetic values for radioligands in extracellular and endosomal conditions 
 
Radioligand/ 
Condition 
koff  
(min
-1
) 
kob  
(min
-1
)
 
kon  
(Molar
-1
 min
-1
) 
Kinetic KD 
(nM) 
Saturation 
KD (nM) 
Fold Δ 
(saturation 
KD/kinetic KD) 
 
[
3
H]Raclopride 
      
 Extra 0.35 ± 0.02 1.12 ± 0.21 0.49 ± 0.26 1.05 ± 0.45 2.01 ± 0.16 1.91 
 Endo 
 
ND 0.03 ± 0.01 ND -/- 9.45 ± 3.60 -/- 
[
3
H]PhNO       
 Extra 0.11 ± 0.02 0.63 ± 1.63 0.43 ± 0.30 0.73 ± 0.12 0.56 ± 0.13 0.76 
 Endo 
 
[
3
H]Spiperone 
0.08 ± 0.06 ND ND -/- 10.32 ± 2.70 -/- 
 Extra 0.05 ± 0.01 0.40 ± 0.15 0.39 ± 0.18 0.62 ± 0.54 0.09 ± 0.01 0.15 
 Endo 0.08 ± 0.03 0.18 ± 0.02 0.12 ± 0.04 0.98 ± 0.45 0.36 ± 0.15 0.36 
 
 
koff (min
-1
); kob (min
-1
); kon (Molar
-1
 min
-1
); Kinetic KD (nM), Saturation KD and Saturation KD 
(nM)/Kinetic KD (nM) fold difference for [
3
H]raclopride (n = 3 extra, n = 5 endo), [
3
H]PhNO (n = 4 
extra, n = 2 endo) and [
3
H]spiperone (n = 3 extra, n = 3 endo; all values are mean ± s.e.mean). All data 
analysed using GraphPad Prism version 5.0 with single site exponential association and dissociation 
fits.  
 
3.4.3.  Sub-cellular fractionation studies 
3.4.3.1.  Protein distribution 
The greatest amount of total pig striatal cellular protein was found in the cytosolic 
fraction for all independent fractionation procedures (see Figure 3.4., Table 3.8.).  
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Table 3.8.  Sub-cellular fractionation data from pig striatal membranes 
 
Radioligand/Fraction 
% Protein per 
fraction 
% Bound per 
fraction 
RSA 
% Total binding 
signal 
 
[
3
H]Raclopride 
 
 
  
 P2 
 P3endo 
 S3 (cyto) 
 
35.56 ± 5.69 
16.24 ± 1.82 
49.12 ± 8.21 
82.51 ± 7.36 
14.33 ± 7.49 
3.16 ± 1.78 
 
2.01 ± 0.32 
0.90 ± 0.49 
0.05 ± 0.03 
Total: 2.96 
67.90 ± 12.43 
30.40 ± 12.54 
1.68 ± 0.89 
 
 
[
3
H]PhNO 
 
   
 P2 
 P3endo 
 S3 (cyto) 
 
35.56 ± 5.69 
16.24 ± 1.82 
49.12 ± 8.21 
79.57 ± 2.49 
17.26 ± 2.60 
3.16 ± 1.70 
 
2.12 ± 0.32 
1.12 ± 0.11
# 
0.06 ± 0.03 
Total: 3.30
** 
64.24 ± 4.59 
33.94 ± 4.96 
1.81 ± 1.10 
 
 
[
3
H]Spiperone 
 
   
 P2 18.05 ± 1.32 67.21 ± 2.93 3.57 ± 0.09 69.01 ± 1.25 
 P3endo 16.13 ± 2.68 24.50 ± 7.20 1.49 ± 0.20
# 
28.75 ± 4.10 
 S3 (cyto) 
 
65.02 ± 4.00 8.28 ± 10.14 
 
0.12 ± 0.15 
Total: 5.18
* 
2.59 ± 2.85 
 
     
 
Per cent of total amount protein per fraction, per cent of total amount of [
3
H]raclopride 
[
3
H]PhNO and [
3
H]spiperone bound to each fraction (P2, P3endo and S3), relative specific 
activity (RSA) and percentage of total binding signal (where 100% = P2 + P3endo + S3) for 
[
3
H]raclopride, [
3
H]PhNO and [
3
H]spiperone from pig striatal membrane fractionation studies 
(n = 3, mean ± s.e.mean). 
*
p < 0.05 and 
**
p < 0.01 represent comparison of total homogenate 
RSA values between radioligands and 
#
 p < 0.05 represent comparison of P3endo RSA values 
between radioligands. 
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Figure 3.4.  Distribution of total cell protein.  
Total protein distribution throughout plasma membrane (P2), microsomal (P3endo) and 
cytosolic (S3) fractions following sub-cellular fractionation of pig striatal membranes.  
Percentage protein determined using µg/ml measured, dilution of protein required for protein 
measurement and total volume of fraction, (n = 3, mean ± s.e.mean). 
 
3.4.3.2.  Total protein bound per fraction 
Assessment of total homogenate binding in fmol i.e. P2 + P3endo + S3 for all three 
radioligands, demonstrated there to be no significant differences observed between 
these ligands ([
3
H]spiperone (3770 ± 1919 fmol), [
3
H]raclopride (3775 ± 1285 fmol) 
and [
3
H]PhNO (2131 ± 1306 fmol; Figure 3.5.)), however a trend was observed for 
lower [
3
H]PhNO total binding, in accordance with previous saturation studies (Table 
3.8. Figure 3.5.). 
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Figure 3.5.  Comparison of [
3
H]spiperone, [
3
H]raclopride and [
3
H]PhNO total 
homogenate binding.  
Total homogenate binding observed following sub-cellular fractionation of pig striatal 
membranes; n = 3 for [
3
H]raclopride and [
3
H]PhNO,  n = 2 for [
3
H]spiperone 
(mean ± s.e.mean).  
 
 
For all three radioligands investigated the majority of cell binding was observed in the 
P2-plasma membrane fraction (and 83 ± 7 %, 80 ± 2 % and 67 ± 3 %, for, 
[
3
H]raclopride, [
3
H]PhNO and [
3
H]spiperone respectively), this was then followed by 
more moderate levels of percentage cell binding in P3endo microsomal fraction and 
low levels of percentage total homogenate binding in the S3 cytosol (Figure 3.6, 
Table 3.8). No significant differences in plasma membrane, microsomal or cytosolic 
percentage total homogenate binding was observed when comparing the cellular 
distribution of all three radioligands.  
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Figure 3.6.  Cellular distribution of total homogenate binding for [
3
H]spiperone, 
[
3
H]raclopride and [
3
H]PhNO. Percentage of total homogenate binding per fraction in 
P2 (plasma membrane), P3endo (microsomal) and S3 (cytosol).  
Homogenates generated from pig striatal membranes; n = 3 for [
3
H]raclopride and [
3
H]PhNO; 
n = 2 for [
3
H]spiperone (mean ± s.e.mean).  
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3.4.3.2.  Cell fraction relative specific activity values  
When both per cent fraction binding and protein levels are taken into consideration by 
generation of relative specific activity (RSA) values (using Equation 3, section 2.2.6.), 
[
3
H]spiperone total homogenate RSA values were significantly greater than those 
obtained for both [
3
H]raclopride (p < 0.05) and [
3
H]PhNO (p < 0.01; Figure 3.7., 
Table 3.8.).  
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Figure 3.7.  Comparison of [
3
H]spiperone, [
3
H]raclopride and [
3
H]PhNO total 
homogenate Relative Specific Activity values.  
Total homogenate binding observed following sub-cellular fractionation of pig striatal 
membranes; n = 3 for [
3
H]raclopride and [
3
H]PhNO,  n = 2 for [
3
H]spiperone 
(mean ± s.e.mean). One-way ANOVA with Tukey post-test were performed using SigmaStat 
3.0. 
*
p < 0.05, 
**
p < 0.01 represent comparison of [
3
H]spiperone RSA to both [
3
H]raclopride 
and [
3
H]PhNO. ANOVA results F(2,5) = 13.49, p = 0.0097. 
 
 
Similar to the percentage of total homogenate binding per fraction, the RSA 
distribution was determined to be highest in the P2 (plasma membrane) fraction for all 
three D2/3-receptor radioligands assessed, followed by the P3 (microsomal fraction) 
and the S3 (cytosol; Figure 3.8., Table 3.8.). 
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Figure 3.8.  Cellular distribution of total homogenate binding RSA values [
3
H]spiperone, 
[
3
H]raclopride and [
3
H]PhNO.  
RSA per fraction in P2 (plasma membrane), P3endo (microsomal) and S3 (cytosol). Total 
homogenates generated from pig striatal membranes; n = 3 for [
3
H]raclopride and [
3
H]PhNO,  
n = 2 for [
3
H]spiperone (mean ± s.e.mean). 
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When comparing the RSA data between radioligands for each cellular fraction, no 
significant differences were found between [
3
H]raclopride, [
3
H]PhNO and 
[
3
H]spiperone for the P2 (plasma membrane) and S3 (cytosol) fractions.  However a 
significantly greater RSA was demonstrated in P3 (microsomal fraction) with 
[
3
H]spiperone (both < 0.05) when compared with [
3
H]raclopride (Figure 3.9., Table 
3.8.). a Trend for a greater P2endo RSA value was observed when comparing 
[
3
H]PhNO and [
3
H]raclopride. 
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Figure 3.9.  P3endo Microsomal fraction RSA values for [
3
H]spiperone, [
3
H]raclopride 
and [
3
H]PhNO.  
RSA per fraction in P3endo for [
3
H]raclopride and [
3
H]PhNO  n = 3,  n = 2 for [
3
H]spiperone 
(mean ± s.e.mean).ANOVA results: F(2,4) = 13.55, p = 0.017. 
 
 
Collectively, the data from the sub-cellular fractionation studies using pig striatal 
membranes demonstrate for all three of the D2/3 ligands tested, that the P2 plasma 
membrane fraction constitutes the largest proportion of the total binding signal, with 
the P3endo microsomal fraction also contributing a substantial amount of binding to 
the striatal tissues (see Table 3.8.).  
 
Taking the RSA into account and the percentage of total protein per fraction, the 
majority (~65%) of the total binding signal associated with [
3
H]raclopride, 
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[
3
H](+)PhNO and [
3
H]spiperone appears to reside with the membrane bound D2/3 
receptors; with a substantial (~30%) contribution derived from the microsomal D2/3 
receptors; and the cytosolic fraction contributing negligibly to the overall PET signal 
(~2%; Figure 3.10., Table 3.8.). 
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Figure 3.10.  Representation of homogenate binding as a function of cell protein, 
(Laduron, 1977).  
Relative specific activity (RSA) versus per cent total protein per fraction histogram for 
[
3
H]raclopride, [
3
H](+)PhNO and [
3
H]spiperone from pig striatum sub-cellular fractionation.  
n = 3 for [
3
H]raclopride and [
3
H]PhNO,  n = 2 for [
3
H]spiperone (mean ± s.e.mean). 
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3.5.  Discussion 
The data presented in this chapter suggest that following enhancement of endogenous 
dopamine and translocation of D2 and D3 receptors to the endosomal compartments, a 
significant reduction in the ability of these receptors to bind typical D2/3 receptor PET 
radioligands would be observed. This decrease in ability to bind would be mainly 
driven by reductions in affinity of receptor for the ligands in these sub-cellular 
compartments and not changes in receptor availability. The extent of affinity change 
from membrane bound conditions to endosomal conditions for [
3
H]spiperone, 
[
3
H]raclopride and [
3
H]PhNO was in the same rank order as their previously reported 
sensitivities to endogenous dopamine release in vivo i.e.: 
 
[
3
H]/[
11
C]PhNO >  [
3
H]/[
11
C]raclopride > [
3
H]/[
11
C]n-methyl spiperone 
 
To further examine the relevance of these affinity shifts, in terms of the contribution 
of the cell compartments to total tissue binding, fractionation studies were performed. 
These studies demonstrated that under basal conditions, the majority of striatal 
binding with all three D2/3 receptor ligands would originate from membrane bound 
receptors (~65 %) and that the microsomal fraction would contribute around ~30 % to 
total tissue binding. The cytosol would not significantly contribute to tissue binding.  
 
We suggest that the data presented here will allow a greater understanding of the 
cellular processes involved in the signal changes observed within a system known to 
be sensitive to neurotransmitter release. Therefore, these findings may also aid in the 
translation of such imaging paradigms to other neurotransmitter systems. 
 
3.5.1.  The effect of ionic conditions on D2/3 receptor radioligand binding 
The effect of changing ionic conditions on D2/3 receptors in in vitro homogenate 
binding studies have previously been characterised, some of these studies are 
highlighted in Table 3.9.: 
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Table 3.9.  Summary of effects of changing assay conditions on D2/3 receptor binding 
previously reported 
 
ligand Protein Source Binding Conditions Result Reference 
Agonists     
[
3
H]Quinpirole D3-CHO cells 120mM Na
+
, Mg
2+
 
exclusion, Gpp(NH)p 
Na
+
: ↓% high affinity 
fraction, no change KD 
Mg
2+
: no change KD or Bmax 
Gpp(NH)p: ↓% high affinity 
fraction 
(Malmberg 
and Mohell, 
1995) 
 Rat striatum 120mM Na
+
, Mg
2+
 
exclusion, Gpp(NH)p 
Na
+
: ↓Bmax 
Mg
2+
: ↓KD 
Gpp(NH)p: ↓KD 
(Malmberg 
and Mohell, 
1995) 
[
3
H]Dopamine Rat striatum 2mM Mg
2+
, GTP, 3-
300mM Na
+
 
Mg
2+
: ↑ Bmax 
Na
+
: ↓ Bmax.  
GTP: ↓% high affinity 
fraction, no change KD 
(Hamblin 
and Creese, 
1982) 
[
3
H]NPA Steer anterior 
pituitary 
1-100mM Na
+
, 1-
100mM Ca
2+
, 10mM 
Na
+
  
Ca
2+
: ↓KD 
Mg
2+
: ↓KD 
Na
+
: ↓Bmax 
(Sibley and 
Creese, 
1983) 
Antagonists     
[
125
I]epidepride 
 
LZR1 cells Decrease pH, 100mM 
Na
+
 
pH: ↓ KD in acidic 
conditions, bi- to monophasic 
Na
+
: ↓Ki, ↑dissociation  
(Neve, 
1991a) 
[
3
H]spiperone Rat striatum 120mM Na
+
, 120mM 
K
+
 and 120mM Li
+
, 
100µM Gpp(NH)p  
Na
+
: no change in KD or Bmax, 
D2
high
 to D2
low 
K
+
: no change in KD or Bmax 
Li
+
: no change in KD or Bmax 
Gpp(NH)p: no change in KD 
or Bmax 
Gpp(NH)p + Na
+
: D2
high
 
converted to D2
low
 
(Grigoriadis 
and Seeman, 
1985b) 
[
3
H]raclopride Rabbit 
caudate/putamen 
150mM Na
+
, 150mM 
Li
+
, 150mM K
+ 
Na
+
: ↓ KD, more than Li
+
, 
↑DA Ki
 
Li
+
:↓ KD, faster Kon than with 
Na
+
, ↑DA Ki  
K
+
: no change in KD or Bmax 
(Reader et 
al., 1990b) 
 
 
    
Typically for agonist ligands inclusion of sodium causes a shift from mixed D2
high
 and 
D2
low
 receptor containing populations to D2
low
 only, reducing receptor availability 
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(Sibley and Creese, 1983, Hamblin and Creese, 1982, Malmberg and Mohell, 1995). 
A reduction in NPA affinity has also been observed in D2/3 expressing rat tumours 
(Abolfathi and Di Paolo, 1991), but Grigordiadis and Seeman (1985a) failed to 
observe any differences in kon/koff, which would result in altered affinity values (since 
KD = koff/kon). Discrepancies here maybe due to subtle alterations in binding of 
[
3
H]spiperone by the different levels of sodium which was used by Abolfathi and Di 
Paolo (1991) to measure NPA affinity via competition binding; whereas Grigordiadis 
and Seeman (1985a) assessed the effects of sodium on [
3
H]NPA directly. For 
antagonist ligands inclusion of sodium in assay buffer generally increases D2/3 
receptor affinity (Sokoloff et al., 1992, Neve, 1991a, Watanabe et al., 1985). Inclusion 
of potassium in assay buffers with rabbit caudate/putamen preparations did not affect 
D2/3 receptor affinity or availability (Reader et al., 1990b). 
 
The effects of changing ionic conditions with antagonist radioligands is class specific 
i.e. butyrophenone ligands and substituted benzamide ligands are differentially 
effected by changes in sodium and pH. Spiperone (a butyrophenone) binding seems to 
be relatively unaffected by changes in pH or sodium concentration, whereas 
epidepride (a substituted benzamide) shows a 6.5 fold decrease in affinity for the D2/3 
receptors when pH is changed from 8-6.8. In addition to this, the absence of high 
concentrations of sodium (100 mM) in the assay buffer caused a further drop in 
affinity of epidepride at pH 6.8 (8.2 fold; (Neve 1991)), but no change with spiperone. 
In support of this, [
3
H]spiperone was less affected than [
3
H]raclopride by changes in 
pH and sodium in our assay system also. Dependency on pH has been further 
investigated, and it is thought that the binding of classical antagonists, such as 
spiperone and haloperidol to D2/3 receptors is dependent on ionisation of a single 
amino acid residue which occurs at a pKa of 6.0 (D'Souza and Strange, 1995). In 
contrast, the binding of atypical antagonists such as raclopride and epidepride is 
dependent upon ionisation of two groups (pKa of between 6 and 7). When these 
findings are put into the context of the cellular environments used in our assay 
system, it could be argued that in the mildly acidic endosome the butyrophenone 
antagonists might still be able to bind as only one amino acid ionisation is needed and 
the pKa is around 6, but with benzamide compounds, one of the two amino acid 
residues will be de-ionised in the endosome. This may induce conformational changes 
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or alterations in hydrogen-binding and correlate with the decreased affinity in the 
endosomal pH. Further to this, Grigordiadis and Seeman (1985a), noted no change in 
[
3
H]spiperone affinity, receptor availability or D2
high
:D2
low
 ratio following inclusion or 
exclusion of 120 mM sodium, potassium or lithium with rat striatal preparations, 
whereas [
3
H]domperidone (Seeman et al., 2003) and [
3
H]raclopride (Reader et al., 
1990b) binding are significantly altered.  
 
Inclusion of magnesium and calcium ions in assay buffers have been shown to 
increase affinity of agonist ligands such as NPA and apomorphine (Sibley and Creese, 
1983, Abolfathi and Di Paolo, 1991). However, in the studies reported in this chapter, 
no significant reduction in affinity was observed in extracellular (0.56 ± 0.13 nM) 
versus the intracellular environment (0.35 ± 0.05 nM) for [
3
H]PhNO, whereas 
magnesium and calcium are both reduced compared with the extracellular. When, pH 
was further dropped from 7.0 to 6.0 (intracellular to endosomal) and magnesium and 
calcium remain reduced compared with the extracellular, [
3H]PhNO’s affinity 
significantly dropped (from 0.35 ± 0.05 nM to 10.32 ± 2.70 nM). It could be inferred 
that the dramatic loss of affinity observed in the data presented here in the endosomal 
condition by [
3
H]PhNO was mainly pH driven. Furthermore, no change in affinity 
was observed with changes in either magnesium or calcium, therefore [
3
H]PhNO 
would be expected behave differently to the [
3
H]NPA in this particular assay system. 
 
It is known that as a protein moves from the extracellular through to intracellular and 
endosomal environments, changes in the concentrations of a number of monovalent 
and divalent ions take place for example Na
+
, Mg
2+
, Ca
2+
, Cl
-
 and pH (H
+
). Changes 
in concentrations of all these ions have been addressed in the in vitro buffer systems 
used in this chapter. As a result, the buffers utilised in these studies are as closely 
aligned to those conditions found throughout the various in vivo cell compartments as 
possible.  
 
Various amino acid residues within the D2 receptor structure have been identified 
which are crucial for antagonist and agonist ligand binding, G-protein coupling and 
regulation of binding by sodium. The Neve group have hypothesised that sodium and 
hydrogen ions interact at specific D2 receptor amino acid residues and that these 
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interactions can alter receptor conformation, and thus change the ability to bind 
various ligands (Neve, 1991a, Neve et al., 1991). This conformational shift was 
demonstrated by the observation that a decrease in hydrogen ions (shift from pH 6.6 
to 7.5) caused a 75 % reduction in D2 receptor density following treatment of the 
alkylating agent NEM (Neve et al., 1991). This effect was partially reversed by 
inclusion of sodium in the assay buffer or mutation of aspartate-80 to alanine.  
 
Literature data therefore suggests that D2 receptor changes conformation following 
exposure to different levels of hydrogen and sodium ions, and that different amino 
acid residues are exposed during this shift. Neve et al (1999) suggest aspartate-80 is 
involved in the regulation of D2 receptors by sodium and hydrogen ions. The binding 
abilities of epidepride, dopamine, NPA and sulpiride are insensitive to alterations in 
sodium or hydrogen ion concentration in C6 glioma cells stably expressing the point 
mutated D2-alanine-80 (Neve et al., 1991). Changes in affinity for all ligands except 
spiperone were observed following changes in ion concentrations with wild type D2 
(Neve et al., 1991). An ancillary binding pocket for the docking of D2 receptor 
antagonist ligands such as the substituted benzamides has been proposed at Aspartate-
46 (Teeter et al., 1994). Changing cellular ionic environments may cause a 
conformational change of the ancillary binding pocket required for [
3
H]raclopride and 
[
3
H]PhNO binding, but not [
3
H]spiperone, thereby reducing the receptor affinity for 
[
3
H]raclopride and [
3
H]PhNO. This would also be expected to take place in vivo 
following dopamine release and translocation of D2 to intracellular conditions, where 
hydrogen ion concentrations are higher and sodium are lower.  
 
Taken together with the data presented in this chapter, we observe that radioligands of 
different chemical classes, which bind to the same receptor, are differentially sensitive 
to changing cellular environments. These sensitivities might confer sensitivity to 
endogenous dopamine release in vivo. Further assessment of other radioligands 
sensitivities to different cellular environments, prior to extensive in vivo imaging may 
help predict sensitivity to release and facilitate endogenous imaging paradigms to 
other neurotransmitter systems.  
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3.5.1.1.  Cell internalisation studies with D2/3 receptor ligands 
The effect of receptor internalisation on D2/3 receptor binding has been previously 
reported in over-expressing cell systems (Guo et al., 2010a). Following treatment of 
D2
Short
 receptor-HEK293 cells with quinpirole, the affinity of various ligands was 
decreased. Guo et al (2010) suggest this affinity shift would be expected to translate 
to a decrease in the expected BPs seen with these ligands once inside the cell. 
However, the magnitude of the change in affinity for some ligands was not related to 
the degree of BP change seen after endogenous release of dopamine in vivo. However, 
this relationship, was observed with the change in in vitro BP values presented in this 
chapter with native tissues. For example, in cells a similar change in affinity is seen 
with raclopride, NMSP and PhNO, whereas in vivo it is thought that spiperone/NMSP 
is relatively insensitive to changes in local dopamine concentration (Hartvig et al. 
1997) and that PhNO is more sensitive than raclopride (Shotbolt et al. 2010). This 
may be related to effects of both changes in affinity and subtle changes in receptor 
availability, which are taken into consideration with the change in in vitro BP values.  
 
3.5.1.2.  Effects of ionic conditions on receptor kinetics 
Changes in receptor equilibrium binding kinetics following exposure to different 
cellular environments may underpin differences in receptor affinity. Few studies have 
investigated the effects of different ionic conditions on D2/3 receptor binding with 
radioligands relevant to the PET community. Inclusion of potassium or sodium ions 
have no effect of [
3
H]NPA association parameters (Grigoriadis and Seeman, 1985a). 
Reader et al (1990) show that the association of [
3
H]raclopride in rabbit neostriatal 
preparations was slower when sodium was included in the assay buffer when 
compared with the addition of lithium. The dissociation of [
3
H]raclopride was 
unaffected by either ion (Reader et al., 1990a). However, Neve (1991) show that the 
dissociation of [
125
I]epidepride is increased when pH is shifted from 7.3 to 8.0. For 
[
3
H]spiperone, dissociation was slower at pH 6.8 compared with pH 7.3 and 8.0 
(Neve, 1991b). Together these data suggest [
3
H]raclopride affinity would decrease 
following incubation with sodium i.e. in the extracellular environment, when 
compared with its incubation with other monovalent ligands (since if kon reduces and 
we assume koff remains unchanged with sodium, KD increases, thus affinity 
decreases). However, Reader et al (1990) do not report kinetic values in the absence 
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of sodium making inferences to the buffer system used in this report unreliable. 
Furthermore, assuming association is not affected by changes in pH (association is not 
reported by Neve et al (1991)) and that [
3
H]raclopride behaves the same as 
[
125
I]epidepride, affinity would reduce in the endosomal condition compared with the 
extracellular by an increase in koff. These data are in agreement with the findings 
presented in this chapter, but since other ionic conditions are not reported and kon has 
not been determined by Neve et al (1991), conclusions on any changes in receptor 
kinetics which may underlie affinity shifts in our data cannot definitively be made.  
 
The saturation studies reported in this chapter determined the KD to be the main 
influence for the decreased binding potential when the D2/3 receptor was incubated in 
intracellular and endosomal cellular environments compared with the extracellular 
environment. The kinetic studies reported in this chapter have further explored the 
nature of the changes in the KD in these ionic environments and contribute to our 
understanding of the mechanisms underlying the changes observed in vivo following 
translocation to the endosomal compartment. Following dopamine release and 
internalisation to the endosomal compartment, [
3
H]raclopride and [
3
H]PhNO binding 
can be hypothesised to reduce due to a reduction in affinity, driven by alterations in 
binding kinetics. Interestingly, [
3H]spiperone’s kinetics were not altered in endosomal 
condition. These support, both homogenate binding studies, which suggest 
[
3
H]spiperone binding is insensitive to changes in sodium and hydrogen ion 
concentration and in vivo dosing data suggesting intracellular trapping or 
accumulation of [
3
H]spiperone following endocytosis of D2/3 receptors with no 
change in affinity (Chugani et al., 1988). Importantly, assessment of a radioligand’ s 
binding kinetics has been demonstrated here to reflect sensitivity to endogenous 
neurotransmitter release in vivo i.e. incomplete binding kinetics in the endosomal 
environments for both [
3
H]raclopride and [
3
H]PhNO (both sensitive to dopamine in 
vivo), complete binding kinetics in the endosomal environment for [
3
H]spiperone (not 
sensitive to dopamine in vivo). 
 
3.5.2.  Sub-cellular fractionation binding 
Sub-cellular fractionation binding studies were performed using pig striatal 
membranes. To ensure that pig D2/3 receptor protein behaves the same as the rat in 
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relation to changes in ionic conditions and radioligand binding, the data presented 
here were compared with saturation binding data in extracellular, intracellular and 
endosomal conditions with [
3
H]raclopride, [
3
H]PhNO and [
3
H]spiperone performed in 
pig tissues (see Appendix 3.7.1.). These data show that receptor availability was 
approximately double in rat compared with the pig; this was true for all ligands tested 
in all conditions (p < 0.001). There was a trend for a reduced affinity in the rat 
compared with the pig for all ligands tested in all conditions; but this did not reach 
significance. All three radioligands behaved the same in the pig as they did in rat 
homogenate preparations, in relation to the different cellular environments. 
Specifically, a reduction in affinity was observed in the endosomal environment for 
[
3
H]raclopride and [
3
H]PhNO compared with the extracellular, but not [
3
H]spiperone. 
However, for [
3
H]spiperone a reduction in in vitro BP in the endosomal environment 
compared with the extracellular was observed in the rat, but not the pig. Given this 
information, the use of pig tissue was considered appropriate for the translation of rat 
binding to pig sub-cellular fractionation studies. Furthermore, since large amount of 
striatal tissue are required for fractionation studies, this allowed for a reduction in 
animal usage. 
 
The cellular and sub-cellular distribution of dopamine receptors have previously been 
described (Bloch et al., 2003, Chugani et al., 1988, Sun et al., 2003, Voulalas et al., 
2011, Yung et al., 1995). However, here we describe for the first time Relative 
Specific Activity values generated in physiologically relevant buffers, for three 
radioligands, of great interest to the PET community and whose sensitivity to 
endogenous neurotransmitter release in vivo has been extensively assessed. 
 
Preliminary Western blots were conducted using the same membrane fractions as 
those used for radioligand binding (Appendix 8.1.2.). However, despite the same 
amount of protein being loaded per gel well (determined before addition using a 
colorimetric method using bicinchoninic acid assay), this has not been confirmed 
immunologically using a housekeeping protein expression, such as GAPDH or 
β-tubulin (for further discussion see appendix 8.1.2.). Preliminary fraction bands for 
D2 and D3 receptor protein are given in Appendix 8.1.2.. The largest proportion of 
total homogenate protein was observed in the cytosolic fraction (S3). In addition, the 
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greatest immunoreactivity for both D2 and D3 receptors was also observed in the 
cytosolic fraction using Western blotting. Interestingly, this large D2 and D3 receptor 
protein pool in the cytosolic fraction led to little or no specific binding. Perhaps 
cytosolic D2 and D3 receptors are not in the correct tertiary conformation necessary for 
binding. Suggesting that cytosolic D2 and D3 would not contribute to any PET signal 
observed in vivo with [
11
C]raclopride, [
11
C]spiperone or [
11
C](+)PhNO in a 
non-challenged situation. The percentage total binding signal obtained for P2 and P3 
for [
3
H]raclopride, [
3
H](+)PhNO and [
3
H]spiperone suggest that a substantial 
proportion (~30 %) of the signals observed in vivo could be due to subcellular, 
microsomal binding, with the highest levels of binding emanating from the plasma 
membrane fractions (~65 %).  
 
The P3endo RSA levels for both [
3
H]spiperone and [
3
H]PhNO were greater than those 
observed for [
3
H]raclopride. This may be due to an increased levels of D3 receptor in 
the sub-cellular compartments which would lead to increases in [
3
H]PhNO binding in 
the microsomal compartments compared with [
3
H]raclopride due to their relative 
D2:D3 receptor selectivity. This has not been observed in the Western blots presented 
in Appendix 8.1.2., where D3 receptor immunoreactivity appears the same in plasma 
membrane and microsomal fractions. However, D3 receptor cytoplasm and 
intracellular vesicle localisation has been noted in transiently transfected CHO cell 
lines and within the rat VTA (Diaz et al., 2000). Increased [
3
H]spiperone binding in 
microsomal fractions maybe due to sequestered levels of 5HT2A receptors. 
[
3
H]Spiperone has been shown to have significant affinity at 5HT2A receptors 
(~0.5 nM in transfected HEK293 cells) (Pritchett et al., 1988). Furthermore, the 
majority 5HT2A receptors located on dendrites of rat VTA dopaminergic cells have 
been shown to be sub-cellularly located, associated with endoplasmic reticulum and 
golgi vesicles (Doherty and Pickel, 2000) which would also be included in the 
P3endo-microsomal binding presented in this section. 
 
Collectively, the sub-cellular fractionation data presented in this chapter demonstrates 
that a significant portion of binding associated with [
3
H]raclopride, [
3
H]PhNO and 
[
3
H]spiperone would be due to microsomal D2/3 receptor binding at a lower affinity to 
those receptors present at the cell membrane. Furthermore, I have shown that ~65% of 
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the total binding with these radioligands is associated with the plasma membrane. 
Should agonist-induced receptor internalisation be a key factor in determining 
sensitivity to neurotransmitter release, this receptor pool represents the total amount 
of receptor able to endocytose, and therefore decrease tissue binding post-challenge in 
vivo. Therefore, these previously unreported receptor populations, and their 
contribution to total tissue binding for [
3
H]raclopride, [
3
H](+)PhNO and 
[
3
H]spiperone, should also be determined for other receptor radioligands, whose 
sensitivity to endogenous neurotransmitter release in vivo is currently under 
investigation. 
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3.6.  Conclusions 
The data presented in this chapter demonstrate that for the D2/3 receptor radioligands 
investigated, the change in in vitro BP from the extracellular to the endosomal 
environment was related to sensitivity to endogenous dopamine release previously 
observed in vivo i.e.: 
 
[
11
C/
3
H](+)PhNO > [
11
C/
3
H]raclopride > [
11
C/
3
H]spiperone 
 
Inclusion of other D2/3 receptor PET ligands in this assay system would be of interest 
to investigate. For example, the agonist, [
3
H]NPA, whose sensitivity to endogenous 
dopamine release is thought to lie in between that of [
3
H]PhNO
 
and [
3
H]raclopride; 
along with other high affinity antagonist ligands, such as [
3
H]FLB457 and 
[
3
H]fallypride.  
 
This chapter also shows that under non-pharmacologically challenged conditions in 
vitro, the majority of binding for the PET ligands [
3
H]PhNO, [
3
H]raclopride and 
[
3
H]spiperone in the pig striatum would be associated with the D2/D3 receptors 
present in the plasma membrane (~65 %). In addition, it is shown that a substantial 
proportion of the signal (~30 %) observed for these three radioligands in the absence 
of a challenge, would be due to microsomal receptor binding, albeit with a reduced 
affinity compared with those present at the plasma membrane. Finally, although the 
greatest proportion of total homogenate protein and D2/3 receptor immunoreactivity 
was observed in the cytosol, this fraction would not significantly contribute (< 5%) to 
the overall binding of the D2 and D3 receptor PET ligands, [
3
H]raclopride, 
[
3
H](+)PhNO and [
3
H]spiperone.  
 
How the receptor immunoreactivity and radioligand binding would alter in each 
sub-cellular fraction following a pharmacological challenge remains to be determined. 
However, the methodology used here i.e. representation of fraction binding data as 
RSA values, and inclusion of relevant physiological buffers throughout the 
fractionation procedure, allow for a more accurate reflection of D2/3 receptor cellular 
binding distribution. Furthermore, we suggest that an in vitro assay system, such as 
that implemented in this chapter, for predicting sensitivity to endogenous 
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neurotransmitter release in vivo, would be invaluable in order to the further the 
imaging neurotransmitter release with PET and SPECT field.  
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CHAPTER 4 
Imaging Endogenous Opioid Peptide Release With Radioligand 
Binding 
 
4.1.  Introduction 
The General Introduction of this thesis highlighted previously reported studies 
demonstrating the reproducible nature of imaging the opioid receptors (namely µ, δ 
and κ), with PET.  Studies investigating the regulation of opioid receptors in patient 
populations versus healthy controls have also been discussed.  Collectively, these 
previous studies demonstrate that a better understanding of the opioid receptor system 
in both disease and neurophysiological processes is desired by many researchers.  
Another way some groups have attempted to gain a greater understanding of the 
functionality of the opioid receptor system, and its role in various central processes, is 
via imaging the release of endogenous opioid peptides.  The majority of these studies 
have involved physiological challenge paradigms, such as stimulation of ascending 
pain pathways (Scott et al., 2007, Sprenger et al., 2006).  However, a pharmacological 
paradigm, similar to that implemented with the D2/3 receptor system remains to be 
formally assessed preclinically with the non-selective radioligand [
3
H]diprenorphine, 
and the selective agonist radioligand, [
11
C]carfentanil.  A pharmacological challenge 
paradigm would also allow for further elucidation of the interaction of the opioid 
receptor system with other neurotransmitter systems e.g. GABA and glutamatergic. 
Interestingly, dopamine-opioid neurotransmitter system interactions have previously 
been described (Table 4.1.). A greater understanding of the cellular mechanisms 
underlying the signal changes in physiological or pharmacological challenge studies 
will aid interpretation of data from studies previously conducted with opioid receptor 
PET radioligands   
 
Internalisation processes are thought to contribute to alterations in binding of opioid 
receptor PET ligands following endogenous opioid peptide release in vivo. The 
General Introduction of this thesis provided evidence that demonstrates the three main 
opioid receptor sub-types (µ, δ and κ) are sensitive to agonist-induced internalisation 
processes following exposure to their endogenous opioid peptides. Determination of 
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the ability for an indirect pharmacological challenge to cause opioid receptor 
internalisation in vivo, in parallel with the assessment of the ability for an opioid 
receptor radioligand to bind to internalised receptors, may be of critical importance 
for predicting if a particular PET radioligand will be sensitive to endogenous release 
in vivo.  
4.1.1.  A pharmacological challenge for imaging endogenous opioid peptide release 
Various preclinical literature suggests direct or indirect modulation of the nigrostriatal 
and mesolimbic dopaminergic system may alter the release and expression of 
endogenous opioid peptides (Table 4.1.). 
 
Dopaminergic tone may have an inhibitory effect on enkephalin levels and 
transmission since haloperidol treatment (Trujillo et al., 1990), 6OHDA lesioning of 
dopamine terminals (Sivam, 1989, Li et al., 1990) and depletion of dopamine using 
reserpine (Peterson and Robertson, 1984) all led to increases in met-enkephalin or 
pro-enkephalin mRNA levels (Trujillo et al., 1990).  Indirect stimulation of dopamine 
receptors using dopamine transport uptake inhibitors, such as amphetamine or 
cocaine, led to increases (Turchan et al., 1998)(Li et al., 1990)(Jaber et al., 1995) and 
decreases (Cole et al., 1995) in striatal dynorphin and pro-dynorphin levels.  These 
effects were shown to be blunted following dopaminergic denervation (Sivam, 1989).  
 
The mechanism of action behind these changes in endogenous opioid peptide levels 
following dopamine receptor activation remains to be elucidated. Nevertheless if this 
pharmacological release system could be substantiated in vivo with PET, it would 
provide a valuable tool for gaining a better insight into the neurobiological processes 
occurring within conditions such as substance abuse and chronic pain syndromes.  
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Table 4.1.  Studies investigating the effect of dopamine system modulation on 
endogenous opioid peptide levels 
 
 
Paradigm Measured Change in Opioid Peptide Reference 
7 x Apomorphine (5mg/kg s.c.) Dynorphin A (1-8)  ↑83% striatum1 (Li et al., 1990) 
7 x D-Amphetamine (5mg/kg 
s.c.) 
Dynorphin A (1-8) ↑83% striatum 
6-OHDA striatal lesions MET-enkephalin ↑ striatum 
6 days Cocaine (i.v. self-
administration) 
β-endorphin ↓ septum (1 hr post-admin) 
↓ nucleus accumbens, striatum, 
hippocampus (18 hrs post-
admin) 
↑ plasma (18hrs post-admin) 
(Sweep et al., 
1989) 
D1 stimulation, striatal neuron 
cultures 
Pro-dynorphin mRNA ↑ following dopamine (Cole et al., 1995) 
15 x haloperidol (1mg/kg i.p.) Pro-enkephalin ↑54% striatum (Trujillo et al., 
1990) 
1 x cocaine (20mg/kg i.p.) 
1 x D-Amphetamine (2.5mg/kg 
i.p.) 
Pro-dynorphin mRNA 
Pro-dynorphin mRNA 
↑ 180% nucleus accumbens2 
↑ 266% nucleus acumbens3 
(Turchan et al., 
1998) 
1 x cocaine (20mg/kg i.p.) Plasma β-endorphin ↑~200% 20 minutes post-admin (Moldow and 
Fischman, 1987) 
1 x D-amphetamine (1.1mg/kg 
i.p.) 
 
Met-enkephalin 
 
No change 
 
(Harsing Jr et al., 
1982) 
SKF38393 (1µM, D1 agonist) 
LY141865 (1µM, D2 agonist) 
Organ bath β-
endorphin 
Organ bath β-
endorphin 
No change 
↓ 43% and 55% 
(Vermes et al., 
1985) 
1 x ethanol (2mg/kg i.p.) 
1 x cocaine (20mg/kg i.p.) 
 
1 x D-amphetamine (2mg/kg 
i.p.) 
 
Nucleus accumbens 
microdialysate β-
endorphin 
measurements 
↑ 55% (1 hour post-admin) 
↑ 58% (1 hour post-admin for 2 
hours) 
↑ 160% (90 minutes post-admin 
for 2 hours) 
(Olive et al., 
2001) 
1 x D-amphetamine (1.5mg/kg 
s.c.) 
1 x D-amphetamine (5mg/kg 
s.c.)  
 
14 x D-amphetamine (5mg/kg 
s.c.) 
Striatum 
preproenkephalin-A, 
dynorphin mRNA 
↑ 23% preproenkephalin A 
↑ 24% dynorphin 
↑ 35% preproenkephalin A 
↑ 32% dynorphin 
↑ 42% dynorphin 
(Jaber et al., 
1995) 
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2 x reserpine (3mg/kg s.c.) Striatal met-enkephalin 
levels 
↑ 50-60% for 20 days post-final 
administration 
(George and 
Kertesz, 1987) 
1 x ethanol (2.8g/kg i.p.) β-endorphin 
microdialysate central 
amygdala  
dynorphin A 1-8 
microdialysate central 
amygdala  
↑~150% 60 minutes post-dose 
for 3 hours 
 
↑~80% 120 minutes post-dose 
for 2 hours 
(Lam et al., 2008) 
    
1
Also occurred in 6OHDA treated animals, the more depleted striatal dopamine, the ↑ the increase in 
dynorphin reactivity following APO treatments.
2
Single cocaine administration decreased kappa opioid 
receptor expression in striatum.
3
Single amphetamine administration decreased κ-opioid expression in 
nucleus accumbens. 
 
A number of studies outlined in Table 4.1. required multiple dosing of challenge 
compounds, which could be clinically impractical (and unethical for many patient 
populations), and hence some of the paradigms in Table 4.1. would not be viable or 
translatable to a clinical imaging protocol. However, with respect to β-endorphin 
release, various studies have shown increased levels following single doses of 
pharmacological challenge compounds within a short time frame (Olive et al., 2001, 
Moldow and Fischman, 1987, Lam et al., 2008, Harsing Jr et al., 1982).  Cocaine has 
been shown to increase peripheral concentrations of β-endorphin in plasma measured 
by radioimmunoassay (Moldow and Fischman 1987).  However, Moldow and 
Fischman (1987) showed this peripheral response may be regulated entirely at the 
pituitary level, and as such may not be mimicked in other central brain structures 
(such as the ventral tegmental area and the nucleus accumbens) via the arcuate 
nucleus of the hypothalamus.  Microdialysis studies have subsequently shown that 
following single administration of substances known to increase striatal dopamine 
concentrations, such as amphetamine, cocaine and ethanol, an increase in opioid 
peptide levels have been observed (Lam et al., 2008, Olive et al., 2001).  
Administration of amphetamine (2 mg/kg) and cocaine (20 mg/kg)  in rat has been 
shown to lead to a 160 % and 58 % increase in the β-endorphin dialysate 
concentrations of the nucleus accumbens, respectively (Olive et al. 2001).  
Furthermore, Roth-Deri and co-workers (2003) report increases in microdialysate 
β-endorphin content following cocaine treatment (Roth-Deri et al., 2003).  These data 
suggest that POMC neurons may be more responsive to acute changes in dopamine 
levels than enkephalin or dynorphin interneurons, and therefore could contribute to 
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reduced opioid receptor radioligand binding within the time frame of a 
pharmacological challenge imaging paradigm.  
 
Studies given in Table 4.1. indicate that modulation of endogenous dopamine levels 
and/or dopamine receptor activation in the striatum and nucleus accumbens can alter 
both circulating levels and transcription of various endogenous opioid peptides and 
their precursors. Specifically, these data suggest that acute administration of 
dopamine transporter blockers, such as amphetamine and cocaine, may lead to 
significant increases in brain and plasma β-endorphin levels. Therefore, assuming that 
amphetamine and cocaine have negligible affinity at opioid receptor sites, the effects 
of such compounds could be used to non-invasively image the release of endogenous 
opioid peptides in vivo with opioid receptor radioligands such as [
11
C]diprenorphine 
and [
11
C]carfentanil. 
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4.2.  Aims 
Given the information that has been reviewed in the previous sections, and the various 
methodologies that have been developed in Chapter 2, the development of a 
pharmacological challenge to image the release of endogenous opioid peptides was 
investigated. Furthermore, the effect of agonist-induced receptor internalisation on the 
binding signals observed was also examined. 
 
 The effects of receptor internalisation on the binding properties of 
[
3
H]diprenorphine and [
11
C]carfentanil will be assessed in vitro in rodent tissue 
homogenates and cell lines expressing the human forms of the µ-, δ- and κ opioid 
receptors, using radioligand binding assays.  
 
To investigate the effect of endogenous opioid peptide release on brain uptake of two 
widely used opioid receptor radioligands, [
3
H]diprenorphine and [
11
C]carfentanil: 
 
 The ability of the known dopamine releasing agents, D-amphetamine to reduce 
[
3
H]diprenorphine and [
11
C]carfentanil binding will be assessed in rat brain 
using ex vivo microdissection. 
 
 The ability of methadone, a compound known to have high affinity, and induce 
endocytosis at µ receptors, to displace both [
3
H]diprenorphine and 
[
11
C]carfentanil will also be assessed. 
 
Additionally, the effect of receptor internalisation on the binding of these radioligands 
will be determined from the following sets of studies: 
 
 Changes in binding in different cell compartments will be assessed separately for 
both [
3
H]diprenorphine and [
11
C]carfentanil following amphetamine 
pre-treatment using ex vivo sub-cellular fractionation and in vitro radioligand 
binding.  The effects of a positive control for µ-opioid receptor internalisation, 
methadone, will also be investigated. 
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4.3.  Methods 
4.3.1.  Membrane preparation 
Membranes were prepared using the methods outlined in Section 2.1. using tissues 
isolated from male Sprague Dawley rats (~250 g; Table 4.2. for tissue details). The 
final pellets were re-suspended in Tris buffer to approximately 10 mg/ml. 
4.3.2.  Cell culture 
4.3.2.1.  µ receptor-CHO growth 
Chinese hamster ovary (CHO) cells stably expressing the human µ receptor were 
grown as an adherent cell layer in culture.  The following growth medium 
components were used for growth and passage: EX-CELL® serum and L-glutamine 
free medium, foetal bovine serum (10 %), geneticin (400 µg/ml) and zeocin 
(250 µg/ml).  Cells were grown to ~70-80 % confluence, and used between passages 9 
and 21.  
4.3.2.2.  δ receptor-CHO growth 
CHO cells stably expressing the human δ receptor were grown as an adherent cell 
layer in culture.  The following growth medium components were used for growth 
and passage: MEME serum free growth medium with Earle’s salts, sodium 
bicarbonate (2.2 g/L), L-glutamine (2.2 g/L), non-essential amino acids (2.2 g/L), 
foetal bovine serum (10 %), hygromycin B (0.3 mg/ml) and geneticin (0.2 mg/ml).  
Cells were grown to ~70-80 % confluence, and used between passages 15 and 20. 
4.3.2.3.  ĸ receptor-CHO growth 
CHO cells stably expressing the human ĸ receptor were grown as an adherent cell 
layer in culture.  The following growth medium components were used for growth 
and passage: DMEM:F12 with L-glutamine and HEPES, serum free growth medium, 
foetal bovine serum (10 %) and geneticin (0.2 mg/ml). Cells were grown to ~70-80% 
confluence, and used between passages 10 and 20. 
4.3.3.  Cell preparation for binding 
Cells were harvested from flasks via brief treatment with trypsin (1:10, 2-3 minutes at 
37°c) and diluted in a small volume of phosphate buffered saline including foetal 
bovine serum (to inhibit the action of trypsin and cell degradation).  Cell harvesting 
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occurred between cell passage numbers 9 and 21.  Cells were counted at 1:10 and 
1:100 dilution in trypan blue using a haemocytometer.  Cell viability was estimated.  
Average cell numbers per flask were:  
 
 
µ receptor-CHO = 3.46 x 10
6
 ± 0.12 x 10
6
 cells/ml 
δ receptor -CHO = 2.62 x 106 ± 0.30x 106 cells/ml 
ĸ receptor -CHO = 2.60 x 106 ± 0.75 x 106 cells/ml 
 
 
For use in radioligand binding studies, cells were harvested on the morning of the 
assay and diluted in their appropriate assay buffer to ~300,000 cells/ml for µ 
receptor-CHO and ~250,000 cells/ml for both δ receptor-CHO and ĸ receptor-CHO.  
The cell suspensions were homogenised using an electric polytron homogeniser and 
centrifuged at 32,000 g (20 minutes 4 °C).  The supernatant was discarded and the 
protein concentration of the membrane pellet determined.  Membranes were 
subsequently diluted to the desired assay concentration (200 µg protein/well or 
0.5 µg/ml). 
 
4.3.4.  In vitro Radioligand binding  
Specific details relating to protein and radioligand concentrations and compound used 
to define the specific binding component can be found in Table 4.2. All assays were 
conducted using the methods outlined in Section 2.2. Specific radioligand assay 
conditions are outlined below in Table 4.2.  [
11
C]Carfentanil binding studies were not 
performed on cells since this radioligand is selective for the μ-opioid receptor and 
radioactive productions were limited. 
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Table 4.2.  Radioligand binding assay conditions for each radioligand implemented 
 
Radioligand 
(Target) 
Concentration 
Range 
(nM) 
Incubation 
(mins) 
Compound for 
specific binding 
definition (µM) 
Tissue
 
Protein 
concentration 
per well (µg)) 
[
3
H]Diprenorphine
#
 
(µ, δ, ĸ) 
0.001 - 3 90 
Naloxone 
(10) 
Whole brain 
(minus 
cerebellum) 
400 
[
3
H]Diprenorphine
#
 
(µ, δ, ĸ) 
0.001 - 3 90 
Naloxone 
(10) 
µ-CHO 
membranes 
200 
[
3
H]Diprenorphine
#
 
(µ, δ, ĸ) 
0.001 - 3 90 
Naloxone 
(10) 
δ-CHO 
membranes 
200 
[
3
H]Diprenorphine
#
 
(µ, δ, ĸ) 
0.001 - 3 90 
Naloxone 
(10) 
ĸ-CHO 
membranes 
200 
[
11
C]Carfentanil
$ 
(µ) 
0.003 - 10 30 
Naloxone 
(10) 
Whole brain 
(minus 
cerebellum) 
400 
 
#
Antagonist. 
$
Agonist. 
 
 
For competition studies with endogenous peptides, tissue homogenate membranes 
were incubated with a single concentration of [
3
H]diprenorphine (0.15 nM) or 
[
11
C]carfentanil (0.3 nM) and a concentration range of the following opioid peptides: 
β-endorphin (10 pM - 10µM), met-, leu-enkephalin and endomorphin-1 and -2 
(3 pM - 100 µM), dynorphin-A and -B (30 pM - 300 µM). Assays were terminated at 
90 and 30 minutes for [
3
H]diprenorphine and [
11
C]carfentanil, respectively. KD 
values, previously determined with [
11
C]carfentanil and [
3
H]diprenorphine in the 
extracellular condition, were used to generate Ki values (affinity constants) using the 
method of Cheng and Prusoff (Cheng and Prusoff, 1973).  Filter bound 
[
11
C]carfentanil was determined using a Wizard 1470 γ-counter (Perkin Elmer). For 
[
11
C]carfentanil assays, specifically bound radioactivity was decay corrected to the 
time of radioligand addition to the assay wells. 
 
 
Protein concentration determinations and data analysis were conducted as outlined in 
Sections 2.5. and 2.6. 
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4.3.5.  In vivo studies – uptake and distribution of [3H]diprenorphine and 
[
11
C]carfentanil 
All studies were carried out in accordance with the UK Animals (Scientific 
Procedures) Act 1986.  Adult, male Sprague Dawley rats (~250 g; Charles River) 
were allowed to acclimatise for a minimum of 48 hours prior to study days. Rats were 
injected with either saline, D-amphetamine hemisulfate salt (2.0 mg/kg i.p.) or 
methadone hydrochloride (0.35 mg/kg i.p.) and replaced to their cages. Sixty minutes 
later subjects were injected with either [
3
H]diprenorphine (8.24 ± 0.21 MBq i.v.) or 
[
11
C]carfentanil (12.24 ± 1.05 MBq i.v.) and returned to their cages for a further 
30 minutes prior to cervical dislocation and rapid brain extraction (Figure 4.1.).  
 
 
 
 
Figure 4.1.  Schematic of challenge agent and radioligand dosing for ex vivo studies 
Drug Treatment: saline, amphetamine (2.0 mg/kg i.p.) or methadone (0.35 mg/kg i.p.). LCD: 
Live Cervical Dislocation. 
 
 
The brain was divided in half down the midline. The right hemisphere of all subjects 
was rapidly frozen by submersion in isopentane (-40 
o
C) for crysectioning and ex vivo 
autoradiography. The left hemisphere of all subjects was dissected into the following 
brain regions and assessed for uptake of either γ-emission-counting ([11C]carfentanil) 
or solubilisation and β-scintillation counting ([3H]diprenorphine): hypothalamus, 
thalamus, striatum, hippocampus, amygdala, prefrontal-, cingulate-, 
somatosensory- and visual/temporal-cortex, inferior and superior colliculi, medulla 
and pons, peri-aqueductal grey and cerebellum.  Whole trunk blood samples were also 
taken and spun at 11,000 g for assessment of plasma radioactivity levels.  
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4.3.5.1.  Uptake assessment in brain regions  
Radioactivity uptake values for each brain region dissected were determined by: 
 
Equation 6.  Uptake Value determination 
 
        
                      
                                     
 
 
Where, radioactivity in tissue is determined from the number of counts from the tissue and 
converted to Becquerels/mg of tissue and radioactivity injected per body weight is the number 
of Becquerels injected per gram of body weight. Regions examined from the [
11
C]carfentanil 
studies: Disintegration per minute values (DPM) were decay corrected to the point of 
radioligand injection.   
 
Both Brain Region:Cerebellum and Brain Region:Blood/Plasma ratio values are 
presented in order to take into consideration changes in non-specifically bound 
radioligand following pharmacological challenge. 
 
4.3.5.2.  [
3
H]diprenorphine ex vivo autoradiography 
Following brain extraction and rapid freezing, the tissue was stored at -80 °C until 
sectioning.  Sixteen micron (16 µm) thick, sagittal sections were cut from the right 
hemisphere using a cryostat microtome and mounted onto gelatine-coated (0.3%) 
microscope glass slides.  Prior to being apposed to tritium-sensitive films, sections 
were allowed to thaw and dry completely.  Slides were then arranged into cassettes 
and apposed to β-sensitive hyperfilm for 6 months with [3H]microscale standards.  
The films were immersed through a series of developing, stop and fix baths in order to 
visualise regions of bound radioactivity from the brain sections (Ilford phenisol 
developer, Ilfostop, Hypam fixer and fixer hardener agent). Following development, 
radioactivity bound to regions of interest were quantified using a Micro-Computer 
Imaging Device (MCID).  Levels of radioactivity were converted to fmol (tritium 
bound) / mg tissue using the calibrated [
3
H]microscale standards. 
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4.3.6.  Ex vivo studies – subcellular fractionation and receptor translocation 
Subjects were injected with either saline, D-amphetamine hemisulfate salt (2.0 mg/kg 
i.p.) or methadone hydrochloride (0.35mg/kg i.p.) and replaced to their cages. Ninety 
minutes later subjects were terminated via cervical dislocation, followed by rapid 
brain extraction.  The brain was divided down the midline into two hemispheres, and 
frozen by submersion in isopentane (-40 
o
C): one hemisphere was used for 
immunofluorescence studies (assessment of receptor translocation, see Chapter 5) and 
the other for sub-cellular fractionation and in vitro radioligand binding studies. 
 
4.3.6.1.  Sub-cellular fractionation and in vitro binding 
4.3.6.1.1.  Fraction preparation  
The left hemisphere (minus cerebellum; ~0.5 g) was isolated from saline, 
amphetamine (2.0 mg/kg i.p.) and methadone (0.35 mg/kg i.p.) treated rats. Sub-
cellular fractionation to generate P2-plasma membrane, P3endo-microsomal and S3-
cytosolic cell fractions was conducted as described in Section 2.2.3.  
 
4.3.6.1.2.  Radioligand binding studies 
Radioligand binding studies were performed as described in Section 2.2.4. on n = 5 
independent fractionation procedures from each experimental condition: i.e. n = 5 
animals for saline, amphetamine (2.0 mg/kg i.p.) and methadone (0.35 mg/kg i.p.) for 
both [
3
H]diprenorphine and [
11
C]carfentanil fraction binding (total 30 animals).  
These studies were performed using fixed, concentrations of [
3
H]diprenorphine 
(5 nM) and [
11
C]carfentanil (1 nM).  The specific binding component was determined 
using naloxone (10 µM).  All fractionation samples from P2, P3endo and S3 were 
diluted to 200 µg/well. Assays were incubated for 90 minutes for [
3
H]diprenorphine 
and 30 minutes for [
11
C]carfentanil. For [
11
C]carfentanil assays specifically bound 
radioactivity was decay corrected to the time of radioligand addition to the assay 
wells.   
 
All protein determinations were carried out as described in Section 2.2.5. Data 
analysis was conducted as described in Section 2.2.6.   
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4.4.  Results 
4.4.1.  In vitro binding studies 
4.4.1.1.  [
3
H]Diprenorphine saturation binding studies 
4.4.1.1.1.  Studies in tissue homogenates 
Saturation data from studies conducted in rodent tissues was best fit to a one-site 
model for determination of KD and Bmax values. [
3
H]Diprenorphine has similar 
affinity at all opioid receptor sites.  No changes in affinity were observed following 
exposure to the different cellular environments (Table 4.3.).  Bmax values were 
significantly lower in the intracellular (p < 0.01) and endosomal (p < 0.01) conditions 
compared with the extracellular (see Table 4.3., Figure 4.2). 
 
 
Table 4.3.  KD and Bmax values for [
3
H]diprenorphine tissue binding in the three cellular 
environments 
 
 
KD (nM) and Bmax (fmol/mg protein) values for [
3
H]diprenorphine in rat whole brain minus 
cerebellum (n = 4, mean ± s.e.mean) in the three ionic environments (Extra, Intra and Endo).  
One-way ANOVA with Tukey post-test were performed using SigmaStat 3.0. **p < 0.01 
represent comparison of intracellular or endosomal to the extracellular condition. ANOVA 
results: KD F (2,9) = 2.01, p  = 0.19; Bmax F (2,9) = 13.61, p = 0.002. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Condition KD (nM) Bmax (fmol/mg protein) 
Extra 0.33 ± 0.017 286.1 ± 22
 
Intra 0.27 ± 0.072 261.9 ± 19
**
 
Endo 0.36 ± 0.053
 
127 ± 26
**
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Figure 4.2.  Saturation curves of [
3
H]diprenorphine using rat whole brain minus 
cerebellum in the three physiological environments.  
Results are expressed as the mean ± s.e.mean from four independent observations, each 
performed in triplicate. 
 
When both changes in affinity and receptor availability are taken into consideration 
with one output variable i.e. in vitro BP, binding was significantly lower in the 
endosomal environment for [
3
H]diprenorphine compared with both the intracellular 
and extracellular (Table 4.4.). 
 
Table 4.4.  Bmax (nM), in vitro BP and Per cent Reduction in in vitro BP observed in the 
endosomal condition compared with the extracellular condition values for 
[
3
H]diprenorphine in the three cellular environments 
Condition Bmax (nM
$
) In vitro BP 
% Change From 
Extracellular In vitro 
BP 
Extra 10.42 ± 1.08 35.59 ± 1.60 100 
Intra 9.54 ± 0.71 35.83 ± 3.04 103.71 ± 7.61
 
Endo 5.33 ± 1.20
**/#
 17.36 ± 0.69
**/##
 50.33 ± 1.86
**/## 
 
Values for [
3
H]diprenorphine using rat whole brain minus cerebellum (n = 4, 
mean ± s.e.mean) in the three ionic environments (Extra, Intra and Endo).  One-way ANOVA 
with Tukey post-test were performed using SigmaStat 3.0.  **p < 0.01 represent comparison 
of endosomal to the extracellular condition.  #p < 0.05 and ##p < 0.01 represent comparison 
between endosomal and the intracellular condition.  Bmax in nM calculated using Equation 1 
(Section 2.2.6.). 
$
Assumes 1g of tissue equivalent to 1ml.  In vitro BP values determined 
using Equation 2 (Section 2.2.6.). ANOVA results: In vitro BP F (2,9) = 27.43, p  < 0.001. 
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4.4.1.1.2.  Studies in CHO cells 
Data from studies conducted in stably transfected CHO cells were best fitted to a 
single-site model for KD and Bmax determination.  Affinity was significantly lower 
with µ-CHO cells in the endosomal compared with the extracellular condition 
(p < 0.05 Table 4.5.; Figure 4.3.).  Additionally,  Bmax values were lower with both µ 
receptor-CHO and δ receptor-CHO cells in the endosomal condition compared with 
the extracellular (p < 0.05 for µ and p < 0.01 for δ).  No significant differences in Bmax 
were observed in any of the conditions tested with ĸ receptor-CHO cells.  
 
Table 4.5.  KD and Bmax values for [
3
H]diprenorphine cell binding studies in the three 
cellular environments 
 
 
KD (nM), Bmax (DPM) and %Bmax values for [
3
H]diprenorphine in stably expressing µ- δ- or ĸ-
receptor CHO cells (n  = 4, mean ± s.e.mean) in the three ionic environments (Extra, Intra and 
Endo).  One-way ANOVA with Tukey post-test were performed using GraphPad Prism 5.0. 
*p < 0.05 and **p < 0.01 represent comparison of endosomal with the extracellular condition. 
#p < 0.05 and ##p < 0.01 represent comparison between endosomal and the intracellular 
condition. 
$
p < 0.05 represents comparison between intracellular and extracellular condition. 
ANOVA results: µ receptor-CHO, KD F (2,9) = 20.48, p < 0.001; Bmax F (2,9) = 7.70, 
p = 0.011. δ receptor-CHO, KD F (2,9) = 1.83, p = 0.22; Bmax F (2,9) = 10.92, p = 0.004. ĸ 
receptor-CHO, KD F (2,9) = 1.80, p = 0.22; Bmax F (2,9) = 0.283, p  = 0.761. 
Cell Type Condition KD (nM) Bmax (DPM) 
%Bmax of 
Extracellular 
µ receptor -CHO 
Extra 0.55 ± 0.02 23620 ± 1991
 
100 
Intra 0.85 ± 0.09 24908 ± 1857
 
106 ± 6 
Endo 4.38 ± 0.81
* 
14785 ± 2103
*/# 
64 ± 12
*/# 
δ receptor -CHO 
Extra 0.64 ± 0.10 9487 ± 1166 100 
Intra 0.44 ± 0.11 7157 ± 788
 
76 ± 5
$ 
Endo 0.41 ± 0.06 3912 ± 416
** 
45 ± 3
**/## 
ĸ receptor-CHO 
Extra 0.31 ± 0.08 6645 ± 3130 100 
Intra 0.47 ± 0.13 7042 ± 2654 132 ± 26 
Endo 0.96 ± 0.41 4381 ± 2260 60 ± 10
*/# 
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Figure 4.3.  Changing affinity values for [
3
H]diprenorphine binding to µ, δ or ĸ 
receptor-CHO cells in the three physiological environments .   
Results are expressed as the mean ± s.e.mean from four independent observations, each 
performed in triplicate. 
 
 
Due to Bmax values in cell studies being dictated by the number of cells per/well and 
the inherent variability in cell counting and cell viability between passage and assay 
day, percentage Bmax changes for the intracellular and endosomal conditions were 
calculated as a function of the extracellular Bmax. A significant reduction in percentage 
Bmax was observed in the endosomal compared with the extracellular and also in the 
intracellular compared with the endosomal condition for all three cell lines (i.e. µ-, δ-, 
κ receptor-CHO cells).  The percentage Bmax was also significantly lower in the 
intracellular compared with the extracellular condition for the δ-receptor CHO cells 
(Table 4.5.; Figure 4.4.). 
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Figure 4.4.  Percentage Extracellular Bmax values for [
3
H]diprenorphine binding to µ, δ 
or ĸ receptor CHO cells in the three physiological environments.   
Results are expressed as the mean ± s.e.mean from four independent observations, each 
performed in triplicate. 
 
4.4.1.2.  Competition binding studies with endogenous opioid 
peptides - [
3
H]diprenorphine 
The following rank order of affinities for [
3
H]diprenorphine labelled sties was 
observed using a range of unlabelled endogenous opioid peptides: endomorphin-1 > 
endomorphin-2 > met-enkephalin > leu-enkephalin > β-endorphin > dynorphin-A > 
dynorphin-A (Table 4.6., Figure 4.5.).  For leu- and met-enkephalin and 
endomorphin-1 and -2, data were best fitted to a two-site model where the high 
affinity binding site represented 39%, 40%, 50% and 46% of total binding, 
respectively, for these 4 endogenous opioid peptides. 
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Table 4.6.  Ki values generated for a range of endogenous opioid peptides from 
competition studies performed with [
3
H]diprenorphine in rat whole brain (minus 
cerebellum) tissue homogenates in the extracellular condition 
 
Opioid Peptide High Affinity Site (nM) Low Affinity Site (nM) 
β-endorphin 300 ± 9 -- 
Leu-enkephalin 200 ± 55 42,200 ± 18,000 
Met-enkephalin 125 ± 35 18,900 ± 6,500 
Dynorphin A 1.3 ± 0.1 -- 
Dynorphin B 0.6 ± 0.1 -- 
Endomorphin-1 45.5 ± 5.9 7,100 ± 600 
Endormorphi-2 65.6 ± 10.4 19,300 ± 8,100 
 
n = 3 for dynorphin-A/-B and β-endorphin; n = 4 for Leu-enkephalin and endomorphin-2; 
n = 4 for Met-enkephalin and endomorphin-1; mean ± s.e.mean.  Data analysed using 
GraphPad 5.0. 
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Figure 4.5.  [
3
H]Diprenorphine competition binding curves for endogenous opioid 
peptides 
 
 
4.4.1.3.  [
11
C]Carfentanil saturation binding studies 
Data from [
11
C]carfentanil saturation studies all fitted to a single-site model for KD 
and Bmax determination.  No significant differences in affinity were observed for 
[
11
C]carfentanil between any of the cellular environments tested.  Receptor 
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availability (Bmax) values were significantly lower in the endosomal compared with 
the extracellular condition (p < 0.05; Table 4.7., Figure 4.6.).  
 
Table 4.7.  KD and Bmax values for [
11
C]carfentanil tissue binding in the three cellular 
environments 
 
 
KD (nM) and Bmax (fmol/mg protein) values for [
11
C]carfentanil in rat whole brain minus 
cerebellum (n = 5, mean ± s.e.mean) in the three ionic environments (Extra, Intra and Endo).  
One-way ANOVA with Tukey post-test were performed using SigmaStat 3.0. *p < 0.05 
represent comparison of intracellular or endosomal to the extracellular condition. ANOVA 
results: KD F (2,9) = 0.80, p  < 0.48; Bmax F (2,12) = 4.27, p  = 0.04. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.  Saturation binding curves of [
11
C]carfentanil using rat whole brain minus 
cerebellum in the three physiological environments.   
 
When in vitro binding potentials were determined for [
11
C]carfentanil in the three 
cellular environments, no significant differences were observed between any of the 
conditions investigated.  However a trend for a lower in vitro BP was observed in the 
Condition KD (nM) Bmax (fmol/mg protein) 
Extra 0.32 ± 0.13 81.5 ± 11.6 
Intra 0.80 ± 0.68 66.4 ± 16.5 
Endo 0.77 ± 0.46
 
52.7 ± 10.4
*
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endosomal condition compared with the extracellular (Table 4.8.).  This may be 
driven by the variability observed with KD values in the endosomal condition. 
 
Table 4.8.  Bmax (nM), in vitro BP and Percentage reduction in in vitro BP observed in the 
endosomal condition compared with the extracellular condition values for 
[
11
C]carfentanil in the three cellular environments 
 
Condition Bmax (nM
$
) In vitro BP 
% Change From 
Extracellular In vitro 
BP 
Extra 7.1 ± 3.6 19.9 ± 8.3 100 
Intra 6.5 ± 3.7 15.6 ± 9.5 92.8 ± 46.5 
Endo 5.4 ± 2.5 9.7 ± 3.1 52.2 ± 11.1 
 
Values for [
11
C]carfentanil using rat whole brain minus cerebellum (n = 5, mean ± s.e.mean) 
in the three ionic environments (Extra, Intra and Endo).  One-way ANOVA with Tukey 
post-test were performed using SigmaStat 3.0. Bmax in nM calculated using Equation 1. 
$
Assumes 1g of tissue equivalent to 1ml.  In vitro BP values determined using Equation 2. 
ANOVA results: In vitro BP F (2,12) = 0.47, p  = 0.64. 
 
 
4.4.1.4.  Competition binding studies with endogenous opioid 
peptides - [
11
C]carfentanil 
All peptides displaced [
11
C]carfentanil binding, with data best fitting to a single-site 
model of binding.  The following rank order of affinities were observed for the 
endogenous peptides tested: β-endorphin > endomorphin-1 > endomorphin-2 > leu-
enkephalin > met-enkephalin (Table 4.9.).  Dynorphin-A and -B were excluded from 
this series of experiments due to their low affinity for the µ-receptor. 
 
 
Table 4.9.  Ki  values generated for a range of endogenous opioid peptides from 
competition studies performed with [
11
C]carfentanil in rat whole brain (minus 
cerebellum) tissue homogenates in the extracellular condition 
 
β-endorphin 
(nM) 
Leu-enkephalin 
(nM) 
Met-enkephalin 
(nM) 
Endomorphin-1 
(nM) 
Endormorphin-2 
(nM) 
22 ± 7 124 ± 102 176 ± 110 34 ± 15 57 ± 20 
 
n = 4 for all peptides tested; mean ± s.e.mean.  Data analysed using GraphPad 5.0. 
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4.4.2.  In vivo studies uptake and distribution of [
3
H]diprenorphine and 
[
11
C]carfentanil 
4.4.2.1.  [
3
H]Diprenorphine dosing 
For this study, rats received an average of 0.86 ± 0.19 MBq dose of [
3
H]diprenorphine 
administered i.v. in a volume of 206 ± 5.1 µl. Following administration, the highest 
uptake in saline treated animals was observed in the colliculi, periaqueductal grey 
(PAG), thalamus, amygdala and striatum of these rodents.  A significant effect of both 
brain region (p < 0.001) and drug treatment (amphetamine and methadone; p < 0.01) 
on [
3
H]diprenorphine uptake values was observed.  However, no interaction between 
brain region and drug treatment was observed (Table 4.10. and Figure 4.7.).  
 
Table 4.10.  Brain uptake values for [
3
H]diprenorphine 
 
Region
*** 
Saline
##
 Amphetamine
##
 Methadone
##
 
superior colliculi 130.76 ± 25.31 129.33 ± 16.98 160.00 ± 12.97 
PAG 111.29 ± 20.86 113.54 ± 13.69 119.30 ± 19.92 
inferior colliculi 102.88 ± 16.73 114.65 ± 24.73 129.73 ± 31.91 
thalamus 85.05 ± 16.30 92.82 ± 14.59 112.44 ± 16.85 
hypothalamus 81.88 ± 13.50 86.92 ± 14.91 79.41 ± 29.90 
striatum 79.86 ± 14.86 84.32 ± 11.87 108.19 ± 20.46 
prefrontal 73.34 ± 14.82 81.28 ± 16.69 93.85 ± 18.48 
spinal cord 72.12 ± 15.04 63.59 ± 12.24 99.86 ± 7.30 
amygdala 69.59 ± 17.43 80.00 ± 19.19 107.83 ± 12.42 
olfactory tubercle 66.45 ± 8.28 72.06 ± 7.17 86.90 ± 16.17 
hippocampus 60.48 ± 12.57 59.91 ± 11.06 91.75 ± 7.44 
somatosensory 59.53 ± 10.35 67.09 ± 13.73 81.98 ± 22.86 
anterior cingulate 59.29 ± 10.26 72.22 ± 10.40 91.92 ± 18.03 
visual cortex 57.83 ± 11.03 59.96 ± 9.91 62.72 ± 17.91 
medulla and pons 55.87 ± 11.46 64.49 ± 11.80 74.92 ± 16.22 
cerebellum 15.29 ± 2.53 15.03 ± 1.93 47.19 ± 14.72 
Plasma 14.02 ± 2.30 14.40 ± 0.21 17.57 ± 3.51 
Blood 7.78 ± 2.55 7.43 ± 1.29 12.79 ± 2.62 
n = 5 for all rats treated with saline and amphetamine; n = 4 for all rats treated with 
methadone. n = 3 for blood and plasma in all treatment groups; mean ± s.e.mean.  Two-way 
ANOVA with Tukey post-test performed with SigmaStat 3.0. ## p < 0.01 treatment effects; 
***p < 0.001 region effects. 
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Figure 4.7.  Brain uptake for [
3
H]diprenorphine.   
n = 5 for all rats treated with saline and amphetamine; n = 4  for all rats treated with 
methadone. n = 3 for blood and plasma for all treatment groups; mean ± s.e.mean. ANOVA 
results: Region F (15,174) = 8.73, p  < 0.001; Treatment F (2,174) = 7.25, p  < 0.001; 
Region x Treatment F (30,174) = .0219, p  = 1 
 
 
 
In order to correct uptake values in brain regions for any changes in non-specific 
uptake, values were determined for the cerebellum, plasma and whole blood.  There 
was an apparent increase in whole blood compared with Saline and Amphetamine 
treated animals but like the plasma this did not reach significance.  However, 
cerebellum uptake values were significantly higher in methadone treated animals 
compared with saline and amphetamine (both p < 0.01; Figure 4.8.)  
 
 
Figure 4.8.  [
3
H]Diprenorphine
 
cerebellum, whole blood and plasma uptake values  
ANOVA results: Cerebellum F (2,9) = 4.52, p  < 0.04; Blood F (2,9) = 1.79, p  < 0.22; 
F (2,9) = 0.64, p  < 0.55. 
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When changes in cerebellum uptake were taken into consideration there was an 
apparent reduction in [
3
H]diprenorphine uptake across all brain regions. This reached 
significance in three regions (superior and inferior colliculi, and periaqueductal grey) 
when comparing saline with methadone (p < 0.01); and amphetamine with methadone 
(p < 0.01, 0.05 and 0.01 respectively for all three regions; Figure 4.9.). 
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Figure 4.9.  Brain uptake for [
3
H]diprenorphine – region:cerebellum values. 
n = 5 for saline and amphetamine treated groups.  n = 4  for the methadone treated group.  
n = 3 for blood and plasma for all treatment groups; mean ± s.e.mean; two-way ANOVA with 
Tukey post-test performed with SigmaStat 3.0.* p < 0.05, **p < 0.01. ANOVA results: 
Region F (14,164) = 6.78, p  < 0.001; Treatment F (2,164) = 37.26, p  < 0.001; 
Region x Treatment F (28,164) = 0.372, p  = 0.98. 
 
 
When changes [
3
H]diprenorphine binding relative to whole blood uptake were taken 
into consideration, a significant effect of both brain region (p < 0.01) and drug 
treatment (p < 0.01) on [
3
H]diprenorphine uptake values was observed.  No 
significant differences were observed between regions in all treatment groups (Figure 
4.10.).  
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Figure 4.10.  Brain uptake for [
3
H]diprenorphine – region:whole blood values. 
n = 5 for saline and amphetamine treated groups; n = 4 for methadone treated group; 
mean ± s.e.mean. ANOVA results: Region F (17,183) = 9.06, p < 0.001; Treatment 
F (2,183) = 1.91, p < 0.15; Region x Treatment F (34,183) = 0.247, p  = 1. 
 
When changes in [
3
H]diprenorphine binding relative to plasma uptake levels were 
taken into consideration a significant effect of uptake into brain regions was detected 
(p < 0.001).  However, no effects of drug treatment were observed (Figure 4.11.). 
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Figure 4.11.  Brain uptake for [
3
H]diprenorphine – region:plasma values.   
n = 5 for all brain saline and amphetamine treated groups; n = 4 methadone treated group; 
mean ± s.e.mean. ANOVA results: Region F (15,174) = 8.78, p < 0.001; Treatment 
F (2,174) = 0.038, p  < 0.96; Region x Treatment F (30,174) = 0.248, p  = 1. 
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No relationship was detected between uptake following saline treatment and 
percentage change in uptake following either amphetamine or methadone whether the 
data were used with or without ratioing to blood or cerebellar uptake (Appendix 
8.2.1.). 
4.4.2.2.  [
11
C]Carfentanil dosing 
Rodents received an average of 12.4 ± 1.05 MBq of [
11
C]carfentanil i.v. with an 
averaged mass dose of 6.8 ± 0.87 µg/Kg or 1.64 ± 0.22 µg/animal.  The highest 
uptake was observed in the amygdala, hypothalamus, periaqueductal grey and the 
superior and inferior colliculi.  Lowest uptake levels were found in the cerebellum 
(Table 4.11.).  When comparing raw uptake values, there was a significant effect of 
both treatment and tissue region on the [
11
C]carfentanil binding (both p < 0.001). 
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Table 4.11.  Brain uptake values for [
11
C]carfentanil 
 
Region
*** 
Saline
##
 Amphetamine
##
 Methadone
##
 
Hypothalamus 1.52 ± 0.67 0.68 ± 0.073$$
 
0.87 ± 0.11 
Superior Colliculi 1.40 ± 0.54 0.73 ± 0.23$$
 
0.74 ± 0.15
$ 
Inferior Colliculi 1.11 ± 0.18 0.70 ± 0.11 1.11 ± 0.18 
PAG 1.29 ± 0.31 0.77 ± 0.13 1.10 ± 0.10 
Amygdala 1.22 ± 0.14 0.53 ± 0.027$
 
0.99 ± 0.14 
Medulla 0.79 ± 0.18 0.34 ± 0.054 0.51 ± 0.081 
Thalamus 0.78 ± 0.079 0.49 ± 0.079 0.70 ± 0.060 
striatum 0.71 ± 0.044 0.56 ± 0.072 0.69 ± 0.082 
Prefrontal Cortex 0.55 ± 0.091 0.42 ± 0.046 0.53 ± 0.080 
Hippocampus 0.55 ± 0.047 0.33 ± 0.035 0.45 ± 0.042 
Visual cortex 0.50 ± 0.091 0.29 ± 0.074 0.48 ± 0.054 
Anterior Cingulate 0.45 ± 0.057 0.38 ± 0.041 0.46 ± 0.070 
Somatosensory 
cortex 
0.37 ± 0.082 0.33 ± 0.025 0.41 ± 0.059 
Cerebellum 0.12 ± 0.01 0.12 ± 0.019 0.14 ± 0.018 
Plasma
@ 
398.4 ± 33.2 394.7  ± 73.4 446.1 68.1 
Blood
@ 
346.7 ± 16.8 316.4  ± 92.0 354.0  ± 29.2 
 
n = 4 for saline and amphetamine treated groups; n = 5 for methadone treated group. n = 3 for 
blood and plasma for all treatment groups; mean ± s.e.mean; two-way ANOVA with Tukey 
post-test performed with SigmaStat 3.0. ## p < 0.001 treatment effects; ***p < 0.001 region 
effects. 
$
 p < 0.05 and 
$$
p < 0.01 represent comparisons between amphetamine or methadone 
and saline treated animals.  @ Data represented as uptake per mg of whole blood or plasma. 
 
 
An interaction was observed between brain region and treatment in the superior 
colliculi, amygdala and hypothalamus.  Specifically, a significant reduction was 
observed with the superior colliculi in amphetamine and methadone treated group 
compared with saline (both p < 0.01).  [
11
C]Carfentanil uptake was also significantly 
reduced in the amphetamine treated groups in the hypothalamus (p < 0.01) and 
amygdala (p < 0.05) compared with saline (Table 4.11, Figure 4.12.). 
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Figure 4.12.  Brain uptake for [
11
C]carfentanil.   
n = 4 for saline and amphetamine treated groups; n = 5 methadone treated group.  Two-way 
ANOVA with Tukey post-test performed with SigmaStat 3.0.  *p < 0.05 and **p < 0.01 
represent comparisons between amphetamine or methadone and saline treated animals. 
ANOVA results: Region F (13,123) = 7.56, p < 0.001; Treatment F (2,123) = 11.936, 
p  < 0.001; Region x Treatment F (26,123) = 0.733, p  = 0.820. 
 
 
Uptake values were also expressed as ratios of cerebellum uptake values in order to 
remove any changes in non-specific [
11
C]carfentanil brain uptake associated with this 
region.  Plasma and whole blood uptake were also determined.  No significant 
differences in cerebellar, blood or plasma uptake were observed in the methadone or 
amphetamine treated groups compared with saline (Figure 4.13.). 
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Figure 4.13.  [
11
C]Carfentanil cerebellum, whole blood and plasma uptake values 
ANOVA results: Cerebellum F (2,9) = 0.44, p < 0.66; Blood F (2,6) = 0.128, p < 0.89; Plasma 
F (2,6) = 0.22, p = 0.808. 
 
 
When the tissue region:cerebellar ratios were generated, a significant reduction in 
uptake  was observed in the amphetamine and methadone treated groups (both 
p < 0.05) in the hypothalamus when compared with the saline treated group (Figure 
4.14.). 
 
Figure 4.14.  Brain tissue region:cerebellum uptake values for [
11
C]carfentanil 
n = 4 for all brain regions with saline and amphetamine. n = 5 for all brain regions with 
methadone. Two-way ANOVA with Tukey post-test performed with SigmaStat 3.0.  
*
p < 0.05 
represent comparisons between amphetamine or methadone and saline treated animals. 
ANOVA results: Region F (12,114) = 5.607, p < 0.001; Treatment F (2,114) = 11.904, 
p < 0.001; Region x Treatment F (24,114) = 0.743, p = 0.797. 
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For either Uptake Values or Brain Tissue Uptake:Cerebellum values, a relationship 
was observed between the uptake of [
11
C]carfentanil in brain regions from the saline 
treated group and the percentage change following either amphetamine or methadone 
treatment (Figure 4.15.).  Specifically, an increased regional uptake under saline 
conditions was related with an increased percentage change following either 
amphetamine (uptake values r
2
 = 0.23, p = 0.001; tissue cerebellum r
2
 = 0.18, 
p = 0.0011) or methadone (uptake values r
2
 = 0.22, p < 0.0001; tissue cerebellum 
r
2
 = 0.23, p < 0.0001; Figure 4.15.).  
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Figure 4.15.  Correlation between regional uptake following saline treatment with per 
cent change in uptake following either amphetamine or methadone.  
n = 4 for saline and amphetamine treated groups and n = 5 for methadone treated group.  
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4.4.3.  Ex vivo studies - subcellular fractionation 
4.4.3.1.  Studies with [
3
H]Diprenorphine 
Following sub-cellular fractionation, no significant differences in total cell protein 
levels were observed between saline, amphetamine and methadone treated groups in 
P2, P3endo or S3 (Figure 4.16.).  The largest abundance of cell protein was found in 
the cytosol (S3) for all groups.  The smallest amount of cell protein was found in the 
microsomal fraction (P3endo; Figure 4.16.). 
 
 
 
 
 
 
 
Figure 4.16.  Distribution of cell protein between P2, P3endo and S3 fractions (n = 5).  
One-way ANOVA performed with GraphPad Prism 5.0. ANOVA results: Saline 
F (2,11) = 0.049, p < 0.952; Treatment F (2,11) = 0.091, p < 0.91; Region x Treatment 
F (2,11) = 0.011, p = 0.988. 
 
 
No specific binding of [
3
H]diprenorphine was observed in any of treatment groups in 
the cytosol.  As a result, for [
3
H]diprenorphine: the total homogenate binding, the 
percentage total binding per fraction and all relative specific activity calculations have 
only been generated for the membrane (P2) and microsomal (P3endo) fractions.  
There was no significant difference observed between the total homogenate binding 
for [
3
H]diprenorphine following saline (1302  218 fmol), amphetamine 
(1240  157 fmol) or methadone (1046  80 fmol) treatments (Figure 4.17.). 
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Figure 4.17.  Total homogenate [
3
H]diprenorphine binding from saline, amphetamine 
and methadone treated rats (n = 5).   
One-way ANOVA performed with GraphPad Prism 5.0. ANOVA results: F (2,12) = 0.67, 
p < 0.53. 
 
The percentage total homogenate binding per fraction data suggests for all treatment 
groups the majority of cell binding is present in the membrane fraction (between 
94-97%) and that the microsomal fraction would contribute very little to the overall 
total tissue binding (between 3-6%; Figure 4.18.).  No significant differences in 
percentage of total homogenate fraction binding were observed between any of the 
treatment groups in either the membrane or microsomal fractions (Figure 4.18.). 
 
 
Figure 4.18.  Per cent total homogenate binding per fraction in saline, amphetamine and 
methadone treated rats (n = 5).   
One-way ANOVA performed with GraphPad Prism 5.0. ANOVA results: P2 F (2,12) = 1.56, 
p < 0.25; P3endo F (2,11) = 2.83, p  = 0.10 
 
When both protein abundance per fraction, and per cent total homogenate binding per 
fraction were taken into consideration, RSA values are generated (see Equation 4).  
The total homogenate RSA values for [
3
H]diprenorphine were not found to be 
significantly different between treatment groups (3.86  0.47 for saline; 3.38  0.23 
for amphetamine and 3.56  0.31 for methadone; Figure 4.19.). 
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Figure 4.19.  Total homogenate [
3
H]diprenorphine RSA values in saline, amphetamine 
and methadone treated rats (n = 5). 
One-way ANOVA performed with GraphPad Prism 5.0., RSA values determined using 
Equation 3 (Section 2.2.6.). ANOVA results: F (2,9) = 0.46, p = 0.65. 
 
 
When the RSA values were separated into their corresponding P2 and P3endo 
components, amphetamine (P2: 3.04  0.25; P3endo: 0.34  0.11) and methadone 
(P2: 3.01  0.44; P3endo: 0.55  0.13) treatment groups were not significantly 
different compared with the saline treated group (P2: 3.34  0.50; P3endo: 
052  0.13; see Figure 4.20). 
 
Figure 4.20.  RSA values per fraction in saline, amphetamine and methadone treated 
rats (n = 5). 
One-way ANOVA performed with GraphPad Prism 5.0., RSA values determined using 
Equation 4 (Section 2.2.6.). ANOVA results: P2 F (2,9) = 0.197, p < 0.825; P3endo 
F (2,9) = 0.843, p  = 0.462 
 
These data demonstrate that P2 constitutes the largest percentage of total tissue 
binding for [
3
H]diprenorphine: where saline = 87.01  3.92%; 
amphetamine = 91.38  3.25% and methadone = 84.8 ± 4.83%.  This proportion of 
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binding for [
3
H]diprenorphine does not appear to be altered following acute 
amphetamine or methadone treatment.  P3endo contributes to binding of 
[
3
H]diprenorphine in whole brain homogenates but to a much lesser degree: 
saline = 12.99  3.92 %; amphetamine = 8.62  3.24 % and 
methadone = 15.20  4.82 %; Figure 4.21.).   
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Figure 4.21.  [
3
H]Diprenorphine RSA values per fraction as a function of fraction 
protein content in saline, amphetamine and methadone treated rats (n = 5).   
RSA values determined using Equation 3 (Section 2.2.6.). 
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4.4.4.2.  Ex vivo studies – [3H]Diprenorphine autoradiography 
When [
3
H]diprenorphine binding following either saline, amphetamine or methadone 
treatment was assessed using ex vivo autoradiography, a significant effect of both 
region (p < 0.01) and treatment (p < 0.01) were observed. However, individual 
pair-wise comparisons within a region, between treatment groups, demonstrated no 
significant differences (Table 4.12.; Figure 4.22.).  
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Figure 4.22.  Autoradiographical determination of [
3
H]diprenrophine bound in saline, 
amphetamine and methadone treated rats. 
n = 3 for saline, amphetamine and methadone treated groups; mean ± s.e.mean 
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Table 4.12.  Autoradiographical determination of [
3
H]diprenorphine binding 
 
n = 3 for saline, amphetamine and methadone treated groups; mean ± s.e.mean; two-way ANOVA with 
Tukey post-test performed with SigmaStat 3.0. ANOVA results: Region F (33,201) = 2.19, p  = 0.0005; 
Treatment F (2,201) = 4.89, p  = 0.008; Interaction F (66,201) = 0.53, p  = 0.99. 
Region Saline  
(fmol/mg) 
Amphetamine  
(fmol/mg) 
Methadone  
(fmol/mg) 
PAG 125.9 ± 17.6 129.3 ± 16.1 120.5 ± 6.1 
cerebellum 122.5 ± 16.1 134.1 ± 5.4 113.7 ± 6.7 
hypothalamus 138.5 ± 20.3 136.3 ± 9.6 140.4 ± 11.1 
arcuate nucleus 128.1 ± 15.7 113.1 ± 11.8 121.4 ± 5.9 
ventral pallidum 100.9 ± 26.7 95.4 ± 13.1 113.5 ± 12.7 
globus pallidum 120.3 ± 6.6 104.0 ± 10.1 109.3 ± 6.7 
olfactory bulb 118.8 ± 6.0 105.2 ± 8.4 111.4 ± 6.2 
central grey 150.0 ± 11.8 56.3 ± 7.4 87.4 ± 23.6 
caudate nucleus 128.0 ± 17.4 91.1 ±15.9 100.2 ± 18.1 
CA3 120.9 ± 5.6 103.8 ± 6.7 136.3 ± 17.4 
CA1 128.0 ± 17.1 106.6 ± 11.1 138.7 ± 48.3 
dentate gyrus 130.5 ± 10.8 107.9 ± 6.0 120.9 ± 1.5 
entorhinal cortex 129.0 ± 12.7 108.6 ± 11.5 114.5 ± 21.4 
motor cortex (entire) 121.6 ± 13.8 102.0 ± 6.8 114.2 ± 9.4 
motor cortex (layers I - III) 124.6 ± 11.4 99.9 ± 0.8 110.5 ± 3.7 
motor cortex (layer IV) 123.9 ± 12.7 91.4 ± 6.4 94.5 ± 23.3 
motor cortex (layer V) 124.4 ± 11.1 99.5 ± 4.7 95.9 ± 17.9 
cingulate cortex (entire) 125.2 ± 9.6 100.7 ± 4.5 97.8 ± 15.7 
cingulate cortex (layer I - III) 127.6 ± 7.9 98.7 ± 6.8 114.8 ± 8.1 
cingulate cortex (layer IV) 125.4 ± 9.8 93.2 ± 6.6 98.4 ± 20.1 
cingulate cortex (layer V) 128.3 ± 8.5 99.6 ± 9.0 93.5 ± 28.5 
prefrontal cortex (entire) 131.1 ± 6.7 104.2 ± 8.0 93.6 ± 26.9 
prefrontal cortex (layer I - III) 126.5 ± 8.0 100.7 ± 11.5 117.7 ± 9.6 
prefrontal cortex ( layer IV) 125.6 ± 8.8 97.8 ± 11.6 101.9 ± 17.5 
prefrontal cortex (layer V) 127.8 ± 7.3 103.7 ± 12.2 95.5 ± 29.7 
ventral striatum 125.8 ± 6.9 103.6 ± 11.5 97.9 ± 28.0 
dorsal striatum 123.2 ± 10.2 118.4 ± 6.0 130.8 ± 1.8 
superior colliculi 122.5 ± 8.7 119.3 ± 5.6 129.5 ± 3.1 
inferior colliculi 105.9 ± 17.4 115.3 ± 9.1 106.6 ± 9.5 
substantia nigra 112.2 ± 9.0 123.8 ± 9.6 102.9 ± 11.6 
preoptic area 133.2 ± 5.6 125.1 ± 13.9 115.2 ± 7.6 
auditory cortex 103.9 ± 1.9 99.6 ± 19.4 174.2 ± 65.8 
nucleus accumbens 118.1 ± 15.1 96.5 ± 5.5 115.0 ± 8.1 
nucleus tractus sollitarus 113.4 ± 6.2 104.2 ± 7.8 129.5 ± 9.7 
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4.4.3.3.  Studies with [
11
C[Carfentanil 
A single radioactive production of [
11
C]carfentanil was used for fractionation binding 
in all fractions and treatment groups.  [
11
C]carfentanil (3.33 nM) was used from a 
synthesis of 276 GBq/µmol with a radioactive concentration of 441.6 MBq/ml. 
 
Subcellular fractionation procedures were performed on a separate series of saline, 
amphetamine and methadone treated rat brains to those which were used for 
[
3
H]diprenorphine binding.  No significant differences in percentage total protein 
values between treatment groups and cell fractions were observed (Figure 4.23.).  
Similar to the [
3
H]diprenorphine study, the largest proportion of cell protein was 
found in the cytosol (S3) fraction.  The smallest abundance of cell protein was 
observed in the microsomal (P3endo) fraction (Figure 4.23.). 
 
Figure 4.23.  Distribution of cell protein in saline, amphetamine and methadone treated 
rats (n = 4).  
 
Unlike the data presented previously with [
3
H]diprenorphine, specific binding was 
observed in S3 fraction for [
11
C]carfentanil.  Therefore the cytosolic fraction cannot 
be considered to contribute negligibly to total tissue binding with [
11
C]carfentanil, and 
was therefore included in all further analysis.  The total homogenate binding for 
[
11
C]carfentanil was significantly reduced in the amphetamine treated animals 
(2101 ± 59.31 Bq) compared with saline treated animals (2993 ± 253 Bq; p < 0.05). 
No difference was observed between the saline and methadone (2393 ± 166 Bq) 
treated animals for the total homogenate binding (Figure 4.24.). 
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Figure 4.24.  Total homogenate [
11
C]carfentanil binding from saline, amphetamine and 
methadone treated rats (n = 4).  
 One-way ANOVA with Tukey post-test performed with GraphPad Prism 5.0. 
*
 Represents 
p < 0.05. ANOVA results: P2 F (2,6) = 6.51, p = 0.0314 
 
 
The greatest proportion of percentage total homogenate binding was observed in the 
membrane fraction (P2) for all treatment groups; where saline = 94.4  2.5%, 
amphetamine = 87.5  3.6 % and methadone = 90.4  3.3 %; Figure 4,25).  
 
Figure 4.25.  Per cent [
11
C[carfentanil binding per fraction in saline, amphetamine and 
methadone treated rats (n = 4). 
One-way ANOVA performed with GraphPad Prism 5.0. ANOVA results: P2 F (2,9) = 1.21, 
p < 0.34; P3endo F (2,9) = 0.93, p < 0.67; S3 F (2,6) = 0.052, p = 0.95. 
 
 
No significant differences were observed with percentage bound per fraction binding 
between the treatment groups.  However a trend for a treatment effect in microsomal 
values was observed (P3endo; p = 0.08), where both amphetamine (4.1  0.4 %) and 
methadone (4.3  1.1 %) values were increased compared with saline (3.4  0.4 %; 
Figure 4.26.) . 
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Figure 4.26.  Comparison of [
11
C]carfentanil binding per treatment group in P3endo 
fraction (n = 4).  
One-way ANOVA with Tukey post-test performed with GraphPad Prism 5.0. ANOVA 
results: P2 F (2,6) = 6.51, p = 0.0314 
 
 
When RSA values were determined for [
11
C]carfentanil binding, no significant 
differences were observed between the treatment groups (Figure 4.27.). 
 
 
 
 
 
 
 
 
Figure 4.27.  Total homogenate [
11
C]carfentanil RSA values (n = 4).  
One-way ANOVA with Tukey post-test performed with GraphPad Prism 5.0. ANOVA 
results: P2 F (2,9) = 0.091, p = 0.914 
 
 
Similar to the percentage total binding per fraction data, the RSA values demonstrated 
that for all treatment groups, membrane bound opioid receptors contribute the 
majority of the signal observed with [
11
C]carfentanil.  Both the microsomal and 
cytosolic receptors contributed very little to overall tissue binding (Figure 4.28.).  No 
significant differences were observed when the same cell fractions were compared 
between treatment groups. 
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Figure 4.28.  Cell fraction RSA values for [
11
C]carfentanil in saline, amphetamine and 
methadone treated rats (n = 4). 
RSA values determined using Equation 3 (Section 2.2.6.). ANOVA results: P2 F (2,9) = 0.35, 
p < 0.716; P3endo F (2,8) = 0.93, p < 0.43; S3 F (2,6) = 0.052, p = 0.95. 
 
 
These fractionation data demonstrate P2 to constitute the largest percentage of total 
tissue binding with [
11
C]carfentanil (saline = 93.5  0.5 %, 
amphetamine = 90.1  2.4 % and methadone = 91.9  0.5 %).  This distribution of cell 
binding is not altered following acute in vivo amphetamine or methadone treatment.  
Microsomal and cytosolic opioid receptor binding also contribute to the total 
[
11
C]carfentanil signal in whole brain homogenates, but to a much lesser degree 
(microsomal: saline = 5.9  0.7 %, amphetamine = 7.4  1.4 % and 
methadone = 6.4  1.2 %; cytosolic: saline = 1.8  0.5 %, amphetamine = 2.5  0.9 % 
and methadone = 2.5  1.5; Figure 4.29.). 
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Figure 4.29.  [
11
C]Carfentanil RSA values per fraction as a function of fraction protein 
content in saline, amphetamine and methadone (n = 4).   
RSA values determined using Equation 3 (Section 2.2.6.). 
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4.5.  Discussion 
Using the methodology developed in previous chapters, a novel, pharmacological 
approach to imaging endogenous opioid peptides release has been assessed with two 
opioid receptor radioligands.  The contribution of agonist-induced internalisation has 
also been investigated. 
 
Using tissue homogenate in vitro radioligand binding assays, both the agonist, 
[
11
C]carfentanil, and antagonist, [
3
H]diprenorphine, where shown to behave similarly; 
exhibiting significant reductions in receptor availability in endosomal environments 
compared with the environments found at the cell surface.  In cell homogenates stably 
expressing the µ receptor, a significant reduction in affinity for [
3
H]diprenorphine was 
also observed.  In vivo binding data with these ligands suggest that the agonist, 
[
11
C]carfentanil, may be more susceptible to endogenous release following acute 
amphetamine administration compared with the antagonist, [
3
H]diprenorphine.  
Significant reductions in [
11
C]carfentanil binding are observed in the colliculi, 
hypothalamus and the amygdala following amphetamine treatment.  Amphetamine 
treatment also led to a reduction in total homogenate binding sites for [
11
C]carfentanil 
when assessed in vitro using sub-cellular fractionation techniques. No such reductions 
were observed for [
3
H]diprenorphine.  
 
4.5.1.  Methodological 
4.5.1.1.  Influence of ionic conditions on opioid receptor radioligand binding 
The changes in receptor availabilities with [
3
H]diprenorphine and [
11
C]carfentanil are 
different from that which has previously been observed for the D2/3 receptor 
radioligands (i.e. a reduction in affinity in the endosomal condition compared with the 
extracellular).  These findings suggest that different proteins may behave differently 
following translocation to different sub-cellular compartments.   
 
Significant reductions in receptor availability were observed for both 
[
3
H]diprenorphine and [
11
C]carfentanil in tissue homogenates in the endosomal 
environment compared with the extracellular.  No difference in availability for either 
ligand was observed in the intracellular environment compared with the extracellular.  
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Similarly, studies in µ-, δ- and ĸ-receptor CHO cells demonstrated that for 
[
3
H]diprenorphine, these reductions in availability were not due to a single receptor 
sub-type not being able to bind in the endosomal condition, since reductions in Bmax 
were observed in all three cells types.  This suggestion is also extended by the 
observation that the selective δ receptor radioligand [3H]naltrindole (see Appendix 
8.2.2.) also exhibits a significant reduction in Bmax in tissue homogenates. 
 
Various lines of evidence suggest that the µ receptor may be regulated differently by 
changes in ionic conditions compared with both the δ and κ receptors.  In homogenate 
membranes generated from cells stably expressing the µ receptor, a significant 
reduction in affinity was observed with [
3
H]diprenorphine in the endosomal 
environment.  This was not observed with membranes generated from cells stably 
expressing either κ or δ receptors.  These changes in affinity might not have been 
detected in whole brain homogenates, due to the effect of both ĸ and δ receptors in the 
tissue preparation.  Furthermore, no change in affinity was observed with 
[
3
H]naltrindole in the endosomal condition compared with the extracellular in tissue 
homogenates (see Appendix 8.2.2.).  An approximate halving of [
11C]carfentanil’s 
affinity was also observed in tissue homogenates in the endosomal condition 
(0.77 ± 0.46 nM) compared with the extracellular (0.32 ± 0.13nM), although not 
significantly. 
 
The effects of changing ionic conditions on opioid receptor binding, has not been 
extensively investigated.  However, several groups have reported an increase in 
antagonist and a decrease in agonist binding following inclusion of sodium chloride in 
assay buffers (Pfeiffer et al., 1982; Chang et al., 1981).  These data suggest that in the 
buffer system implemented here, a shift from 140 mM in the extracellular buffer to 
10 mM intracellular or endosomal buffer sodium chloride, would lead to an increase 
in receptor availability for [
3
H]diprenorphine in either tissue or cell membrane 
preparations and a decrease in receptor availability for [
11
C]carfentanil.  This sodium 
chloride mediated decrease in agonist receptor availability has been observed in the 
studies presented here with [
11
C]carfentanil. The slight decrease in affinity observed 
in the endosomal condition, may also be due to a reduction of buffer magnesium 
levels (Pfeiffer et al., 1982).  Inclusion of 5 and 10 mM calcium in assay buffers has 
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been shown previously to decrease antagonist specific binding (Pert and Snyder, 
1973).  Calcium levels drop from 1.5 mM in the extracellular condition to 3 µM in the 
endosomal buffer, therefore these changes may also contribute to reductions in 
[
3
H]diprenorphine binding observed in the studies included in this chapter.  
 
Significant reductions in [
3
H]diprenorphine and [
11
C]carfentanil binding are also 
observed when pH was decreased in the endosomal environment compared with the 
extracellular, suggesting that the reduction in binding observed following 
internalisation of all three opioid receptors (since this trend is observed in µ-, δ- and κ 
receptor CHO expressing cells) is due to a conformational change induced in the 
receptor by an increase in hydrogen ion concentration too. Pre-exposure of 
membranes prepared from Sprague Dawley brains to a pH of  4.5 (in the absence of 
sodium or magnesium) is known to reduce [
3
H]-D-ala
2
-met
5
-enkephalin binding by 
~15 % compared with membranes pre-exposed to pH 7.4 (Childers et al., 1983).  A 
36 % reduction in Bmax was observed with [
11
C]carfentanil following a shift from 
pH 7.4 to pH 6.0 in the studies presented in this chapter.  This enhanced reduction in 
binding was observed with [
11
C]carfentanil and may be further explained by 
alterations in other monovalent ions described previously, as well as the pH shift.  
 
Collectively, these data suggest that following translocation to the endosomal 
compartment ~50 % and ~48 % (decrease in in vitro BP from extracellular to 
endosomal environments; Table 4.4. and 4.8.) of receptors in this sub-cellular pool 
will be un-able to bind [
3
H]diprenorphine and [
11
C]carfentanil, respectively. 
 
4.5.1.2.  Changes in binding in vivo - uptake and distribution of [
3
H]diprenorphine 
and [
11
C]carfentanil 
As outlined in the previous section, a significant reduction in [
11
C]carfentanil binding 
was observed following acute amphetamine treatment, and the magnitude of this 
reduction in binding following amphetamine (or methadone) was related to the initial 
regional uptake in saline treated animals. 
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Three regions where the greatest decreases in binding were observed included the 
hypothalamus, amygdala and superior colliculi. These are all relatively small brain 
regions (compared with areas of the cortex or the thalamus, for example); suggesting 
that variability in tissue dissections and tissue weights was not a significant 
contributing factor to the overall variability observed in this set of studies.  No 
significant differences in [
11
C]carfentanil
 
mass dose were observed between treatment 
groups. For all studies the use of anaesthesia was avoided since one hypothesis is that 
amphetamine induces opioid peptide release via its modulation of endogenous 
monoamine levels.  Various methods of inducible anaesthesia have been shown to 
increase monoamine (particularly dopamine) levels (Stahle et al., 1990, Whittington 
and Virág, 2006). Subjects were lightly warmed (5 minutes at 25-28 ⁰C) for tail 
dilation to occur before transfer to a Bollman’s restrainer and radioligand injection.  
Bollman’s restrainer time was minimised as much as possible. There were no 
significant differences in restraint time between the [
3
H]diprenorphine and 
[
11
C]carfentanil studies, therefore we do not expect altered levels of restraint stress to 
contribute to the differences in binding observed.  Finally, brains were extracted 
following rapid live cervical dislocation without perfusion.  This technique was 
chosen to reduce any confounders that may have arisen following either overdose of 
anaesthetic (i.e. rapid activation of GABAA receptor channels following 
pentobarbital) or rising level of CO2 exposure for induction of anaesthesia and 
subsequent dislocation.  In addition subsequent injections and confinement in gas 
chambers are likely to cause further stress, which could increase peptide release.  Live 
cervical dislocation allows for rapid and humane brain extraction and the avoidance of 
other pharmacological interventions. 
 
4.5.1.3.  Ex vivo studies – Autoradiography and Sub-cellular Fractionation binding 
In order to further define discrete regions where opioid receptor radioligand binding 
may be altered following either amphetamine or methadone treatment, ex vivo 
autoradiography was conducted. Due to the time constraints of working with 
[
11
C]carfentanil this was an extremely challenging procedure, requiring optimisation. 
However to reduce animal use, the hemisphere contralateral to that used for ex vivo 
microdissection and uptake assessment were frozen, sectioned and apposed to film. 
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We were unable to achieve rapid optimisation of assay conditions within the number 
of animals used for each treatment condition with the microdissection study. As such 
no data for [
11
C]carfentanil was produced from these studies; but the optimisation 
steps are shown in Appendix 8.2.3.  
 
No significant reduction in [
3
H]diprenorphine binding was observed following either 
amphetamine or methadone treatments using ex vivo autoradiography. Despite these 
findings being consistent with ex vivo microdissection and standard uptake data, these 
studies warranted further assessment. [
3
H]Diprenorphine binding is homogeneous 
throughout the various brain structures analysed. For example cerebellum levels are 
almost equivalent to thalamus and striatum. Qualitatively, binding also appeared the 
same throughout the brain sections and structures were not identifiable (Appendix 
8.2.4.). These data suggest that, despite the expected reduced resolution observed with 
ex vivo autoradiography compared with in vitro, perhaps this study has not worked 
well and the films should be re-apposed and analysed at a later date. 
 
To our knowledge we present here for the first time, the cellular composition of the 
[
11
C]carfentanil binding signal. Specifically, we suggest that ~92 % of 
[
11
C]carfentanil binding in rat whole brain is plasma membrane bound, ~6 % is due to 
receptors in the microsomal fraction and that ~2 % is due to cytosolic µ receptors 
retaining the ability to bind radioligand. Importantly, with respect to the impact of 
receptor internalisation on [
11
C]carfentanil binding signals, we report that 
amphetamine, a compound known to increase brain β-endorphin levels and internalise 
µ receptors, causes a significant reduction in total homogenate [
11
C]carfentanil 
binding sites and a trend for an increase in binding in the microsomal fraction. 
Together, with the in vitro saturation binding data presented in this chapter, this 
suggests that following amphetamine treatment, µ receptor endocytosis reduces total 
tissue binding by increasing the proportion of µ receptors in the microsomal fraction. 
Once present in this compartment [
11
C]carfentanil is subsequently less able to bind. 
We therefore suggest that µ receptor internalisation is a contributing factor to the 
reductions in binding observed in the ex vivo microdissection and uptake assessment 
studies also presented in this chapter. Amphetamine treatment, may also increase µ 
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receptor degradation, which may also account for a decrease in [
11
C]carfentanil 
binding. This will be further explored in Chapter 5. 
 
Consistent with these hypotheses, no change in [
3
H]diprenorphine cell binding 
distribution was observed following either amphetamine or methadone treatment. No 
reductions in total homogenate binding or RSA levels were also observed. These data 
suggest, that should amphetamine or methadone cause significant amounts of receptor 
translocation, then [
3
H]diprenorphine should bind both intra- and extracellularly in a 
similar fashion, and therefore these changes may not reduce the overall total binding 
observed in vivo for this ligand. 
 
An important caveat to mention with respect to the sub-cellular fractionation data 
presented in this chapter is that is has been conducted in whole brain homogenates 
(minus cerebellum). Despite reductions in [
11
C]carfentanil binding being observed 
throughout the brain following either amphetamine or methadone, the magnitude of 
change was related to uptake observed following saline. Therefore, we suggest that 
regional sub-cellular fractionation studies in areas such as hypothalamus, thalamus, 
striatum, cortex, would be advantageous to further assess these changes in receptor 
translocation using radioligand binding. However, since these studies would require 
large numbers of animals, they were not conducted.  
 
4.5.1.4.  Methadone, a positive control 
A methadone treatment group was included in all in vivo and ex vivo studies.  
Methadone was chosen as a compound which has previously been shown to cause 
endocytosis of opioid receptors and should decrease [
11
C]carfentanil binding.  When 
combined with fluorescent microscopy to assess opioid receptor internalisation, 
methadone will also allow for determination of [
3H]diprenorphine’s ability to bind to 
internalised receptors, which has previously been proposed in cell lines (Shapira et al., 
2001) since methadone is not expected to directly inhibit [
3
H]diprenorphine binding 
(Melichar et al., 2005).  See Chapter 5. 
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No changes in [
3
H]diprenorphine binding were observed following methadone pre-
treatment.  The dose used in these studies was identified by Garrido and co-workers 
(1999) as one which provides ‘analgesia with minimum adverse respiratory effects’ 
(Garrido et al., 1999).  Anecdotally, the rats in this study were initially less responsive 
and displayed no signs of altered respiration or distress.  However, the behavioural 
effects of methadone and amphetamine were not formally assessed in these studies.  
At the time of cervical dislocation animals were behaving similarly to saline treated 
animals.  
 
The data presented in this chapter shows a significant increase in cerebellum uptake 
following methadone treatment.  This may suggest that methadone treatment results in 
a change of specific [
3
H]diprenorphine binding in a non-displaceable compartment.  If 
this were the case, the change is likely due to increased δ or κ receptor levels, since no 
change in cerebellum uptake with [
11
C]carfentanil is observed following methadone.  
However, since a generalised increase in whole blood radioactivity was observed and 
a trend for an increase in all regions uptake values was seen following methadone, an 
increase in [
3
H]diprenorphine bioavailability following methadone cannot be ruled 
out.  This hypothesis is supported by Melichar and co-workers (2005) who observed 
an initial increase in striatum and thalamus binding after methadone (from 0 to 90 
minutes), a slight (but non-significant) increase in cerebellum binding following 
methadone dosing, and an increase in plasma level radioactivity content after 
methadone (taken from previously catheterised tail artery).  Increased levels of 
cerebellar [
11
C]diprenorphine binding have also been noted following oxycodone and 
morphine pre-treatment (Hume et al., 2007).  Hume and co-workers (2007) further 
report an increase in plasma [
11
C]diprenorphine 
 
radioactivity content in arterial 
plasma samples taken following a range of other opiate full- and partial agonists, 
consistent with a generalised increase in bioavailability (Hume et al., 2007).  
Displacement of [
3
H]diprenorphine from peripheral µ receptors (in blood cells, 
peripheral nociceptive neurons or in the gut) may lead to an increase in circulating 
free radioactivity, leading to an increase in binding in all regions.  However, since we 
have not determined the time course of methadones effects or measured free fraction 
directly, this cannot be definitively concluded from our data.  
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No significant changes in [
11
C]carfentanil binding were observed following 
methadone treatment.  However a trend for a reduction in binding was observed in 
superior colliculi, periaqueductal grey, medulla and hypothalamus.  Additionally, 
regions with high uptake of [
11
C]carfentanil in the saline treatment group were related 
with the greatest reduction in binding following methadone.  To our knowledge, 
methadone’s’ occupancy in vivo has not been determined with [11C]carfentanil.  Kling 
and co-workers (2000) report decreases in [
18
F]cyclofoxy binding in the thalamus, 
caudate, anterior cingulate and the temporal and frontal cortex following methadone 
treatment.  Changes in binding were related to plasma concentrations of methadone 
(Kling et al., 2000).
  
These changes in binding are not thought to represent changes in 
κ receptor occupancy, to which [18F]cyclofoxy also binds. The plasma levels of 
methadone reported by Kling and co-workers (2000) range from 300 – 400 ng/ml, 
several orders of magnitude greater than those which may be present in the rat plasma 
from the studies presented here (based on Garrido et al (1999)).  Methadone is a 
P-glycoprotein substrate, and its brain entry and anti-nociceptive function is increased 
in animals lacking multi-drug resistance 1a/b gene, which encodes P-glyco protein 
(Hassan et al., 2009).  The subjects in Kling et al (2000) were long-term methadone 
maintained subjects.  It could therefore be speculated that since methadone levels in 
these patients were at a plateau and that they had been receiving treatment for 7.6 
years (mean) P-glyco-protein could be saturated, facilitating further entry of 
methadone into the brain.  Whereas following acute exposure, such as in the studies 
presented here, a lack of transport protein saturation and, subsequently more efflux 
may result in lower brain levels and less inhibition of radioligand binding. Further to 
this, no changes in rat behaviour were noted at the time of brain extraction and 
dissection in methadone treated animals compared with saline, suggesting brain levels 
were perhaps not physiologically high enough to affect behaviours and potentially, 
[
11
C]carfentanil binding significantly. 
 
4.5.1.5.  Amphetamine affinity  
The reduction in [
11
C]carfentanil binding following amphetamine treatment is 
unlikely due to direct competition of amphetamine molecules at labelled µ receptor 
sites.  Using in vitro radioligand binding studies with both [
11
C]carfentanil and 
[
3
H]diprenorphine in tissues and µ receptor-expressing CHO cells the Ki of 
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amphetamine was determined to be > 300 µM and > 100 µM for [
3
H]diprenorphine 
and [
11
C]carfentanil) labelled sites, respectively (sections 8.2.5.). 
 
Sood and co-workers (2009) determined extracellular amphetamine concentrations in 
the rat caudate putamen following 1.0 mg/kg i.p. of drug (Sood et al., 2009).  
Following administration (60-90 minutes), 500 nM of amphetamine was present in 
micro-dialysate samples whilst 300 nM was found to be present in the plasma.  
Assuming a linear relationship between dose and brain amphetamine concentration 
1 µM amphetamine can be assumed in the brains of the animals used in the studies 
presented here at the point of dissection.  Therefore, if the Ki were a minimum of 
101 µM and 301 µM at [
11
C]carfentanil and [
3
H]diprenorphine labelled sites, 
respectively, then a maximum occupancy of amphetamine of 0.49 % and 0.17 % 
could be estimated.  As such, it is not expected that any variation in binding following 
amphetamine pre-treatment is due to direct competition of amphetamine at 
radiolabelled receptor sites. 
 
4.5.1.  Neurobiological mechanisms of signal change  
The data presented in this chapter suggest that the reduction in binding observed 
following amphetamine challenge maybe related to endogenous release of opioid 
peptides.  Furthermore, various lines of evidence support the notion that 
agonist-induced internalisation of µ receptors in vivo have contributed to the reduction 
in binding. 
 
Reductions in binding in the hypothalamus are in agreement with localisation of 
opioid peptide release sites.  Pro-opiomelanocortin expression has previously been 
noted in the intermediate lobe of the pituitary and the arcuate nucleus of the 
hypothalamus (Kineman et al., 1989, Khachaturian et al., 1984).  Further to this, these 
neuronal fibres have been shown to extend to various other regions with high levels of 
µ receptors such as the thalamus, caudate and amygdala.  Endomorphin-1 and -2 cell 
fibres have also been extensively investigated throughout the hypothalamus (Chen et 
al., 2008, Hui et al., 2006).  Dopamine receptor immunoreactivity and binding has 
also been observed in the hypothalamus.  Generalised hypothalamic D1 expression 
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(Boyson et al., 1986) and nuclei specific D2 receptor binding is observed throughout 
the posterior and the dorsomedial hypothalamus (Bouthenet et al., 1987).  Intense 
tyrosine hydroxylase staining is also present in the arcuate nucleus (Bouthenet et al., 
1987).  Together these data suggest that following amphetamine administration and an 
increase in extracellular dopamine levels, activation of stimulatory D1 found on 
pro-opiomelanocortin or endomorphin neurons could lead to release of endogenous 
opioid peptides.  Alternatively, activation of inhibitory D2 receptors on GABAergic 
interneurons could disinhibit either pro-opiomelanocortin or endomorphin neurons 
leading to increased levels of activation and opioid peptide release. 
 
Individual hypothalamic nuclei cannot be dissected in the studies presented here, but 
despite this, high [
11
C]carfentanil whole-hypothalamus uptake and a reduction in 
binding was observed.  Colasanti et al (2012) did not report reductions in the 
hypothalamus following amphetamine using [
11
C]carfentanil.  This may be related to 
the relatively small size of hypothalamic nuclei and the limited spatial resolution 
available with in vivo nuclear imaging.  Furthermore, greater levels of variability in 
this region may be related to manual drawing of hypothalamus as a region of interests.  
The cellular mechanisms hypothesised here to underlie the changes in binding 
observed following amphetamine treatment are likely to also occur in other brain 
regions, outside the hypothalamus.  Disinhibition of enkpehalinergic interneurons in 
the striatum following dopamine mediated inhibition of GABAergic medium spiny 
neurons could result in increased met- and leu-enkephalin release and a subsequent 
reduction in binding.  However, further work is required to truly disentangle the 
cellular mechanisms behind dopamine transporter blockade leading to opioid peptide 
release. 
 
4.5.3.  Human studies with amphetamine release  
Two separate studies have compared the effects of acute amphetamine treatment on 
[
11
C]carfentanil binding (Guterstam et al., 2013, Colasanti et al., 2012).  Colasanti et 
al (2012) report that following 0.5 mg/kg oral D-amphetamine in healthy male 
volunteers, a significant reduction in binding is observed in the putamen, caudate, 
frontal cortex, thalamus, insula and anterior cingulate (Colasanti et al., 2012). Further 
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to this, despite levels of euphoria following amphetamine being significant compared 
with those reported after placebo, increased euphoria, anxiety and restlessness were 
associated with ΔBPND in the ventral striatum, putamen and thalamus, respectively 
(Colasanti et al., 2012).  These data suggest that amphetamine indirectly reduces 
[
11
C]carfentanil binding by release of endogenous opioid peptides in regions where 
firstly, opioid peptides are known to be expressed and secondly, in regions known to 
be involved in anxiety and the stimulant and rewarding effects of amphetamine.  
Despite these findings, Guterstam et al (2013) report no differences in [
11
C]carfentanil 
binding, greater than test- re-test values following amphetamine exposure (30 mg/kg 
i.v., two minutes prior to radioligand injection).   
 
Between these two studies there are various methodological differences which may 
relate to the disparity in findings.  Both the delay between radiotracer administration 
and amphetamine dosing, and route of amphetamine dosing differ between Guterstam 
et al (2013) and Colasanti et al (2012).  Colasanti administered 0.5 mg/kg orally with 
a delay of three hours before radiotracer administration.  Significant euphoria was not 
reported using the simplified amphetamine interview rating scale by Colasanti et al 
(2012).  Three hours were chosen in this study to allow time for absorption of oral 
amphetamine (plasma levels were shown by the same PET centre to peak at 3 hours) 
and for the delayed effect of dopaminergic activation of opioid peptide synthesis and 
release.  The latter of which was shown by Olive et al (2001) to peak ~90 minutes 
following intraperitoneal administration in the rat (Olive et al., 2001). This ~90 
minute time point may not have been captured during the 69 minute image acquisition 
run by Guterstam (2013), who administered 0.3 mg/kg i.v. two minutes prior to 
radioligand injection.   
 
The studies presented in this chapter more closely resemble the experimental protocol 
employed by Colasanti et al (2012) and directly relate to the time course in change of 
micro-dialysate β-endorphin levels observed by Olive et al (2001).  The extra-striatal 
decreases in µ receptor binding 90 minutes following administration of amphetamine 
are regionally distinct from the findings by Colasanti et al (2012), where reductions in 
binding in caudate, putamen, thalamus and frontal cortex were the greatest, but are 
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still in agreement with pro-opiomelanocortin and endomorphin neuron localisation in 
brain. 
 
 
4.5.4.  Further studies  
In order to further quantify the contribution of agonist-induced internalisation on 
changes in binding signals more accurate determination of changes in circulating 
peptide levels following amphetamine challenge are required.  Such studies have been 
conducted with the dopaminergic system, where both PET and microdialysis have 
taken place simultaneously.  These studies have further highlighted that the temporal 
changes in PET signal far out-live the surge in dopamine release in the striatum 
following amphetamine treatment.  Such studies for the opioid peptide system would 
be much more challenging.  For example, multiple peptides need to be recovered from 
the micro-dialysate.  It is likely this would mean that less time points for samples can 
be acquired in order to compensate for the larger volumes that would need to be 
captured.  Furthermore, detection of the peptides in micro-dialysate is much more 
challenging than that for monoamines.  Peptide detection and quantification often 
require separate radioimmuno-assays or enzyme linked immunosorbant assays.  Both 
of these techniques facilitate a longer time period for degradation of peptides to occur 
and the introduction of new variables such as antibody specificity.  Lastly, peptide 
release following amphetamine challenge is likely to be more diffuse across the brain 
and vary more in its peptide enhancing effect by region compared with the effects of 
amphetamine on dopaminergic hubs such as in the ventral tegmental area and the 
nucleus accumbens.  
 
To better understand the role of amphetamine in causing opioid peptide release, 
immunohistochemical studies could be run to observe changes in precursor peptide 
levels using specific antibodies.  These changes could then be co-localised with 
markers of neuronal activation such as c-FOS and the monoamine transporter sites.  
Such studies would potentially further confirm the role of dopamine over serotonin 
and noradrenaline in causing opioid peptide release and allow tracking of activated 
neuronal projections correlated with increased or decreased opioid peptide pre-cursor 
levels. 
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Investigation of other radioligands selective for opioid receptors would be 
advantageous ([
11
C]PEO for example).  Both in in vivo studies, to determine if other 
radioligands may be more sensitive to peptide release than [
11
C]carfentanil but also 
the in vitro work where different cellular buffers are utilised.   
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4.6.  Conclusions 
The studies presented in this chapter demonstrate that agonist induced internalisation 
would be expected to have the following effects on the binding parameters of 
[
3
H]diprenorphine and [
11
C]carfentanil: 
 A reduction in receptor availability in the endosomal compartment compared with the 
membrane fractions for both radioligands 
 A trend for a reduction in affinity of µ receptors for [11C]carfentanil following 
internalisation to endosomes compared with when present at the cell surface 
 A reduction in affinity of µ receptors for [3H]diprenorphine would also be expected in the 
endosomal compartment compared with when present at the membrane, however, this 
effect maybe masked in vivo where both δ and κ receptor are also present. 
 
Administration of D-amphetamine, a compound known to cause β-endorphin release 
in vivo, and methadone, a selective µ receptor agonist, resulted in the following 
changes in [
3
H]diprenorphine and [
11
C]carfentanil uptake: 
 No significant change in [3H]diprenorphine uptake throughout all the brain regions 
investigated 
 A significant reduction in [11C]carfentanil uptake following amphetamine. A relationship 
between [
11
C]carfentanil uptake under saline conditions and reduction in uptake 
following either amphetamine and methadone was also observed. 
 
Sub-cellular fractionation of rat brains previously treated with either D-amphetamine 
or methadone into membrane, microsomal and cytosolic fractions suggest: 
 The majority of cell binding for [3H]diprenorphine in vivo would be observed in the 
membrane fraction. 13 % of total tissue binding would emanate from microsomal opioid 
receptors. 
 The distribution of [3H]diprenorphine binding would not alter following either treatment. 
 The majority of cell binding for [11C]carfentanil in vivo would be observed in the 
membrane fraction. 6 % and 2 %of total homogenate binding would be contributed by 
microsomal and cytosolic µ receptors, respectively. 
 Following D-amphetamine treatment a reduction in total homogenate binding would be 
observed, a trend for a reduction in total homogenate binding would also be observed 
following methadone. Both treatments would result in trend for an increase in 
microsomal [
11
C]carfentanil binding. 
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CHAPTER 5 
The Effects of Pharmacological Challenge Agents on Opioid 
Receptor Cellular Localisation 
 
5.1.  Introduction 
The previous chapter demonstrated that [
11
C]carfentanil maybe more sensitive to 
endogenous opioid peptide release following acute amphetamine treatment than 
[
3
H]diprenorphine.  A positive correlation between brain region uptake following 
saline and per cent reduction following methadone and amphetamine administration 
was also observed with [
11
C]carfentanil.  No such relationships were observed for the 
non-selective opioid receptor antagonist radioligand [
3
H]diprenorphine.  
 
In addition, a decreased ability to bind was observed for both radioligands in buffers 
representative of those found in early, recycling endosomes compared with those at 
the cell surface.  These data suggest that should µ, δ and κ receptors translocate to 
sub-cellular vesicles following agonist exposure, radioligand binding would be 
expected to decrease in vivo.  µ, δ and κ receptors have all been shown to endocytose 
in a clathrin- and dynamin-dependent manner following exposure to both exogenous 
and endogenous agonists (reviewed in chapter one).  The extent to which agonist-
induced internalisation mechanisms contribute to the reduction in binding following 
amphetamine-induced endogenous opioid peptide release is currently unknown. 
 
Amphetamine has previously been shown to increase the concentrations of β-
endorphin in the rat nucleus accumbens following peripheral dosing (Olive et al., 
2001).  Furthermore, transcriptional changes of both dynorphin and enkephalin 
peptides have been observed following amphetamine treatment (Harsing Jr et al., 
1982, Cole et al., 1995).  However, the effect of amphetamine treatment on opioid 
receptor cellular localisation has not, to date, been assessed.  Furthermore, the effects 
of both methadone and amphetamine treatment on expression of µ, δ and κ receptors 
along with recycling endosomes has also not been investigated.  
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5.2.  Aims 
The following set of studies set out to further characterise the influence of agonist-
induced internalisation on opioid receptor radioligand binding for the µ, δ and κ 
opioid receptors: 
 
 Assessment of the effects of acute methadone and amphetamine administration on 
µ, δ and κ receptor cellular localisation in rat brain using fluorescence confocal 
microscopy 
 
 Investigation of receptor trafficking to recycling endosomes by determining 
receptor-Rab5 (a prototypical early endosomal marker) co-localisation 
 
 Determination of changes in µ, δ and κ receptor and early endosome expression 
via grey scale intensity quantification 
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5.3.  Methods 
5.3.1.  Dual labelling immunofluorescence 
In order to determine opioid receptor-endosome co-localisation, dual-labelling 
immunofluorescence was conducted.  
 
Brain sections were cut (20 µm thick) at -16 to -20 °c using a cryostat microtome and 
mounted onto poly-L-lysine coated microscope glass slides.  Tissues were cut such 
that each slide would contain a section from a saline, amphetamine and methadone 
treated animal and were stored at -80 
o
C.  Prior to use, sections were allowed to thaw 
and dry thoroughly for two hours at room temperature. The “Bridge Amplification” 
method was used for labelling opioid receptors (Figure 5.1.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  Standard (Rab5) and Bridge Amplification (opioid receptor) 
Immunolabeling techniques.   
Standard immunofluorescence techniques allow direct detection of primary antibodies with 
fluorescently labelled secondary antibodies.  This was applied for the staining of Rab5.  
However, greater levels of background staining and significantly lower levels of cell opioid 
receptor density compared with circulating endosomes meant that receptor labelling needed to 
be amplified.  The bridge-technique (or indirect method) allows for a 5-fold enhancement of 
the signal compared with the direct method.  Secondary antibodies with multiple biotin 
moieties attached are used for the detection of the primary antibody.   Following this step, 
incubation with fluorophore-conjugated streptavidin allows for multiple molecules of 
streptavidin to bind to a single molecule of the biotinylated secondary antibody thus 
enhancing the signal.  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
   Standard                        Bridge Amplification 
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Opioid receptors were labelled with streptavidin conjugated with a 488 nm 
fluorophore (green emission spectrum) and Rab5, a prototypical early endosomal 
marker, and detected by a 594 nm fluorophore-conjugated secondary (red emission 
spectrum). 
 
The following conditions were used for Immunolabeling of µ, δ and ĸ receptors 
(Table 5.1.): 
 
Table 5.1.  Assay conditions for immunofluorescent labelling of opioid receptors 
 
Receptor Fix Block 1° Incubation Bridge #1/2° Bridge #2 
µ1 
5 minutes, 
4 % PFA$ 
30 minutes, 
10 % FCS%, 
0.1 % triton-X 
µ: 1:100, 2 % FCS, 
0.02 % triton-X 
Rab54: 1:200 
µ: 1:200 biotinylated 
anti-rabbit, 2 % FCS, 
0.02 % triton-X 
Rab5: 1:200 594 nm 
anti-mouse 
µ: 1:200 488 nm 
streptavidin, 2 % FCS, 
0.02 % triton-X 
 
δ2 
5 minutes, 
ice-cold 
acetone 
15 minutes, 5 % 
FCS, 0.01 % 
tween 
δ: 1:100 in 1 % FCS, 
0.01 % tween 
Rab5: 1:200 
δ: 1:200 biotinylated 
anti-rabbit, 2 % FCS, 
0.01 % tween 
Rab5: 1:200 594 nm 
anti-mouse 
δ: 1:200 488 nm 
streptavidin, 2 % FCS, 
0.01 % tween 
ĸ3 
5 minutes, 
4 % PFA 
15 minutes, 5 % 
FCS, 0.01 % 
tween 
ĸ: 1:100, 1 % FCS, 
0.01 % tween 
Rab5: 1:200 
ĸ: 1:200 biotinylated anti-
rabbit, 2 % FCS, 0.01 % 
tween 
Rab5: 1:200 594 nm 
anti-mouse 
ĸ: 1:200 488 nm 
streptavidin, 2 % FCS, 
0.01 % tween 
 
1
Supplied from Novus Biologicals, NBP1-96656, ‘UMB3’. Rabbit monoclonal anti-µ. 
2
Supplied by AbCam, ab66318. Rabbit polyclonal anti-δ. 
3
Supplied by AbCam, ab83293. Rabbit polyclonal anti-ĸ. 
4
Supplied by AbCam, ab50523. Rabbit monoclonal anti-Rab5-65. 
$
Paraformaldehyde. 
%
Foetal calf serum. 
 
Following each step (fixation, blocking or antibody incubations) sections were 
extensively washed with phosphate buffered saline (five times with 2-3mls; pH 7.4).  
A hydrophobic border was drawn using a PAP pen to minimise antibody wastage.  
Primary antibody incubations were conducted overnight at 4 °C and were covered to 
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minimise evaporation.  After incubation with 488 nm streptavidin and washing, 
excess phosphate buffered saline was removed and a drop of ProLong ® reagent with 
DAPI (blue, UV emission spectrum) was added to the sections for cell nucleus 
localisation.  A coverslip was then applied and the section sealed with clear nail 
varnish. 
 
Cell images were captured using a Leica TCS SP5 confocal microscope.  Both capture 
and initial analysis was made using the Leica LAS AF image suite.  Z-stack images 
were captured in the striatum for all experimental conditions for all three primary 
opioid receptor antibodies at 40x and 63x (digital zoom x4) magnification allowing 
for regional and individual cell staining, respectively.  For the µ receptor antibody, 
further stacks were acquired in the hypothalamus at 40x magnification.  All image 
capture conditions were the same between n-numbers and between sections on the 
same slide for saline, amphetamine or methadone conditions.  Further analysis such as 
image overlay and quantification using the mean pixel intensity were made using the 
Image J software (NIH). 
 
5.3.2.  Grey scale intensity quantification 
To further investigate the effects of amphetamine and methadone on opioid receptor 
and endocytic machinery regulation, grey scale mean pixel intensity analysis was 
conducted. Intensity measurements can be inferred to represent changes in protein 
expression. However, this method is semi-quantitative, with values representing fold 
differences in mean pixel intensity above background within the same section. 
Administration of a pharmacological challenge known to cause receptor endocytosis 
may therefore result in the following observations: 
 Increased Rab5 mean pixel intensity, driven by increased protein synthesis, 
reflecting an increase in the number of recycling endosomes.  
 No change in receptor mean pixel intensity since receptors expression is not 
changing, cellular localisation is the only factor driving the changes in co-
localisation observed. Or, 
 Decreased receptor mean pixel intensity due to increased endocytosis to 
degradative, lysosomal endosomes.  
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Preliminary grey scale analysis was performed on the three separate saline, 
amphetamine and methadone treatment groups. Images for both receptor (488nm 
wavelength) and Rab5 (595nm wavelength) immunoreactivity captured from the same 
regions of a tissue section were converted to a 16-bit grey scale image. Mean grey 
scale pixel intensity was determined on ten separate occasions within each image for 
background immunoreactivity and cell staining (Figure 5.2.). 
 
 
 
Figure 5.2.  Representative image of quantification procedure. 
Yellow = cell immunoreactivity quantified, Red = background immunoreactivity quantified. 
 
Image analysis was performed on low (20x optical) magnification, using NIH Image J 
software. An average of grey scale pixel intensities were taken from each image from 
three separate animals for all treatment conditions. To avoid bias, ‘cells’ and 
‘background’ regions for analysis were selected at random and images were labelled 
by rat identification number, rather than treatment group.  
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5.4.  Results 
5.4.1.  Low magnification, single plane immunofluorescence 
5.4.1.1.  µ Receptors 
 
Sections taken from control rat brains demonstrated good fluorescent staining in the 
striatum and the nucleus accumbens (Figure 5.3.).  3,3’-Diaminobenzidine (DAB), 
chromogenic staining was also conducted to determine receptor expression at the 
ultrastructural level (see Appendix 8.3.1.). 
 
 
Figure 5.3.  Immunofluorescence of µ receptors in rat striatum and nucleus accumbens.   
µ receptor staining in control Sprague Dawley brain sections, DAPI (blue) staining used for 
nuclear localisation.  Composite images generated using NIH Image J software.  Images 
captured at x20 optical magnification. 
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5.4.1.2.  δ Receptors 
Sections taken from control brains demonstrated good regional staining in both the 
hippocampus and the striatum (Figure 5.4.).  DAB chromogenic staining was also 
conducted on these sections (Appendix 8.3.1.). 
 
 
Figure 5.4.  Immunofluorescence of δ receptors in rat hippocampus and striatum.   
δ receptor staining in control Sprague Dawley brain sections, DAPI (blue) staining used for 
nuclear localisation.  Composite images generated using NIH Image J software.  Striatal and 
hippocampal images captured at x20  and x10 optical magnification, respectively. 
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5.4.1.3.  ĸ Receptors 
Good regional staining was observed in the hippocampus, hypothalamus and the 
striatum (Figure 5.5.).  Sections taken from control brains were also used for DAB 
chromogenic staining (Appendix 8.3.1.). 
 
 
Figure 5.5.  Immunofluorescence of ĸ receptors in rat hippocampus, hypothalamus and 
striatum.  
ĸ receptor staining in control Sprague Dawley brain sections, DAPI (blue) staining used for 
nuclear localisation.  Composite images generated using NIH Image J software.   Images 
captured at x20 optical magnification. 
 
 
5.4.2.  Confocal microscopy 
High resolution Z-stack images were captured in striatal (and hypothalamic for µ 
receptor) tissue sections taken from rats treated with either saline, amphetamine or 
Hippocampus 
Hypothalamus 
ĸ DAPI Composite 
Striatum 
Chapter 5: Effects of Challenge Agents on Opioid Receptor Cellular Localisation 
 
~ 141 ~ 
 
methadone to assess the effect of these treatments on µ, δ and ĸ receptor cell 
localisation.  Methadone was included as a compound known to cause µ receptor 
internalisation both in vitro and in vivo.  Rab5, a marker for early-recycling 
endosomes, along with receptor staining was conducted (red staining) on these 
sections, in order to further investigate the internalisation processes.  Co-localisation 
of Rab5 and receptor (yellow staining) suggests increased agonist-induced 
internalisation processes either by translocation of Rab5 to the cell membranes or 
translocation of receptors to the cytoplasmic endocytic vesicles.  In all treatment 
groups, intense immunofluorescence was observed for all antibodies tested in low 
magnification of the striatal tissues (Figures 5.6., 5.9. and 5.12. for µ, δ and ĸ, 
respectively). 
 
5.4.2.1.  µ Receptors 
µ receptor-Rab5 co-localisation was observed in all treatments (Figure 5.6.).  
Qualitatively, more Rab5 co-localisation with the receptor (yellow) was observed in 
methadone treated animals compared with saline and amphetamine (Figure 5.6.). 
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Figure 5.6.  Low magnification of µ receptor immunofluorescence in the striatum of 
saline, amphetamine and methadone treated rats. 
µ receptor staining in Sprague Dawley brain sections following either saline, amphetamine or 
methadone treatment.  DAPI (blue) staining = nuclear localisation.  Rab5 (red)  = early 
endosome localisation.  Image stack analysed and composites generated using NIH Image J 
software.  Stacks captured at x20 magnification. Representative images from n = 5. 
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High magnification images were also captured to further determine receptor cell 
localisation changes.  Under the same image capture conditions, µ receptor staining 
intensity appeared greater in amphetamine and methadone treated animals compared 
with saline treated (Figure 5.7.).  Rab5 staining was also mildly increased in 
methadone treated animals (Figure 5.7.). 
 
         
 
Figure 5.7.  High magnification of µ receptor immunofluorescence in striatum of saline, 
amphetamine and methadone treated rats.   
µ receptor staining in Sprague Dawley brain sections following either saline, amphetamine or 
methadone treatment.  DAPI (blue) staining = nuclear localisation. Rab5 (red) = early 
endosome localisation.  Image stack analysed and composites generated using NIH Image J 
software.  Stacks captured at x63 oil immersion optical magnification (and x4 digital zoom).  
Representative images from n = 5. 
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Staining of the µ receptor was also investigated in the hypothalamus at low (x20 
optical magnification).  High magnification images were not captured in this region 
due to a large amount of background staining.  In saline treated animals, µ receptor 
staining appeared throughout the cell, whereas following amphetamine or methadone, 
receptor staining was more punctuate, and cytoplasmic (Figure 5.8.). In methadone 
treated animals Rab5 immunofluorescence appeared substantially more intense 
compared with either amphetamine or saline treated animals (Figure 5.7.).  
Composites images suggest greater receptor-Rab5 co-localisation following either 
methadone or amphetamine compared with saline (Figure 5.8). 
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Figure 5.8.  Low magnification of µ receptor immunofluorescence in hypothalamus of 
saline, amphetamine and methadone treated rats.   
µ receptor staining in Sprague Dawley brain sections following either saline, amphetamine or 
methadone treatment. DAPI and Rab5 staining as above.  Image stack analysed and 
composites generated using NIH Image J software.  Stacks captured at x63 oil immersion 
optical magnification (and x4 digital zoom).  Representative images from n = 2. 
Composite images excluding DAPI immunofluorescence were also generated to allow 
Rab5 and receptor staining alone to visualise and better assess co-localisation. In 
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saline conditions, receptor staining is frequently observed as green alone, for example 
any yellow staining observed in the hypothalamus is mainly membrane bound, 
perhaps reflecting constitutive levels of receptor cycling (Figure 5.9.). After 
amphetamine treatment more co-localisation is observed in the low magnification 
striatum images, but in the same section at a greater magnification an increase in co-
localisation compared with saline is difficult to distinguish (Figure 5.9). Methadone 
treatment leads to greater levels of co-localisation in the hypothalamus, a clear 
increase in overall cell co-localisation is observed. Punctuate cytoplasmic yellow 
staining is also demonstrated (see figure 5.9.). 
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Figure 5.9.  Composite images of saline, amphetamine and methadone treated rat brain 
sections and µ receptor and Rab5 co-localisation.   
µ receptor staining in rat Sprague Dawley brain sections following either saline, amphetamine 
or methadone treatment. Yellow = receptor and Rab5 co-localisation. Image stack analysed 
and composites generated using NIH Image J software. Stacks captured at 63 x oil immersion 
magnification – Striatum2 (and x4 digital zoom) and x20 optical magnification – Striatum1. 
Hypothalamus = representative images from n = 2; high and low magnification 
striatum = representative images from n = 5 
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5.4.2.2.  δ receptor  
No discernible differences in immunofluorescence were observed for δ receptor-Rab5 
co-localisation following any treatment.  A decrease in the number of cells stained 
with δ receptors was observed following amphetamine treatment compared with 
saline and methadone (see figure 5.10.). Furthermore, a decrease in Rab5 intensity 
was observed following methadone treatment (Figure 5.10.). 
        
Figure 5.10.  Low magnification δ receptor immunofluorescence in the rat striatum 
following saline, amphetamine or methadone treatment.   
δ receptor staining in Sprague Dawley brain sections following either saline, amphetamine or 
methadone treatment. DAPI and Rab5 staining as previously described.  Image stack analysed 
and composites generated using NIH Image J software.  Stacks captured x20 optical 
magnification. Representative images from n = 3. 
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High magnification receptor imaging in the striatum show that δ receptor was 
distributed throughout the cytoplasm under saline treatment conditions.  
Amphetamine and methadone treatment did not alter the δ receptor 
immunofluorescence patterns (Figure 5.11.). Rab5 staining was reduced following 
methadone treatment compared with amphetamine and saline (Figure 5.11.).  
 
Figure 5.11.  High magnification images of δ receptor immunofluorescence in the rat 
striatum following saline, amphetamine or methadone treatment.   
δ receptor staining in  Sprague Dawley brain sections following either saline, amphetamine or 
methadone treatment. DAPI and Rab5 staining as previously described.  Image stack analysed 
and composites generated using NIH Image J software.  Stacks captured x63 optical oil 
immersion (and x4 digital zoom) magnification.  Representative images from n = 5. 
 
Composite images without DAPI labelling at both high and low magnification in the 
striatum suggest that amphetamine and methadone do not significantly alter δ receptor 
localisation.  However, a qualitative decrease in immunofluorescence intensity was 
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observed following methadone treatment compared with saline and amphetamine 
(Figure 5.12.).  
 
Figure 5.12.  Composite images of saline, amphetamine and methadone treated brain 
sections and δ receptor and Rab5 co-localisation in striatum. 
δ receptor staining in rat Sprague Dawley brain sections following either saline, amphetamine 
or methadone treatment. Yellow = receptor and Rab5 co-localisation. Image stack analysed 
and composites generated using NIH Image J software. Stacks captured at 63 x optical oil 
immersion - Striatum
2
 (and x4 digital zoom) and x20 optical magnification – Striatum1. 
Representative images from n = 5 (high magnification) and n = 3 (low magnification). 
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5.4.2.3.  ĸ receptor 
Intense ĸ receptor staining was observed at the membranes of numerous cells within 
the striatum under saline conditions. Global immunofluorescence for ĸ receptors 
appeared increased following amphetamine treatment and the number of cells stained 
for ĸ receptors appeared to decrease following methadone treatment (Figure 5.13.).  ĸ 
receptor-Rab5 co-localisation appeared to be at its greatest under saline conditions 
compared with both amphetamine and methadone conditions (Figure 5.13.). 
 
Figure 5.13.  Low magnification images of ĸ receptor immunofluorescence in the rat 
striatum following saline, amphetamine or methadone treatment.   
ĸ receptor staining in Sprague Dawley brain sections following either saline, amphetamine or 
methadone treatment. DAPI and Rab5 staining as described previously. Image stack analysed 
and composites generated using NIH Image J software. Stacks captured x20 optical 
magnification. Representative images from n = 3. 
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High magnification imaging of the ĸ receptor demonstrated that under saline 
conditions, ĸ receptor immunofluorescence was located both throughout the cell 
cytoplasm and at the cell membrane (Figure 5.14.).  Amphetamine treatment did not 
alter receptor or Rab5 staining; whilst methadone treatment caused an increase in 
cytoplasmic ĸ receptor staining concurrent with an increase in Rab5 
immunofluorescence at the periphery of the cells (Figure 5.14.). 
 
Figure 5.14.  High magnification images of ĸ receptor immunofluorescence in the rat 
striatum following saline, amphetamine or methadone treatment. 
ĸ receptor staining in Sprague Dawley brain sections following either saline, amphetamine or 
methadone treatment. DAPI and Rab5 staining as described previously.  Image stack analysed 
and composites generated using NIH Image J software. Stacks captured x63 optical oil 
immersion (x4 digital zoom) magnification. Representative images from n = 5.  
Composite images without DAPI labelling at both high and low magnification in the 
striatum suggest that amphetamine does not significantly alter δ receptor localisation.  
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However, a qualitative increase cytoplasmic receptor immunofluorescence intensity 
was observed following methadone treatment compared with saline and amphetamine 
(Figure 5.15.).  
 
Figure 5.15.  Composite images of saline, amphetamine and methadone treated brain 
sections and δ receptor and Rab5 co-localisation in striatum. 
ĸ receptor staining in rat Sprague Dawley brain sections following either saline, amphetamine 
or methadone treatment. Yellow = receptor and Rab5 co-localisation. Image stack analysed 
and composites generated using NIH Image J software. Stacks captured at x63 optical oil 
immersion – Striatum2 (and x4 digital zoom) and x20 optical magnification – Striatum1. 
Representative images from n = 5 (high magnification) and n = 3 (low magnification). 
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5.4.3.  Mean grey scale pixel intensity 
Preliminary grey scale analysis was performed on the three treatment groups.  Ten 
individual quantifications were performed per n-number in each tissue section, in each 
treatment group, for both background and cell intensity.  Image analysis was 
performed in transformed, low magnification, 32-bit grey scale images using NIH 
Image J software. 
 
5.4.3.1.  μ-Receptors 
No significant differences in Rab5 pixel intensity (saline 8.91 ± 1.08, amphetamine 
8.68 ± 1.24 and methadone 10.71 ± 1.92) were observed in striatum of saline, 
amphetamine or methadone treated animals (Figure 5.16.).  There was a reduction in 
pixel intensity for the µ receptor (saline 8.48 ± 1.89, amphetamine 7.10 ± 0.97 and 
methadone 4.35 ± 2.45) but this failed to reach significance (Figure 5.16.). 
 
Figure 5.16.  Grey scale analysis of µ receptor and Rab5 pixel intensity in the rat 
striatum following saline, amphetamine or methadone treatment. 
Image analysis conducted with NIH Image J software. n = 2 for all treatment groups 
(mean ± s.e.mean).  One-way ANOVA performed using GraphPad Prism 5.0. ANOVA 
results: Rab5 F(2,27) = 0.58, p = 0.56; µ F(2,26) = 1.29, p = 0.29. 
 
 
Rab5 immunofluorescence was significantly increased in the hypothalamus of both 
the methadone (26.66 ± 2.26,p  < 0.001) and amphetamine (17.29 ± 1.44, p  < 0.05) 
treated animals compared with saline (10.99 ± 1.08; Figure 5.17.).  In addition, Rab5 
immunofluorescence was also significantly greater in methadone treated animals 
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compared to amphetamine (p < 0.01; Figure 5.17.).  No significant changes in µ 
receptor immunofluorescence were observed between the treatment groups (saline 
8.49 ± 2.18, amphetamine 10.80 ± 2.07 and methadone 10.77 ± 1.27; Figure 5.17).  
 
Figure 5.17.  Grey scale analysis of µ receptor and Rab5 pixel intensity in the rat 
hypothalamus following saline, amphetamine or methadone treatment. 
Image analysis conducted with NIH Image J software.  n = 2 for all treatment groups, 
mean ± s.e.mean.  One-way ANOVA performed with GraphPad Prism 5.0.  
*
 p < 0.05, 
**
 
p < 0.01, 
***
 p < 0.001. ANOVA results: Rab5 F(2,27) = 22.34, p < 0.0001; µ F(2,27) = 0.49, 
p = 0.62. 
 
5.4.3.2.  δ-Receptors 
Consistent with high and low magnification cell images, there was a trend for a 
reduction in Rab5 immunofluorescence observed in methadone treated animals 
(4.08 ± 0.39) compared with saline (6.97 ± 1.02) and amphetamine treated animals 
(5.99 ± 0.87; Figure 5.18.).  Furthermore, δ receptor staining was significantly 
reduced in amphetamine treated animals (1.87 ± 1.75) compared with saline 
(9.48 ± 1.34, p < 0.05; Figure 5.18.). 
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Figure 5.18.  Grey scale analysis of δ receptor and Rab5 pixel intensity in the rat 
striatum following saline, amphetamine or methadone treatment.   
Image analysis conducted with NIH Image J software. n = 2 for all treatment groups, 
mean ± s.e.mean.  One-way ANOVA performed with GraphPad Prism 5.0. 
*
 p < 0.05. 
ANOVA results: Rab5 F(2,22) = 0.058, p = 0.18; δ F(2,25) = 0.73, p = 0.49. 
 
5.4.3.3.  κ Receptors 
A significant reduction in Rab5 mean pixel intensity was observed in the sections 
taken from methadone (5.12 ± 0.61) treated animals compared with both 
amphetamine (9.23 ± 1.34, p < 0.05) and saline treated animals (8.57 ± 0.60, p < 0.05; 
Figure 5.19.).  No significant differences in ĸ receptor immunofluorescence were 
observed between any of the treatment groups (saline 7.98 ± 0.90, amphetamine 
10.12 ± 2.17 and methadone 7.36 ± 1.62; Figure 5.19.).   
 
Figure 5.19.  Grey scale analysis of ĸ receptor and Rab5 pixel intensity in the rat 
striatum following saline, amphetamine or methadone treatment. 
Image analysis conducted with NIH Image J software. n = 2 for all treatment groups, 
mean ± s.e.mean.  One-way ANOVA performed with GraphPad Prism 5.0. 
*
 p < 0.05. 
ANOVA results: Rab5 F(2,25) = 0.73, p = 0.49; ĸ F(2,25) = 0.73, p = 0.048. 
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5.5.  Discussion 
In the previous section we have demonstrated that a pharmacological challenge (acute 
amphetamine exposure), known to cause endogenous opioid peptide release and 
decrease [
11
C]carfentanil binding also increases µ receptor-Rab5 co-localisation. 
 
5.5.1.  Immunofluorescence distribution 
The brain region immunoreactivity observed in this chapter is in agreement with 
previous reports of opioid receptor antibody and radioligand binding studies (Mansour 
et al., 1988).  Specifically, intense immunoreactive cells were observed in the striatum 
for all receptor sub-types.  Μu receptors were observed as patch formations, whilst δ 
and ĸ were more diffuse.  Furthermore, µ receptor expression was also observed in 
the nucleus accumbens and the hypothalamus; δ receptor expression in the pyramidal 
cell layer and the dentate gyrus of the hippocampal formation and ĸ receptor 
expression in both the hippocampal and hypothalamic regions.  Importantly, all the 
regions investigated with immunofluorescence techniques in this chapter, are also 
areas where [
11
C]carfentanil and [
3
H]diprenorphine uptake has also been identified in 
chapter four. 
 
5.5.2.  Receptor translocation  
Methadone has previously been shown to increase µ receptor internalisation by 
approximately 25-45 % in HEK or 293-SF cells (Keith et al., 1998, Whistler et al., 
1999).  To date this has never been assessed ex vivo in tissue preparations.  
Substances known to indirectly cause endogenous opioid peptide release such as 
ethanol (Olive et al., 2001, Lam and Gianoulakis, 2011) have previously been shown 
to effect µ receptor-Rab5 co-localisation in the spinal cord (He and Whistler, 2011), 
but this has never been shown for the dopamine transporter blocker amphetamine. 
 
No significant change in either Rab5 or µ receptor grey scale pixel intensity was 
observed following either amphetamine or methadone compared with saline in the 
striatum.  Despite this, qualitatively an increase in Rab5-receptor co-localisation was 
observed in this region following amphetamine, particularly in low magnification 
images.  In addition, a marked increase in co-localisation was observed in the 
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hypothalamus of both methadone and amphetamine pre-treated animals compared 
with saline.  The increase in co-localisation was also observed in combination with an 
increase in Rab5 mean pixel intensity, suggesting that both amphetamine and 
methadone induced an up regulation of endocytic cellular machinery, such as 
recycling endosomes.  Due to time restraints and methodological complexities 
associated with multiple image stack capture during confocal microscopy imaging, 
additional brain regions were not assessed.  However, in light of the data presented in 
chapter four of this thesis, an investigation of µ receptor trafficking in other regions 
would be of interest.  For example, the cerebellum, since this could allow for further 
interrogation of the observed increase in [
3
H]diprenorphine uptake following 
methadone. 
 
No dramatic differences in δ or κ receptor-Rab5 co-localisation were observed 
following either amphetamine or methadone treatment.  Methadone was not expected 
to have high affinity at either δ or κ receptor sites (Kristensen et al., 1995).  A subtle 
increase in κ receptor cytoplasmic staining was observed following methadone in the 
striatum, whereas Rab-5 expression decreased.  These changes in localisation may be 
due to downstream signalling of µ receptors situated on the same neurons as κ 
receptors in the striatum.  These processes may initiate internalisation of κ receptors 
in a Rab5/recycling endosome independent manner such as lipid-raft mediated 
endocytosis (Le Roy and Wrana, 2005).  
 
5.5.3.  Translocation and Radioligand binding changes 
Various lines of evidence now suggest that, at least in the striatum and hypothalamus, 
the decrease in [
11
C]carfentanil binding observed following amphetamine challenge 
may be associated with altered levels of plasma membrane µ receptors.  Firstly, we 
present that the greatest level of Rab5-µ receptor co-localisation following 
amphetamine challenge, is observed in the same brain region where the greatest 
reduction in [
11
C]carfentanil binding is also observed following amphetamine.  
Secondly, in vitro binding data from chapter four suggest that following endocytosis, 
[
11
C]carfentanil is significantly less able to bind, than when present at the plasma 
membrane.  Finally, whole brain homogenate binding, following amphetamine 
Chapter 5: Effects of Challenge Agents on Opioid Receptor Cellular Localisation 
 
~ 159 ~ 
 
administration demonstrates a significant reduction in [
11
C]carfentanil binding sites, 
but no significant change in µ receptor expression was observed in either of the two 
brain regions investigated with immunofluorescence semi-quantification techniques.  
These findings suggest that the loss of binding sites is not due to degradation of 
receptor proteins, but an alteration in receptor localisation or access to the radioligand 
binding site itself.  
 
The absence of both significant δ and κ receptor localisation changes suggest that 
amphetamine may not alter endogenous dynorphins or enkephalins to a significant 
degree.  Alternatively the peptide expression changes previously identified, following 
dopamine receptor modulation (Table 4.1.), do not translate to an increase in 
circulating opioid peptide levels and receptor activation within the time-frame and 
acute amphetamine exposure regimen studied here.  The findings presented here are 
also in agreement with radioligand binding data from chapter four demonstrating no 
change in binding following amphetamine treatment with the non-selective 
radioligand [
3
H]diprenorphine.  For example, it could be hypothesised that ~60% of 
[
3
H]diprenorphine labelled sites (the abundance of labelled sites being accounted for 
by δ and κ in rat brain (Mansour et al., 1988)) have remained at the plasma membrane 
or at their basal cell localisation, at least in the striatum.  Assuming this absence of 
change has occurred in all brain regions, only µ receptors have endocytosed following 
amphetamine, meaning that only 40% of total brain [
3
H]diprenorphine is subject to 
changes in binding following receptor translocation.  We have also previously shown, 
similar to [
11
C]carfentanil, that [
3
H]diprenorphine is less able to bind inside the cell 
compared to outside.  However, [
3
H]diprenorphine is an antagonist, whereas 
[
11
C]carfentanil is an agonist.  Therefore not all [
3
H]diprenorphine bound µ receptors 
will be able to bind amphetamine-induced released agonist peptides.  A fraction will 
be low affinity or non G-protein coupled at any one time. Therefore, following 
agonist induced endocytosis of µ receptors bound by [
3
H]diprenorphine, no change in 
binding in vivo may be observed since the selective increase in β-endorphin levels 
may be masked by the lack of effects at other receptors also bound by 
[
3
H]diprenorphine. 
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5.6.  Conclusions 
Together, these data suggest that: 
 Acute amphetamine treatment and the µ receptor-selective agonist, methadone 
results in agonist induced internalisation of µ receptors in the striatum and the 
hypothalamus. 
These data also: 
 Confirm previous reports that amphetamine treatment leads to the production of 
µ-receptor selective opioid peptides. 
 
These changes in µ-receptor localisation are likely a contributing factor to the 
reductions in binding observed with [
11
C]carfentanil following either pharmacological 
challenge identified in chapter four of this thesis. 
 
Furthermore, no significant changes either δ and κ receptor localisation were 
observed, this suggests: 
 Amphetamine treatment may not lead to an increase in circulating endogenous 
peptides selective for either δ and κ receptors 
Subsequently, these findings also suggest: 
 The lack of effect of either amphetamine or methadone treatment on 
[
3H]diprenorphine binding in chapter four, may be due to a lack of δ and κ 
receptor internalisation. 
 Alternatively, the specific effect of both pharmacological treatments on µ-
receptors is masked in whole brains with the non-selective antagonist radioligand 
[
3
H]diprenorphine. 
 
Collectively,  
 Perhaps a threshold level of receptor internalisation may be required before 
observable signal changes are seen in vivo, and 
 Agonist radioligands may be better for detecting endogenous opioid peptide 
release than antagonists  
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CHAPTER 6 
The Effects of Different Cellular Environments on PET Ligand 
Binding 
6.1.  Introduction 
The effects of different environments on radioligand binding have been assessed in 
the previous chapters.  In addition, the extent to which these individual cell 
compartments contribute to overall tissue binding along with how this distribution 
may change following a novel pharmacological challenge have been investigated. 
 
The following section describes the translation of some of these radioligand binding 
methodologies to other PET radioligand target proteins.  Specifically, the effects of 
different cellular environments on the binding of radioligands for the ionotropic 
GABAAα1/α5 receptor, the GPCR dopamine D1 receptor, and the serotonin 
transporter (SERT) have been investigated. 
 
The following sections will briefly outline the PET radioligand protein target, whether 
the protein is subject to cellular trafficking and any attempts that have been made with 
respect to imaging endogenous neurotransmitter release with this protein and its 
respective radioligand. 
 
6.1.1.  GABAergic neurotransmitter system and GABAA 
The GABAA receptor consists of five sub-units; each with four transmembrane 
spanning domains, a large extracellular N-terminus with a cys-loop and an 
intracellular loop between M3 and M4 (Sieghart and Sperk, 2002, Bera et al., 2002, 
Nayeem et al., 1994).  Various GABAA receptor isoforms are present in the human 
brain, each consisting of different combinations of sub-units, namely α1-6, β1-3, γ1-3, 
Є, δ, θ, π.  The most common combinations of subunits are given in Table 6.1. 
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Table 6.1.  Subtype combinations and regional and cellular distributions of the most 
abundant GABAA receptors in the CNS 
 
Sub-Unit Combination Brain Region Expression Cellular Location 
α1β2γ2 
Cortex, Colliculi, GP, SN, Cerebellar 
GC 
Synaptic 
α2β2/3γ2 Hippocampus, Striatum, Amygdala Synaptic 
α3βxγ2/γ3 Cortex, RN, Thalamus Synaptic 
α4βxγ2 DG, Striatum, PVN, Thalamus Peri-, Extra-Synaptic 
α6β2δ Cerebellum, Medulla Peri-, Extra-Synaptic 
α5β3γ2/γ3 Hippocampus Peri-, Extra-Synaptic 
 
Table adapted from (Fritschy and Mohler, 1995, Fritschy et al., 1992, Sieghart and Sperk, 
2002, Rudolph et al., 2001, McKernan and Whiting, 1996, Olsen and Sieghart, 2008, 
Maloteaux et al., 1987). Typical 2:2:1 α:β:γ stoichiometry. GP = Globus Pallidus, 
SN = Substantia Nigra, RN = Raphe Nucleus, PVN = Paraventricular Nucleus, DG = Dentate 
Gyrus. 
 
 
The GABAA receptor is implicated in a variety of physiological and pharmacological 
responses, for example learning, memory and cognition (typically α5-), 
benzodiazepine induced sedation (typically α1-), anxiolysis (typically α2-, α3-, α4-) 
and anticonvulsant (α3-containing receptors).  
 
6.1.1.1.  Imaging the GABAA receptor and endogenous GABA release with 
[
11
C]Ro15-4513 
 [
11
C]Ro154513 is an α5- preferring benzodiazepine receptor inverse agonist (Mohler 
et al., 1984, Myers et al., 2012a, Maeda et al., 2003, Lingford-Hughes et al., 2002), 
showing high uptake in the hippocampus, cortex, accumbens, amygdala and  
Olfactory bulb (Nakano et al., 1998, Lingford-Hughes et al., 2002, Sieghart et al., 
1987).  [
11
C]Ro15-4513 imaging has been implemented in various patient populations 
where, for example, reductions in prefrontal cortical and hippocampal binding have 
been associated with an increased negative symptom score in schizophrenic patients 
(Asai et al., 2008).  In addition, decreased binding of [
11
C]Ro15-4513 in the 
accumbens and subcallosal areas has been observed in patients with autism spectrum 
disorder compared with healthy controls (Mendez et al., 2013), and lastly, a decrease 
in binding to the hippocampus, nucleus accumbens and amygdala of abstinent alcohol 
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dependent men has been measured compared with control subjects (Lingford-Hughes 
et al., 2012). 
 
[
11
C]Ro15-4513 has been assessed for its sensitivity to endogenous GABA release 
following a pharmacological challenge in vivo (Tyacke et al., 2009, Myers et al., 
2012b).  Circulating GABA concentrations can be pharmacologically enhanced by 
inhibiting GABA’s enzymatic break down (via GABA transaminase) using 
compounds such as vigabatrin (Jolkkonen et al., 1992, Benturquia et al., 2004).  
Alternatively, GABA concentrations can be enhanced by inhibiting its re-uptake into 
the pre-synaptic terminal (via GABA transporters (GATs)).  Pre-synaptic GAT-1 
inhibitors such as NNC-711 and astrocytic GAT-3 inhibitors such as SNAPP-5114 
have been shown to significantly increase GABA concentrations in rat CA3 
hippocampal microdialysate samples (Kersante et al., 2013).  Additionally, various 
studies have shown increases in central GABA concentrations following 
administration of the non-selective GAT blocker, tiagabine (Dalby, 2000, Fink-Jensen 
et al., 1992).  
 
Various lines of evidence suggest that [
11
C]Ro15-4513 may be a desirable radioligand 
for imaging GABA release not only due to its α1/α5 selectivity, but also because of its 
inverse-agonist properties. These may make [
11
C]Ro15-4513 more sensitive to 
endogenous GABA release by the GABA-shift (see Figure 6.1.) than other GABAA 
receptor antagonist radioligands such as [
11
C]flumazenil (Verhoeff et al., 1999, 
Schmid et al., 1996).  
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Figure 6.1.  Representation of the GABA-shift in relation to benzodiazepine-receptor 
site radio-labelling.  
Radioligand saturation studies are depicted where specific binding has been determined by 
using an excess of unlabelled benzodiazepine receptor site ligand to define the contribution of 
non-specific binding to observed signals. 
 
 
The GABA-Shift:  The binding of agonist benzodiazepine receptor ligands such as 
[
3
H]flunitrazepam has been shown to increase following administration of GABA 
enhancers (Figure 6.1.A.). A decrease in diazepam ID50 (i.e. increased affinity) at 
[
3
H]flumazenil labelled sites is observed following tiagabine administration. 
Additionally, the IC50 of a range of benzodiazepine receptor agonists have been 
shown to be potentiated by the inclusion of GABA in in vitro competition binding 
assays. Antagonist binding is shown as being unaffected by changes in GABA levels, 
both affinity and receptor availability remain unchanged in an excess or depletion of 
GABA (Figure 6.1.B.). This is also thought to be the case in vivo where no change in 
binding with radioligands such as [
11
C]flumazenil are observed following 
perturbations of GABA despite increases in GABA being shown with magnetic 
resonance spectroscopy. Inverse-agonists of the benzodiazepine receptor site such as 
β-carboline derivatives β-CCM, β-CCE and DMCM, have been shown to decrease in 
affinity following exposure to enhanced GABA levels using in vitro binding (Figure 
6.1.C.). The ability of inverse agonists to decrease the threshold of seizure type-
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discharge in EEG recordings from baboons has also been shown to be reduced 
following enhancement of GABA levels with vigabatrin, suggesting an decrease in 
inverse agonist efficacy or affinity with increased GABA concentrations in vivo. 
Tyacke et al (2009) show that the binding of [
3
H]Ro15-4513 is shifted in the opposite 
direction to that observed following enhancement of GABA levels, after depletions of 
GABA levels using administration of the glutamic acid-decarboxylase inhibitor 
isoniazid. 
(Maloteaux et al., 1987, Kemp et al., 1987, Wood et al., 1984, Mohler and Richards, 
1981, Verhoeff et al., 1999, Prather et al., 1991). 
 
Assessment of [
11
C]Ro15-4513’s sensitivity to increases in endogenous GABA levels 
using tiagabine is currently underway. Initial data suggest a significant decrease in 
binding is observed in the hippocampus and the anterior cingulate gyrus following 
tiagabine at the α1 receptor subtype and a significant increase in binding is observed 
following tiagabine globally at the α5 receptor sub-type (Myers et al., 2012b).  
 
6.1.1.2.  Agonist-Induced Internalisation of GABAA 
Cellular trafficking of GABAA receptors is well characterised (Michels and Moss, 
2007).  Clathrin mediated endocytosis of GABAA has been shown to occur on a 
constitutive and use dependent level, recycling GABAA at the cell surface (Barnes, 
2000, Michels and Moss, 2007, Vithlani et al., 2011).  Both insertion of newly 
synthesised or recycling of membrane bound receptors is thought to occur mainly at 
extra-synaptic sites.  Therefore lateral mobility of GABAA receptors and 
post-translocation synaptic cytoskeleton anchoring for α2-containing receptors and 
extra-synaptic anchoring for α5-containing receptors, has been described (Jacob et al., 
2008).  GABAA receptors associated with clathrin coated pits have been identified at 
the electron microscopy level (Tehrani and Barnes, 1993), the abundance of receptors 
found in these pits have been shown to change following lorazepam treatment 
(Barnes, 1996). This information suggests that GABAA receptors are susceptible to 
pharmacologically induced internalisation following both GABA and benzodiazepine 
receptor agonist. 
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6.1.2.  Serotonin Transporter (SERT) 
SERT is a twelve membrane spanning protein, sharing significant amino acid identity 
with other monoamine transporters such as the dopamine and noradrenaline 
transporters.  Primarily located pre-synaptically on serotonergic neurons projecting 
from the dorsal and medial raphe in the mid-brain, SERT co-transports serotonin 
along with Na
+
 and Cl
- 
into the cell whilst transporting K
+
 out of the cell in a  1:1:1:1 
stoichiometry (reviewed in (Rudnick, 2006)).  Pharmacological SERT blockade by 
selective serotonin re-uptake inhibitors have proven efficacious in improving 
outcomes in a variety of patient populations such as major depression (Emslie et al., 
1997, Clerc et al., 1994), panic disorder (Stahl et al., 2003) and generalised anxiety 
disorder (Hoehn-Saric et al., 2004).  In addition to the effects of selective SERT 
blockers in alleviating neuropsychiatric symptoms, various illicit drugs such as 
D-amphetamine, D-methamphetamine and MDMA are all non-selective SERT, 
Noradrenaline Transporter (NAT) and Dopamine Transporter (DAT) blockers 
(reviewed in (Rothman and Baumann, 2003).  
 
6.1.2.1.  SERT Imaging and imaging 5HT release with [
11
C]DASB 
[
11
C]DASB is routinely implemented in order to non-invasively image SERT.  
[
11
C]DASB provides an increased cortical signal to noise ratio compared with other 
SERT PET radioligands (Jensen et al., 2003, Szabo et al., 2002, Huang et al., 2002), 
allowing for further investigation of SERT outside the mid-brain, striatum and raphe.  
Differences in SERT binding using in vivo [
11
C]DASB imaging have been observed 
between those with increased body mass index, and in patients with anxiety and 
obsessive compulsive disorder compared with healthy controls (Erritzoe et al., 2010, 
Reimold et al., 2008a, Matsumoto et al., 2010, Miller et al., 2009, Maron et al., 2004).  
Additionally, alterations in SERT binding have been reported following drug use.  
Decreased SERT binding after recreational exposure to 
3,4-methylenedioxymethamphetamine (MDMA) have also been observed using 
[
11
C]DASB imaging (Erritzoe et al., 2011, Reneman et al., 2001, McCann et al., 2005, 
McCann et al., 1998, Semple et al., 1999, Buchert et al., 2004).  
 
The majority of studies which have assessed [
11
C]DASB sensitivity to endogenous 
5HT have used 5HT depletion.  Low–tryptophan diets in combination with 
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tryptophan-free amino-acid drink supplements on study days (reviewed in (Bell et al., 
2001)) have been shown to significantly decrease plasma and CSF tryptophan and 
5-HIAA (a 5HT metabolite), suggesting decreased 5HT turnover (Carpenter et al., 
1998).  In vivo microdialysis studies in the rat hippocampus suggest that similar 
tryptophan depletion regimes result in 5HT levels of around 65% in depleted animals 
compared with controls (Stancampiano et al., 1997).  Two studies in humans using in 
vivo PET imaging with [
11
C]DASB to image SERT combined with tryptophan 
depletion demonstrated no measurable change in binding in any of the regions 
investigated (Talbot et al., 2005, Praschak-Rieder et al., 2005), despite observing 
significant reductions in plasma tryptophan.  As a result of these latter studies it is 
generally assumed that [
11
C]DASB binding is not sensitive to endogenous 5HT levels 
(further reviewed (Paterson et al., 2010)). 
 
6.1.2.2.  SERT Internalisation 
Using immunogold electron microscopy, the SERT protein has been found to 
associate both at the plasma membrane and the cytoplasm of axons and dendrites of 
raphé neurons (Tao-Cheng and Zhou, 1999).  SERT has been seen to endocytose in a 
clathrin-dependent manner to transferrin-positive endosomes following treatment of 
cells with 5HT directly (Kittler et al., 2010), compounds known to cause an increase 
in 5HT (Kivell et al., 2010) and pharmacological substrates such as MDMA 
(Whitworth et al., 2002, Kittler et al., 2010, Kivell et al., 2010).  SSRIs have also been 
shown to decrease SERT radioligand binding, in the absence of gene expression 
changes (Benmansour, 2002).  These studies are consistent with findings from in vivo 
imaging studies where a decrease in binding has been observed in some recreational 
MDMA users (Reneman et al., 2006, Erritzoe et al., 2011) and a decrease in 
[
11
C]DASB binding observed in SSRI withdrawn patients with uni-polar depression 
(Reimold et al., 2008b). 
 
 
6.1.3.  The Dopamine1 Receptor 
The D1 receptor is a seven trans-membrane spanning G-protein coupled receptor.  
High levels of expression of D1 receptor mRNA and radioligand binding are detected 
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in the caudate nucleus, caudate putamen, nucleus accumbens and layers II, V and VI 
of the frontal and visual cortex (Hurd et al., 2001, Cortes et al., 1989, Savasta et al., 
1986).  No D1 receptor mRNA has been noted in the brainstem, cerebellum and 
diencephalon of post-mortem human brain (Hurd et al., 2001).  Electron microscopy 
studies combined with tryptophan hydroxylase staining in the monkey and human 
cortex suggest that D1 receptors are localised extra-synaptic along the dendritic spines 
of glutamatergic pyramidal neurons (Smiley et al., 1994).  The activation of D1 
receptors has been implicated in locomotor activity, learning and memory and the 
rewarding effects of many addictive drugs (Beaulieu and Gainetdinov, 2011).  As 
such there is a strong interest in D1 receptor imaging in Parkinson’s, addiction and 
schizophrenia research.  
6.1.3.1.  D1 receptor imaging and endogenous dopamine release with 
[
11
C]SCH23390 
[
11
C]SCH23390 is D1 receptor antagonist radioligand showing high uptake in the 
putamen and the frontal cortex in humans (Farde et al., 1987).  [
3
H]/[
11
C]SCH23390 
has been tested for its sensitivity to changes in endogenous dopamine following 
pharmacological challenge such as amphetamine (to increase dopamine) or reserpine 
(to deplete dopamine) using both ex vivo dissection and in vivo imaging techniques 
(reviewed in (Laruelle, 2000a)).  Reserpine treatment 24 hours before injection of 
[
3
H]SCH23390 caused an increase in radiotracer uptake (striatum:cerebellum) in the 
mouse, this was reversed by amphetamine treatment (Inoue et al., 1991).  However, 
baboons pre-dosed with 0.5 and 1.0mg/kg of amphetamine where shown to 
demonstrate a small decrease in binding, however this was within the test re-test 
variability, suggesting that [
11
C]SCH23390 is not sensitive to dopamine release in the 
cortex or striatum (Abi-Dargham et al., 1999).  These findings are in agreement with 
studies performed in the Cynomolgus monkey where the effects of reserpine depletion 
and amphetamine enhancement on [
11
C]SCH23390 binding show no change in uptake 
in vivo (Chou et al., 1999).  It is therefore generally accepted that the D1 receptor 
radioligand [
11
C]SCH23390 is not sensitive to manipulation in endogenous dopamine. 
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6.1.3.2.  Internalisation of the D1 receptor 
Internalisation of the D1 receptor has been described in cell lines stably expressing the 
receptor.  Treatment of Sf9 cells with dopamine results in a significant decrease in 
surface receptor binding concomitant with a decrease in high affinity dopamine 
receptor sites (Ng et al., 1995).  Agonist-induced internalisation of the D1 receptor has 
been described in vivo using electron microscopy.  Control brain slices taken from the 
rat show the D1 is primarily located at the membrane of cell bodies and dendrites of 
striatal neurons with a small amount (<5%) being found associated with the 
cytoplasm.  Following intra-peritoneal or intra-striatal injection of SKF82958, or 
intra-peritoneal injection of amphetamine, a significant increase in the amount of 
endosomal structures immunoreactive for D1 of striatal cell bodies and dendrites was 
observed, whilst a decrease in membrane structure immunoreactivity was also 
observed (Dumartin et al., 1998).  
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6.2.  Aims 
In order to further understand the effect that agonist-induced internalisation may or 
may not be having on PET signals observed with the radioligands [
11
C]Ro15-4513 
(GABAA), [
11
C]DASB (SERT) and [
11
C]SCH23390 (D1) in vivo, the following 
studies were conducted using in vitro homogenate binding: 
 
 Affinity and receptor availability for each radioligand using in vitro 
radioligand binding assays were determined in different cellular 
environments, reflective of those found throughout the agonist-induced 
internalisation pathway. 
 
 In vitro BP values were generated in order to investigate the effects of 
changes in both affinity and receptor availability in one output measurement, 
similar to that utilised in in vivo imaging. 
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6.3.  Methods 
6.3.1.  Membrane Preparation 
Membranes were prepared using the methods outlined in Section 2.1. with tissues 
isolated from male Sprague Dawley rats (~250 g; see Table 6.2. for tissue details).  
For generation of membrane pellets for [
3
H]Ro154513 binding, the hippocampal 
membrane pellets were further washed by centrifugation (32,000 g, 20 minutes, 4 °C)  
in Tris buffer, 4 times to remove any endogenous GABA (according to (Bowery et al., 
1983)).  The final pellets were re-suspended in Tris buffer to approximately 
10 mg/ml. 
 
6.3.2.  Radioligand Binding Assay 
Specific details relating to protein and radioligand concentrations and compound used 
to define the specific binding component can be found in Table 6.2.  All assays were 
conducted using the methods outlined in Section 2.2.  Specific radioligand assay 
conditions are outlined below (Table 6.2.). 
 
Table 6.2.  Radioligand binding assay conditions for each radioligand implemented 
 
Radioligand 
(Target) 
Radioligand 
Concentrati
on Range 
(nM) 
Incubation 
Time 
(mins) 
Compound for 
Specific Binding 
Definition (µM) 
Tissue
 
Protein 
Concentration 
per Well (µg) 
[
3
H]Ro145413 
(GABAAα1/α5) 
0.1 – 50 60 
Flumazenil 
(10) 
Hippocampus 250 
[
3
H]DASB 
(SERT) 
0.10 – 30 60 
Citalopram 
(10) 
Striatum 500 
[
3
H]SCH23390 
(D1) 
0.01 – 30 60 
Butaclamol 
(1) 
Striatum 500 
 
For [
3
H]Ro154513 binding, the membrane pellets were thawed and further washed by 
centrifugation (11,000 g, 20 minutes, 4°C)  in Tris buffer, 4 times.  Protein 
concentrations determinations and data analysis were conducted as outlined in 
Sections 2.5 and 2.6. 
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6.4.  Results 
6.4.1.  [
3
H]Ro15-4513 
The data from all conditions were best fitted to a single site.  No significant difference 
in affinity or availability was observed for [
3
H]Ro15-4513 between any of the cellular 
environments tested (Table 6.3., Figure 6.2.). When in vitro BP values are generated 
using Equation 2 (Section 2.2.6.), no significant difference was observed between any 
of the cellular environments tested (Table 6.3). 
 
Table 6.3.  KD and Bmax and in vitro BP for [
3
H]Ro15-4513 
 
Environment KD (nM) 
Bmax (fmol/mg 
protein) 
Bmax (nM) In Vitro BP 
Extra 
Intra 
Endo 
12.27 ± 1.18 
13.94 ± 1.26 
12.47 ± 1.46 
3738 ± 233 
3897 ± 373 
2803 ± 329 
117.7 ± 11.2 
129.0 ± 15.6 
113.4 ± 8.7 
9.7 ± 0.6 
9.4 ± 0.7 
9.3 ± 0.8 
 
KD (nM), Bmax (fmol/mg protein and nM) and in vitro BP values for [
3
H]Ro15-4513 in rat 
hippocampus (n = 4, mean ± s.e.mean) in the three cellular environments.  One-way ANOVA 
with Tukey post-test were performed using SigmaStat 3.0. Bmax (nM) calculated using 
Equation 1 (Section 2.2.6.) and in vitro BP values generated using Equation 2 (Section 2.2.6.; 
n = 4, mean ± s.e.mean). ANOVA results: KD F(2,9) = 0.49; p = 0.62. Bmax F(2,9) = 3.47; 
p = 0.076. In vitro BP F(2,9) = 0.087; p = 0.92. 
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Figure 6.2.  [
3
H]Ro15-4513 saturation curves using rat hippocampal homogenates 
performed in three different cellular environments  
n = 4. 
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6.4.2.  [
3
H]DASB 
The data from all conditions were best fitted to a single site.  Both affinity and 
apparent receptor availability values were significantly lower in the intracellular and 
endosomal environment compared with the extracellular.  A plateau was not able to 
be reached at maximum concentrations in either the endosomal or intracellular 
condition for [
3
H]DASB.  KD and Bmax estimation was therefore not possible in these 
two environments (data published (Quelch et al., 2012); see Table 6.4, Figure 6.3.). 
 
Table 6.4.  KD and Bmax and In vitro BP for [
3
H]DASB 
 
Environment KD (nM) Bmax (fmol/mg protein) Bmax (nM) In Vitro BP 
Extra 
Intra 
Endo 
1.4 ± 0.092 
--/-- 
--/-- 
158.42 ± 15.81 
--/-- 
--/-- 
4.74 ± 0.56 
--/-- 
--/-- 
Extra: 5.74 ± 2.01 
--/-- 
--/-- 
 
KD (nM), Bmax (fmol/mg protein and nM) and in vitro BP values for [
3
H]DASB in rat 
stratum (n = 5, mean ± s.e.mean) in the three cellular environments.  One-way ANOVA with 
Tukey post-test were performed using SigmaStat 3.0. Bmax (nM) calculated using Equation 1 
(Section 2.2.6.) and in vitro BP values generated using Equation 2 (Section 2.2.6.; n = 5, 
mean ± s.e.mean). --/-- = Not determinable. 
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Figure 6.3.  [
3
H]DASB saturation curves using rat striatal homogenates performed in 
three different cellular environments  
n = 5. 
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 6.4.3.  [
3
H]SCH23390  
The data from all conditions were best fitted to a single site.  Affinity values were 
significantly lower for [
3
H]SCH23390 in the endosomal condition compared with the 
extracellular (p<0.001) and the intracellular conditions (p<0.001; see Table 6.5., 
Figure 6.4.).  No significant change in receptor availability was observed between any 
of the cellular environment tested, however a trend for a lower receptor availability 
was observed in the endosomal environment compared with the extracellular and 
intracellular (p = 0.059; Table 6.5., Figure 6.4.). When both changes in affinity and 
receptor availability are taken into account (by generation of in vitro BP values) none 
of the buffers tested had any significant effect on [
3
H]SCH23390 binding in the rat 
striatum (Table 6.7.). However, a higher in vitro BP is observed in the intracellular 
environment compared with both the extracellular and the endosomal, but this did not 
reach significance. 
 
 
Table 6.7.  KD, Bmax and In vitro BP for [
3
H]SCH23390. 
 
Environment KD (nM) Bmax (fmol/mg protein) Bmax (nM) In Vitro BP 
Extra 
Intra 
Endo 
 
0.56 ± 0.04 
0.96 ± 0.03
* 
2.7 ± 0.23
**/## 
 
121.33 ± 17.27 
136.03 ± 25.51 
70.9 ± 2.01 
2.01 ± 0.40 
7.13 ± 3.02 
3.91 ± 0.74 
3.56 ± 0.63 
7.25 ± 3.01 
1.39 ± 0.18 
 
KD (nM), Bmax (fmol/mg protein and nM) and in vitro BP values for [
3
H]SCH23390 in rat 
striatum (n = 4, mean ± s.e.mean) in the three cellular environments.  One-way ANOVA with 
Tukey post-test were performed using SigmaStat 3.0. Bmax (nM) calculated using Equation 1 
(Section 2.2.6.) and in vitro BP values generated using Equation 2 (Section 2.2.6.; n = 4, 
mean ± s.e.mean). ANOVA results: KD F(2,9) = 70.1; p < 0.001. Bmax F(2,9) = 3.67; 
p = 0.068. In vitro BP F(2,9) = 2.78; p = 0.12. 
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Figure 6.4.  [
3
H]SCH23390 saturation curves using rat striatal homogenates performed 
in three different cellular environments  
n = 4 
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6.5.  Discussion 
The data presented in this chapter outlines the varied effects that cellular trafficking of 
different types of target proteins may have on radioligand binding.  Furthermore, 
these data show that the data previously presented in chapters 2 and 3 of this thesis, 
are not restricted solely to G-protein coupled receptors, but also apply to other 
proteins such as transporters and ionotropic receptors.  
 
GABAA - No changes in binding were observed following exposure of the pentameric 
GABAA receptor to different cellular buffers.  This suggests that agonist-induced 
endocytosis or increased sequestration of the GABAA as a result of GABA release, 
disease state, pharmacotherapy or drug use, would result in no change in binding.  
Direct occupancy, down-regulation and degradation or the GABA-shift may therefore 
be the main factors contributing to changes in binding observed with [
11
C]Ro15-4513 
in vivo. 
 
SERT - A dramatic reduction in the ability of the twelve membrane-spanning SERT 
protein to bind was observed in both the cytosolic and endosomal environments 
compared with those found at the plasma membrane.  These data suggest that 
following administration of substances known to cause endocytosis of SERT (e.g. via 
pharmacotherapies such as SSRIs, or recreational drug use such as MDMA), the 
observed in vivo changes in binding with [
11
C]DASB may be related to a reduced 
ability to bind in the endosomal or cytosolic compartments.  
 
D1 receptor - A significant decrease in affinity was observed in the endosomal 
condition for the seven trans-membrane spanning D1 receptor radioligand 
[
3
H]SCH23390.  However, when changes in both affinity and receptor availability in 
these conditions were taken into consideration i.e. by generation of in vitro BP values, 
no significant differences were observed.  This data supports in vivo studies 
suggesting that [
11
C]SCH23390 may not be sensitive to acute changes in endogenous 
dopamine levels.  
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6.5.1.  GABAA receptor binding 
The GABAA receptor has been shown to internalise both constitutively and in a 
use-dependent manner following exposure to its endogenous agonist.  Our data 
suggest that endocytosis of GABAA receptors to intracellular vesicles following 
increases in extracellular GABA concentrations may not alter the binding ability of 
[
11
C]Ro15-4513.  The changes in binding observed in such studies are therefore more 
likely explained by the GABA shift.  In addition, changes observed in patient 
populations or dependent subjects are perhaps better explained by endocytosis and 
rapid degradation of receptors in lysosomes or changes in receptor transcription rather 
than by a decreased ability of [
11
C]Ro15-4513 to bind in sub-cellular compartments.  
 
6.5.1.1.  GABAA receptor binding in different physiological environments 
The effect of various ions on both GABA and benzodiazepine receptor site binding 
has been previously investigated.  Inclusion of sodium chloride in assay buffers dose 
dependently increases [
3
H]diazepam binding in rat whole brain homogenates, by an 
increase in receptor affinity.  The facilitation of binding by sodium chloride was 
further potentiated by inclusion of GABA in assay buffer (Martin and Candy, 1978).  
[
3
H]Diazepam binding is also pH dependent, displaying an inverted-U shape, with 
peak binding at pH 7.5 (Mohler and Okada, 1977).  However, changes in pH from 
4.5 - 8.5 did not significantly alter [
3
H]Ro15-4513 receptor binding in α1β2γ2 stably 
expressing HEK293 cells (Wieland et al., 1992).  To our knowledge α5 pH sensitivity 
has not been specifically tested.  
 
Many of the studies previously described have been conducted with benzodiazepine 
receptor agonist ligands.  However, [
3
H]Ro15-4513 is an inverse agonist and our 
studies suggest that significant changes in sodium, potassium, chloride and pH result 
in no significant alteration in either affinity or availability.  Therefore, it could be 
hypothesised that [
11
C]Ro15-4513’s binding site is allosterically modulated 
differently by mono- and divalent ions to that of benzodiazepine agonists.  
 
In comparison to the previous studies described, we have used homogenates from rat 
hippocampus, containing both α1 and α5 receptors.  Both α1 and α5 are bound by 
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[
3
H]Ro15-4513.  Preliminary studies with tiagabine in healthy males suggest a 
decrease in α1 binding and an increase in α5 binding may be observed in vivo (Myers 
et al., 2012b).  These receptor sub-types maybe differentially sensitive to changes in 
binding conditions implemented in our assay system.  Changes in binding at one 
receptor sub-type may negate the effects of another when binding is investigated in a 
tissue preparation containing both α1 and α5.  Further studies investigating the effects 
of our cellular environments using selective compounds for either individual α1 or α5 
sub-types may be advantageous or in cell lines selectively expressing either α1- or 
α5- containing GABAA. 
 
6.5.2.  SERT binding 
6.5.2.1.  SERT binding in different physiological environments 
The regulation of SERT radioligand binding by changes in ionic conditions has 
previously been investigated.  For example, the binding of both the cocaine derivative 
β[125I]CIT and [3H]imipramine is potentiated by increases in sodium concentration 
(Humphreys et al., 1994, Wall et al., 1993).  Furthermore, the binding of 
[
3
H]imipramine and 5-HT is pH insensitive and promoted by increases in chloride 
concentration, whereas the binding of β[125I]CIT is pH sensitive and chloride ion 
insensitive (Wall S., 1992).  The amino acids Cys-109 and Cys-357 have been 
proposed to confer monovalent action sensitivity to radioligand binding 
(Androutsellis-Theotokis et al., 2001).  The data presented here suggest, that like 
other SERT radioligands, the binding of DASB is sensitive to changes in ionic 
conditions.  Specifically, a decrease in sodium and chloride concentrations 
significantly reduced both affinity and receptor availability in the intracellular 
condition compared with the extracellular.  This decrease in binding ability was 
further potentiated by a significant decrease in pH (in the endosomal condition), such 
that no binding parameters could be determined in either of these unfavourable 
conditions.  
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5.5.2.2.  SERT binding and internalisation of SERT 
Together with the data presented in this chapter, various lines of evidence suggest that 
altered [
11
C]DASB binding observed in vivo, in patient or drug using populations, 
maybe related to altered levels of intracellular SERT sequestration: 
 Mitogen Activated Protein Kinases (MAPKs) are proposed to be involved in 
surface SERT expression.  p38-MAPK has been shown to be involved in the re-
distribution of SERT proteins between surface and intracellular stores by acting 
downstream of protein kinase C (PKC) (Samuvel et al., 2005).  Subsequently, 
induction of depressive-like behaviours in animals leads to decreases in frontal 
cortex MAPK1 (Qi et al., 2006). 
  PKC activation is paralleled by a decrease in SERT cell surface expression (Qian 
et al., 1997).  SSRIs, which are commonly used to treat various affective 
disorders, have also been observed to facilitate PKC phosphorylation 
(Ramamoorthy and Blakely, 1999) and down regulation of membrane bound 
SERT (Benmansour et al., 1999).  Interestingly, an increase in soluble PKC levels 
have been observed in the frontal cortex of Alzheimer’s Disease free suicide 
victims with a history of depression compared with the brains of healthy controls 
(Coull et al., 2000).  
 Other SERT substrates such as MDMA have also been shown to cause an increase 
in membrane bound protein kinase C (PKC) (Kramer et al., 1995, Kramer et al., 
1998), which is known to modulate SERT surface expression.  Furthermore, both 
MDMA and 5HT has been shown to endocytose SERT directly (Whitworth et al., 
2002, Kittler et al., 2010, Kivell et al., 2010).  
 
Taken together, these data suggest that alterations in proteins known to regulate SERT 
at the plasma membrane (by either underlying pathology or compound exposure) in 
patient or recreational drug using populations, may lead to a change in SERT 
radioligand binding and hence underpin the observed reduction in binding in these 
groups with [
11
C]DASB.  
 
6.5.3.  D1 receptor binding in different physiological environments 
The data presented here suggest that despite reductions in affinity in the endosomal 
condition, when both receptor availability and affinity are taken into account, no 
Chapter 6: The Effects of Different Cellular Environments on PET Ligand Binding 
 
 
~ 181 ~ 
significant change in binding would be observed following intracellular trafficking of 
D1 for [
11
C]SCH23390. A dramatic increase in in vitro BP was observed in the 
intracellular condition when compared with the extracellular and the endosomal, 
however, the physiological significance of this receptor compartment to overall tissue 
binding remains to be determined. 
 
6.5.3.1.  D1 receptor binding and ionic conditions. 
Consistent with data presented in this chapter, changes in assay sodium levels have 
previously been shown to alter [
3
H]SCH23390 affinity without effecting receptor 
availability (Tomic et al., 1993, Niznik et al., 1986).  Sodium has also been shown to 
convert [
3
H]SCH23390 bound D1 population from both high and low affinity to low 
affinity only, thereby reducing dopamine’s overall affinity for the D1 (Tomic et al., 
1993, Niznik et al., 1986).  Inclusion of magnesium and calcium in assay buffers have 
been shown enhance [
3
H]SCH23390 binding in rat striatum via an increase in receptor 
availability rather than affinity (Braestrup and Andersen, 1987).  However given the 
concentration ranges which have been investigated by Braestrup et al (1987) and 
those which are included in the cellular buffer system implemented in this chapter  it 
is not envisaged that changes in either cation concentration would have impacted 
significantly on receptor binding.  
 
6.5.3.2.  D1 receptor binding in vivo 
Various PET studies have been conducted in schizophrenic patients with respect to D1 
receptor density.  No changes are routinely observed in the striatum, whereas both 
increases and decreases in D1 receptor binding have been observed in the cortex 
(Thompson et al., 2009).  This has also been observed in some but not all ex vivo post-
mortem studies of brains from schizophrenic patients (Seeman and Niznik, 1990).  It 
is thought that differences in [
11
C]SCH23390 sensitivity to externalisation of 
receptors may underlie these discrepancies (Thompson et al., 2009).  Given the data 
included in this chapter, it could be suggested [
11
C]SCH23390 would not be sensitive 
to changes in externalisation.  This supports studies showing the inability of this 
ligand to detect differences in binding between control and schizophrenic subjects 
(Karlsson et al., 2002).  Future studies investigating the ability of [
3
H]NNC1112 to 
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binding in different cellular environments would be of interest in order to further 
confirm changes in binding observed in patients versus controls with other D1 
receptor radioligands.  
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6.6.  Conclusions 
The data presented in this chapter further extends that presented in previous sections 
with other PET protein targets and their radioligands. Specifically, the data 
demonstrates that different types of protein targets, known to undergo cellular 
trafficking, are differentially sensitive to changes in their cellular environment with 
respect to their ability to bind prototypical PET radioligands.  Furthermore, these data 
translate to findings previously presented in vivo with these radioligands. 
 
No changes in either receptor affinity or availability was observed for the ligand-gated 
ionotropic GABAA receptor when labelled with [
3
H]Ro15-4513.  This suggests 
changes in [
11
C]Ro15-4513 binding observed following perturbations in endogenous 
GABA are more likely to be explained by alterations in receptor conformation and 
their influences on benzodiazepine receptor binding i.e. The GABA-Shift.  
Additionally, no changes in in vitro BP were observed for the D1 receptor antagonist 
radioligand [
3
H]SCH23390.  These findings also support in vivo data suggesting that 
[
11
C]SCH23390 might not be sensitive to endogenous dopamine release following 
amphetamine administration.  In contrast, a dramatic reduction in both the 
intracellular and endosomal binding ability were observed with [
3
H]DASB.  These 
findings may have significant implications when interpreting data from clinical PET 
studies in patient and recreational drug using populations using this PET ligand. 
 
Collectively, these data demonstrate the importance of investigating a given 
radioligand and its associated protein targets’ sensitivity to binding in different 
cellular compartments.  Not only with respect to interpreting the signal changes 
observed in in vivo endogenous release and patient population imaging paradigms, 
but for understanding the mechanisms of action of various pharmacotherapies and 
recreational drugs.  
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CHAPTER 7 
General Discussion 
 
The data presented in this thesis aimed to: 
1. Investigate the effect receptor internalisation may have on binding signals 
observed during in vivo competition binding studies with D2/3 receptor 
radioligands (Pages 50 – 54).   
2. Characterise the cellular composition of the binding signals observed for 
three widely implemented D2/3 receptor radioligands in physiologically 
relevant tissues and assay conditions (Pages 55 – 63).   
3. Translate the methodologies initially characterised with  the D2/3 system to 
other receptor systems, via assessment of the ability of a novel 
pharmacological challenge to cause endogenous opioid peptide release and 
alter radioligand binding (Page 97 – 105). The effects of receptor 
translocation as a result of pharmacological challenge, was assessed using 
both in vitro (89 – 96) and ex vivo (Page 106 – 116) radioligand binding 
and immunofluorescence techniques (Page 142 – 156). 
4. Determine the effects of protein translocation from the cell surface to 
sub-cellular compartments using three commonly used PET radioligands 
for target proteins distinct from G-proteins (i.e. transporters and ion 
channels), in order to extend my hypothesis beyond G-protein coupled 
receptor - radioligand interactions (Page 173 – 176).  
 
7.1.  Implications for imaging dopamine release with D2/3 receptor radioligands 
I have demonstrated for the D2/3, receptors, a system known to be reproducibly 
sensitive to endogenous dopamine release in vivo, that following receptor 
internalisation, the ability of [
3
H]/[
11
C]raclopride, [
3
H]/[
11
C]PhNO and 
[
3
H]/[
11
C]spiperone to bind is significantly reduced. This reduction in binding is 
primarily driven by a reduced affinity in the endosomal compartment as a result in 
altered equilibrium kinetics. The magnitude of this reduction is related to the 
sensitivities of these radioligands to endogenous dopamine release in vivo. 
Furthermore, I have demonstrated that the majority of striatal binding observed for 
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these three radioligands in vivo would be due to receptors embedded in the plasma 
membrane. However, a significant proportion of this signal, at least for [
3
H]/ 
[
11
C]raclopride and [
3
H]/[
11
C]PhNO, would be due to receptors in the microsomal cell 
fraction binding with a significantly lower affinity. Despite the majority of total cell 
protein being found in the cytosol and a considerable amount of D2/3 receptor 
immunoreactivity, the cytosolic fraction had a very small amount of specific 
receptor/ligand binding. So this fraction would be expected to contribute very little to 
overall cell binding with any of the D2/3 radioligands tested. 
 
Significant reductions in affinity in the endosomal compartment, driven by marked 
decreases in dissociation rates for [
11
C]raclopride may contribute to the prolonged 
decrease in binding observed in vivo following dopamine release.  
 
The proportion of membrane receptors lost, and their cellular translocation following 
amphetamine treatment remains to be determined for [
11
C]PhNO. Such studies would 
greatly increase our understanding of the cellular basis and overall contribution of 
agonist-induced internalisation to signal changes observed following amphetamine 
treatment with [
11
C]PhNO (Figure 7.1.).  Furthermore, assessment of the proportion 
of both D2
high
 and D3 receptors occupied by dopamine under baseline conditions 
would allow determination of the potential maximum signal change which may be 
expected in vivo (Figure 7.1.). Both of these studies outlined could be conducted using 
the methodology presented in this thesis. 
 
No effect of different cellular environments on [
11
C]spiperone binding likely underpin 
the lack, or paradoxical signal change observed following dopamine release. The 
5HT2A receptor is known to contribute to [
11
C]spiperone binding, however the effect 
of amphetamine treatment on internalisation of 5HT2A has not been assessed. Changes 
in 5HT2A cellular distribution may also contribute to the intracellular trapping and lack 
of sensitivity to endogenous transmitter release observed in vivo with [
11
C]spiperone. 
 
Figure 7.1. demonstrates a summary of our current knowledge regarding the 
distribution of D2/3/ receptors in relation to in vivo imaging with [
11
C]raclopride, 
[
11
C]PhNO and [
11
C]spiperone binding The contributions made to this area by the 
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data presented in this thesis are also highlighted. Changes in affinity and receptor 
kinetics following endocytosis and the size of sub-cellular pools to baseline 
radioligand binding have been determined (Figure 7.1.). Currently, a quantitative 
measure of receptor internalisation following amphetamine treatment in tissues is 
lacking. Such studies have been demonstrated in cell models following direct 
stimulation however, the duration and extent of receptor internalisation remains to be 
confirmed in tissues. Given this additional information a model whereby the overall 
impact of receptor internalisation to the changes in binding signals observed during in 
vivo competition imaging studies with these radioligands may potentially be 
developed. 
 
Alterations in receptor binding ability throughout different cellular compartments 
may be a crucial predictor of a receptor and its associated radioligands sensitivity to 
endogenous release in vivo. The studies presented here build upon current knowledge 
we have for D2/3 receptor radioligands characteristics in vivo (Figure 7.1.). 
These studies are translatable to other receptor systems where translocation both, to 
and from the plasma membrane, may be occurring following administration of 
agonist stimulation of surface receptors. Therefore, we suggest that these studies may 
aid the translation of in vivo competition imaging paradigms to other receptor 
systems, or could be used to predict sensitivity to release prior to extensive in vivo 
studies being conducted.  
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Figure 7.1.  Current knowledge and gaps in our understanding of cellular basis of D2/3 
receptor binding 
1
Ginovart et al (1997). 
2
(Tziortzi et al., 2011).
 3
Cumming et al (2011). Bold text = Determined 
in this thesis. 
 
The contribution of synaptic and extrasynaptic receptors has not been considered 
within this set of studies. Homogenisation and cell fractionation will not distinguish 
between the two receptor pools and therefore the results presented within this thesis 
will reflect changing affinities at both synaptic and extrasyanptic receptors. Laruelle 
(2012) proposes that the D2/3 receptor pool can be sub-divided into four (1) those 
receptors which are occupied by dopamine under baseline conditions (D2
high
, ~10%), 
(2) those which are sensitive to endogenous dopamine release within the synapse 
(D2
high
, ~30%), (3) those which are in the D2
high
 configuration, but that are 
extrasynaptic and not sensitive to release of dopamine following a challenge (~20%), 
and (4) those which are configured in the D2
low
 configuration (~35%) and are 
therefore not sensitive to dopamine release in vivo. Knowledge of the abundance of 
receptor sites which are extrasynaptic further explains the ceiling effect associated 
with this class of PET radioligands. As such, assessment of the contribution of 
extra- versus intrasynaptic receptor localisation and their respective sensitivities to 
endogenous neurotransmitter release for protein targets outside the D2/3 may help 
interpret data obtained implemented in other novel radioligands.  
 
7.2.  Implications for imaging endogenous opioid peptide release. 
Using acute amphetamine treatment as a novel pharmacological challenge, previously 
shown to cause endogenous opioid peptide release, a relationship between regional 
uptake of [
11
C]carfentanil under saline conditions and a reduction in binding 
post-amphetamine is observed. Similar observations were observed with the positive 
control, and µ receptor agonist, methadone. However, no such findings were observed 
with [
3
H]diprenorphine (Figure 7.2.). Differences in radioligand pharmacology likely 
contribute to the disparity observed between these radioligands sensitivity to 
endogenous peptide release following amphetamine challenge. For example, 
[
11
C]carfentanil is high affinity, µ selective agonist radioligand, whereas 
[
3
H]diprenorphine is a non-selective µ, δ and κ receptor antagonist. Furthermore, the 
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ability of amphetamine to alter circulating peptides, selective for κ and δ receptors 
remains to be determined (Figure 7.2.).  
 
Figure 7.2. summarises the findings from the studies presented in this thesis and some 
of the knowledge present in the literature regarding [
11
C]diprenorphine and 
[
11C]carfentanil’s suitability for imaging endogenous neurotransmitter release in vivo . 
Importantly, the differing sensitivities to endogenous peptide release following acute 
amphetamine treatment of [
11
C]diprenorphine and [
11
C]carfentanil and the 
assumptions that can now be made regarding the effects of agonist induced 
internalisation on the changes in binding observed in these studies are demonstrated 
(Figure 7.2.).   
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Figure 7.2. Current status of in vivo competition imaging with acute amphetamine 
challenge with the opioid receptor radioligands [
11
C]diprenorphine and [
11
C]carfentanil 
Bold text = Determined in this thesis. 
 
The occupancy model more than likely contributed to the decreases in binding 
observed during these studies – the affinity of peptides selective for 
[
11
C]diprenorphine and [
11
C]carfentanil labelled sites have been determined (Figure 
7.2.). However, currently changes in circulating levels of endomorphin, enkephalins 
and dynorphins using microdialysis are undetermined.  
 
Importantly, various lines of evidence presented in this thesis suggest that 
agonist-induced internalisation of µ receptors may be contributing to the reductions in 
binding observed in the ex vivo microdissection studies using the identical 
amphetamine dosing protocol (Figure 7.2.).  These are: 
 
 A significant reduction in the ability of [11C]carfentanil to bind in ionic conditions 
representative of  the early endosome was observed when compared with those 
found at the cell surface, using in vitro saturation binding 
 A significant reduction in total homogenate [11C]carfentanil binding sites was 
observed following amphetamine treatment using in vitro radioligand binding 
 A trend for an increase in the amount of [11C]carfentanil binding in microsomal 
fractions was observed following both amphetamine and methadone treatment 
using ex vivo sub-cellular fractionation and in vitro radioligand binding 
 Increased µ receptor-early endosome co-localisation was observed following 
amphetamine and methadone treatment using ex vivo dual labelling 
immunofluorescence 
 A dramatic increase in receptor co-localisation was observed in the hypothalamus, 
where a significant increase in early endosome immunoreactivity was observed 
using mean grey scale intensity analysis, consistent with an upregulation of the 
endocytic pathway 
 
Collectively, these data suggest that activation of dopaminergic receptors following 
endogenous dopamine overflow, can also lead to a release of opioid peptides and a 
subsequent reduction in µ receptor radioligand binding. The reductions in binding 
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observed are likely to be due to a combination of both direct competition of 
radiolabelled sites by endogenous opioid peptides and a reduced ability to bind 
following agonist-induced internalisation to endosomal compartments. However, 
fundamentally, I have demonstrated that internalisation processes are contributing to 
the reductions in binding observed in vivo following endogenous peptide release in a 
neurotransmitter system outside of the D2/3. This further highlights that assessment of 
the ability of a particular radioligand to bind throughout different cell compartments 
maybe a crucial predictor in determining sensitivity to endogenous release in vivo. 
Additionally, these data suggest that the use of pre-clinical experimental 
methodologies such as those developed and reported in this thesis, can successfully 
support, and lead to the development of a protocol that allows for imaging of novel 
neurotransmitters release in vivo. 
 
7.3.  Implications for imaging other PET target proteins 
Building upon the studies presented with both the D2/3 and opioid receptor 
radioligands we have demonstrated the importance of investigating the ability of 
different protein targets to bind in different cell compartments (i.e. ion channels and 
transporter proteins).   
 
The GABAAα1/α5 benzodiazepine receptor inverse agonist [
11
C]Ro15-4513 would  
not be expected to differentiate in terms of its ability to bind at the cell surface and 
within endocytic vesicles. Despite a trend for a reduced receptor availability in the 
endosomal environment, when both affinity and availability were taken into 
consideration we do not expect internalisation processes to contribute dramatically to 
the changes observed in vivo following GABA release. Furthermore, since GABA is 
not expected to bind to the same allosteric site as benzodiazepine agents, direct 
competition does not apply when using [
11
C]Ro15-4513 to image changes in GABA 
concentrations. Subsequently, given the information presented here, we suggest that 
the main contributor to signal changes observed using [
11
C]Ro15-4513 to image 
GABA release may be due to the GABA-shift.  
 
The cellular mechanisms underpinning changes in [
11
C]Ro15-4513 binding following 
tiagabine administration warrant further investigation, since both increases and 
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decreases have been observed at α5 and α1 receptors, respectively in vivo  (Myers et 
al., 2012b). However, the data presented here allow further clarification of the 
changes observed in these studies. Furthermore, these data have wider implications 
with respect to studies conducted in patients or drug using groups. Changes in binding 
observed when comparing patients to healthy controls may previously have been 
inferred to be due to receptor down-regulation or increased sequestration. However, 
we suggest that since [
11
C]Ro15-4513 is equally as able to bind GABAAα1/α5 inside 
the cell as well as on the cell surface that increases or decreases in binding will be 
driven by changes in receptor availability and therefore changes in receptor synthesis 
and/or degradation.  
 
The ability of the serotonin transporter protein to bind [
11
C]DASB in sub-cellular 
compartments was shown to be significantly reduced compared with when it is 
present at the cell membrane. [
11
C]DASB is not thought to be sensitive to endogenous 
5HT release in vivo. The majority of studies with [
11
C]DASB have investigated 
serotonin depletion rather than enhancement. Therefore, the sub-cellular SERT pool 
warrants further investigation. Perhaps, given the data presented in this thesis, the 
translocation of SERT proteins from sub-cellular reserves is not great enough to 
contribute to an increase in [
11
C]DASB binding once at the cell surface. Therefore, 
further studies modulating 5HT augmentation with [
11
C]DASB may provide a better 
means of imaging endogenous 5HT release, since following endocytosis of SERT to 
the endosomal environment its ability to bind would be significantly reduced.  
 
Interestingly, [
11
C]DASB binding is reduced in various disease populations and 
recreational drug using populations. Various proteins known to be involved in the 
regulation of surface levels and intracellular trafficking of SERT are modified in 
certain disease models or by certain pharmacotherapies. Therefore, it may be inferred 
that if [
11
C]DASB binding is reduced in a patient population and the cellular 
trafficking machinery for SERT is also changed in this disease state, that the 
alterations in binding may not represent decreased SERT levels, but increases or 
decreases in the sequestration of SERT at the cell surface.  
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The D1 receptor radioligand [
11
C]SCH23390 was not thought to be sensitive to 
endogenous dopamine release in vivo. Here we suggest that despite significant 
reductions in receptor affinity in the endosomal condition, when both affinity and 
receptor availability changes are taken into account D1 would not be expected to 
exhibit a reduced ability to bind following internalisation. These data are in support of 
in vivo reports where [
11
C]SCH23390 and [
11
C]raclopride have been compared within 
the same animal following the same dose of amphetamine.  
 
Dramatic changes in D1 receptor cellular immunoreactivity has been observed in 
Parkinson’s disease models and patient brain samples when compared with healthy 
controls (with and without L-DOPA treatment). However, no differences in 
[
11
C]SCH23390 binding was observed in these patient populations compared with 
healthy controls.  Assessment of other D1 receptor radioligands sensitivity to binding 
in different cellular environments maybe a crucial milestone in increasing our 
understanding of the cellular mechanisms underlying pathology progression in 
diseases such as Parkinson’s. Furthermore, such studies may also aid the translation of 
in vivo competition imaging to another sub-type of dopamine receptors, outside the 
D2/3 receptors. 
 
 
A summary of the effects of PET radioligand target protein endocytosis is further 
highlighted in table 7.1. The knowledge currently available regarding protein 
trafficking, the cellular proteins involved, the potential changes in this endocytic 
machinery in patient populations and the sensitivity of target radioligands to changes 
in ionic conditions is considered. Fundamentally, the sensitivity of these radioligands 
to endogenous release in vivo is summarised and the potential contribution of target 
protein internalisation in challenge studies or increased sequestration in patient 
population studies is emphasised (Table 7.1.). 
 
  
 
Table 7.1. Summary of the potential effect of PET target radioligand internalisation on binding observed in vivo 
- Refers to radioligand acting as either a substrate or blocker for a transporter protein. * Refers to radioligand acting as an allosteric site inverse agonist. 
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Dopamine                
[11C]Raclopride D2/3  ✓ 2.01
$ 1.33 ✓ ✓ ✓ ✓ x$ ✓$ ✓$ x$ ✓ ✓$ 
[11C]PhNO D2/3 ✓  0.56
$ 2.14 ✓ ✓ ✓ ✓ x$ ✓$ ✓$ x$ ✓ ✓$ 
[11C]Spiperone D2/3  ✓ 0.09
$ 3.65 ✓ ✓ ✓ ✓ x$ x$ ✓$ ✓$ x ✓$ 
[11C]NPA D2/3 ✓  1.10 1.79 ✓ ✓ ✓ ✓  ✓   ✓ ✓ 
[11C]Fallypride D2/3  ✓ 0.05 2.43 ✓ ✓ ✓ ✓     ✓ ✓ 
[18F]FLB457 D2/3  ✓ 0.65 2.90 ✓ ✓ ✓ ✓     ✓ ✓ 
[123I]IBZM D2/3  ✓ 4.2 2.78 ✓ ✓ ✓ ✓     ✓ ✓ 
[11C]SCH23390 D1  ✓ 0.56 2.50 ✓ ✓ ✓ ✓  x
$  ✓$ x ✓ 
Opioid                
[11C]Diprenorphine μ,δ,κ  ✓ 0.33$ 3.32 ✓ ✓ ✓ ✓ x$ ✓$ ✓$ ✓$ x
$ ✓$ 
[11C]Carfentanil μ ✓  0.32$ 3.67 ✓ ✓ ✓ ✓ x$ ✓$ ✓$ x
$ ✓$ ✓$ 
[11C]Cyclofoxy μ,κ ✓  3.00  ✓ ✓ ✓ x      ✓ 
[18F]PEO μ,κ ✓  0.40  ✓ ✓ ✓ x      ✓ 
[11C]GR103545 κ ✓  0.02 3.14 ✓ ✓/ x ✓/ x x      ✓ 
Serotonin                
[11C]McN5652 SERT - - 2.00 4.30 ✓ ✓ ✓ ✓  ✓  ✓  ✓ 
[11C]DASB SERT - - 1.40 1.90 ✓ ✓ ✓ ✓  ✓$ x ✓ x ✓$ 
[11C]MDL100907 5HT2A  ✓ 1.86 3.80 ✓ ✓ ✓ ✓  ✓   x ✓ 
[11C]Altanserin 5HT2A  ✓ 2.56 3.50 ✓ ✓ ✓ ✓  ✓   x ✓ 
[11C]Cimbi36 5HT2A ✓  1.01 3.42 ✓ ✓ ✓ ✓     ✓ ✓ 
[11C]WAY100635 5HT1A  ✓ 0.90 3.28 ✓ ✓/ x ✓/ x ✓     x ✓ 
[11C]CUMI101 5HT1A ✓ 0.15 3.23 ✓ ✓/ x ✓/ x ✓/ x     ✓ ✓ 
[11C]AZ10419369 5HT1B  ✓ 0.40 1.90 ✓/ x ✓/ x ✓/ x ✓     ✓ ✓ 
GABA                
[11C]Flumazenil GABAA ✓  2.00 2.15 ✓ ✓ ✓ ✓  ✓   ? ✓ 
[11C]Ro154513 α1/ α5 * * 12.3 2.18 ✓ ✓ ✓ ✓ x$ x$ x ✓$ ✓ ✓$ 
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Importantly, as well as sensitivity to endogenous release in vivo being related to 
changes in receptor endocytosis or decreased binding parameters in different ionic 
conditions, a lack of sensitivity may also be attributed to these target 
protein/radioligand characteristics. Therefore, we suggest that a better understanding 
of the cellular processes involved in target protein cell surface regulation, in both 
acute endogenous agonist exposure and in patient population studies may help 
streamline the application of imaging endogenous release with novel PET 
radioligands such as [
18
F]PEO, [
11
C]GR103545, [
11
C]CUMI101 or [
11
C]Cimbi36. 
Furthermore, this knowledge will increase our understanding of PET data acquired 
with these ligands. For example, a radioligand expected to bind both endocytosed and 
cell surface target proteins, implemented in a patient population where of target 
protein trafficking machinery is upregulated, may mean that we are underestimating 
the reduction in functioning, cell surface proteins in this condition. Since the 
radioligand in question is only able to detect differences in whole cell amounts of 
protein target, rather than functional/membrane bound target proteins.  
 
 
7.4.  Conclusions 
In conclusion, the importance of assessing a PET radioligand and its protein targets 
ability to bind in sub-cellular compartments has been demonstrated. Such studies will 
allow for the determination of the ability of established and novel PET radioligands to 
bind following agonist induced internalisation processes. These data will ultimately 
aid in the interpretation of pre-existing and future PET data from in vivo competition 
and patient population imaging studies, for the ligands utilised in this thesis. 
Furthermore, the data and methodologies implemented here may aid in the translation 
of imaging other neurotransmitters outside of the dopamine system. Using the 
experimental protocols developed within this thesis, the effects of agonist induced 
internalisation on the binding of two opioid receptor radioligands have been 
investigated following a novel pharmacological challenge. These studies suggest (1) 
the selective agonist radioligand, [
11
C]carfentanil, maybe be more sensitive than the 
non-selective antagonist radioligand, [
11
C]diprenorphine to amphetamine induced 
endogenous opioid peptide release (2) amphetamine induced endogenous opioid 
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peptide release leads to µ receptor internalisation which, (3) is a contributing factor to 
the reductions in binding observed for [
11
C]carfentanil. 
 
Fundamentally, these data illustrate that the Internalisation Hypothesis, originally 
proposed to contribute to changes in D2/3 receptor radioligand binding, may also be 
applied to receptor systems outside the D2/3. Identification of alterations in binding 
ability following translocation to sub-cellular compartments and a better 
understanding of target protein trafficking following endogenous ligand release may 
be a crucial requirement when predicting sensitivity to endogenous release in vivo. 
Therefore, the methodologies developed in this thesis warrant further application to 
other PET radioligand targets.  
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8.1.  Chapter 2 Appendices  
8.1.1.  Rat and Pig binding 
 
Specific details relating to protein, radioligand concentrations and compound used to 
define the specific binding component can be found in Table A.8.1. All assays were 
conducted using the methods outlined in Section 2.2. Specific radioligand assay 
conditions are outlined below (see Table A.8.1.). 
 
Table A.8.1.  Assay conditions for generation of affinity and availability values in pig 
striatal homogenates  
 
Radioligand 
(Target) 
Concentration 
Range 
(nM) 
Incubation 
(mins) 
Compound for 
specific binding 
definition (µM) 
Tissue
 
Protein 
concentration 
per well (µg)) 
[
3
H]Raclopride
 
(D2/3) 
0.03 - 20 
 
60 
Haloperidol 
(1) 
Striatum 250 
[
3
H]PhNO
 
(D2/3) 
0.03 - 300 
 
60 
Haloperidol 
(1) 
Striatum 250 
[
3
H]Spiperone 
(D2/3) 
0.02 - 10 
 
60 
Haloperidol 
(1) 
Striatum 250 
 
Protein concentrations determinations and data analysis were conducted as outlined in 
Sections 2.5 and 2.6. 
 
Bmax vales in pmol/g of protein (or nM) were generated using Equation 1 and in vitro 
binding potentials were generated using Equation 2. 
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Table A.8.2.  Pig D2/3 receptor radioligand binding parameters 
 
KD (nM) and Bmax (fmol/mg protein and pmol/g tissue) and in vitro BP values for 
[
3
H]raclopride, [
3
H]spiperone and [
3
H](+)PhNO pig striatal homogenates (n = 4, 
mean ± s.e.mean) in the three ionic environments (Extra, Intra and Endo).  
 
8.1.2.  Preliminary cell fraction Western blotting for D2 and D3 
8.1.2.1.  Methods outline for Western Blotting 
Samples from each cell fraction (P2, P3endo and S3) were mixed with ice-cold lysis 
buffer (150 mM NaCl, 1% triton X-100, 50 mM Tris HCl) for 30 minutes and 
centrifuged (12,000 rpm, 20 minutes, 4 ⁰C).  A sample of the supernatant was 
assessed for its protein content and the remainder was mixed with laemmli sample 
buffer and heated (70 ⁰C, 10 minutes). Equivalent amounts of sample protein (µg) 
were loaded to a BioRad TGX Any kD pre-cast gel system and separated by 
electrophoresis (35 minutes, 200 mV) in running buffer (25 mM Tris Base, 190 mM 
glycine, 0.1 % SDS).  Gels were transferred to PVDF membranes (60 minutes, 
100 mV) in transfer buffer (25 mM Tris Base, 190 mM glycine, 20% methanol).  
Membranes were blocked with 5% milk-Tris buffered saline-0.1% Tween (TBST) 
Radioligand KD (nM) 
Bmax (fmol/mg 
protein) 
Bmax (pmol/g 
tissue) 
In vitro BP 
% of Extra 
BPp in vitro 
      
[
3
H]Raclopride      
·     Extra 5.75 ± 0.60 153 ± 26 7.53 ± 1.35 1.32 ± 0.23 100 
·     Intra 7.66 ± 1.39 150 ± 33 6.89 ± 1.40 0.99 ± 0.18 75 
·     Endo 41.78 ± 29.20
** 
42 ± 21 2.77 ± 0.97 0.28 ± 0.22
* 
21 
   
   
  
[
3
H](+)PhNO 
  
   
 
 
·     Extra 1.28 ± 0.39 61 ± 7 2.97 ± 0.22 2.96 ± 0.64 100 
·     Intra 1.26 ± 0.33 91 ± 10 3.89 ± 0.31 3.61 ± 0.76 121 
·     Endo 3.05 ± 0.46
* 
55 ± 15 3.53 ± 0.92 0.16 ± 0.04
* 
5 
   
   
  
[
3
H]Spiperone 
  
   
 
 
·     Extra 0.20 ± 0.09 145 ± 17 7.99 ± 1.59 57.78 ± 14.27 100 
·     Intra 0.26 ± 0.09 186 ± 33 9.32 ± 2.13 53.08 ± 14.33 93 
·     Endo 0.42 ± 0.18 127 ± 9 7.93 ± 0.80 35.59 ± 12.80 61 
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(60 minutes, RT) before being probed with primary antibody diluted in 5 % milk-
TBST (overnight, 4 ⁰C). Primary antibodies: Rabbit polyclonal to D3 (1:1250, 
Abcam), goat polyclonal to D2 (1:500, Abcam). Membranes were washed with TBST 
(4 x 10 minutes, RT) then exposed to horseradish peroxidase (HRP) linked secondary 
antibodies diluted in 5 % milk-TBST to visualise primary antibody binding 
(60 minutes, RT).  Secondary antibodies: Rabbit polyclonal to goat IgG-HRP (1:5000, 
Abcam), goat polyclonal to rabbit IgG-HRP (1:5000). 
 
8.1.2.2.  Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.8.1.  Representative Western blots, from pig striatal cell fractions 
 
 
It should be noted in reference to Appendix 8.1.2.2., that none of the antibodies 
implemented have been tested for their specific immunoreactivity with pig proteins. 
Given this caveat, BLAST search (basic local alignment search tool) shows that pig 
and rat D2 receptors differ by only eight amino acid residues, one of which is present 
in the antibody epitope region.  
 
An additional band with S3 was observed for D2 receptors, which was of a lower kDa 
compared to the immunoreactivity observed throughout the other fractions (P2, P3 
and S3). Fishburn and co-workers (1995) suggested that three forms of the murine D2 
receptor exist and that the sub-cellular localisation of these may vary (Fishburn et al., 
1995). A naïve, 45 kDa (in S3) and mature-heavy, 75 kDa (in P2 and P3) forms have 
   P2       P3      S3 
D2 75-100kDa 
D2 50kDa 
D3 50kDa 
  P2         P3       S3 
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been detected in the studies presented here. In agreement with Fishburn and co-
workers (1995), the naïve form of the D2 is present intracellularly (S3) and the 
mature, glycosylated form is present at the plasma membrane (P2). 
 
8.2.  Chapter 3 Appendices 
 
8.2.1.  Relationship between [
3
H]Diprenorphine uptake and decrease post 
amphetamine and methadone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.8.2.  Correlation of [
3
H]diprenorphine binding under saline conditions with 
per cent change in uptake following either amphetamine or methadone 
n = 5 for saline and amphetamine treated groups; n = 4 for methadone treated group; 
mean ± s.e.mean. 
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8.2.2.  [
3
H]Naltrindole Binding 
 
8.2.2.1.  Saturation Methods 
Male Sprague Dawley rat whole brain minus cerebellum membrane homogenates 
were generated as described previously (Section 2.1.).  Saturation radioligand binding 
assays were performed as described previously (Section 2.2.). The range of 
[
3
H]naltrindole concentrations used was: 0.001-10 nM.  
8.2.2.2.  Results 
Naltrindole is a highly selective δ-opioid receptor antagonist.  A significant reduction 
in receptor availability (Bmax) was observed when exposed to the endosomal 
conditions (p < 0.05) compared with extracellular and intracellular conditions (see 
Table A.8.3., Figure A. 8.3.).  No significant difference in receptor affinity was 
observed in any of the conditions tested. 
 
Table A.8.3.  KD and Bmax values for [
3
H]Naltrindole tissue binding in the three cellular 
environments. 
 
KD (nM) and Bmax (fmol/mg protein and pmol/g tissue) values for [
3
H]naltrindole in rat whole 
brain minus cerebellum (n = 4, mean  ±  s.e.mean) in the three ionic environments (Extra, 
Intra and Endo).  One-way ANOVA with Tukey post-test were performed using SigmaStat 
3.0. 
*
p  <  0.05 = comparison of intracellular or endosomal to the extracellular condition.  
 
 
 
 
 
 
Condition KD (nM) Bmax (fmol/mg protein) 
Extra 0.081 ± 0.010 134 ± 4.9 
Intra 0.040 ± 0.012 
*
75 ± 6.2 
Endo 0.041 ± 0.011 
*
38 ± 3.3 
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Figure A.8.3.  Saturation curves of [
3
H]naltrindole using rat whole brain minus 
cerebellum in the three physiological environments. 
Results are expressed as the mean ± s.e.mean from four independent observations, each 
performed in triplicate.  
 
 
8.2.3.  Ex vivo [
11
C]carfentanil autoradiography 
In order to further distinguish changes in [
11
C]carfentanil binding following either 
amphetamine or methadone treatment, ex vivo [
11
C] autoradiography was optimised 
and performed with the contralateral hemisphere used for micro-dissection and uptake 
assessment.  However, despite various optimisation steps, an inadequate amount of 
[
11
C]carfentanil remained post-synthesis (due to the short radioactive half-life) in 
order to compare between the treatment groups. 
 
 
8.2.3.1.  Optimisation steps 
Following injection of radiotracer, rodents were returned to their cages behind a lead 
shield.  After 30 minutes, brains were extracted following termination via cervical 
dislocation.  The brain was divided down the midline and the right hemisphere was 
assessed for brain uptake.  The left hemisphere was rapidly frozen by submersion into 
isopentane (-40
o
C) and mounted onto a cryostat for sectioning.  25 µl of neat 
radioligand was serially diluted at a 1:10 dilution, 10 times.  10 µl of each dilution 
was pipette onto discs of glass fibre filter paper attached to an empty microscope 
slide.  This slide would allow for quantification of bound radioactivity in tissue 
sections in Becquerels, and provided a means for generating a standard curve for this 
radioligand.  The following section thicknesses were trialled: 20, 40, 60, 80, 100, 
120 µm.  Two image capturing methods were compared: apposition to β-sensitive 
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films (since PET radioisotopes are high energy, low penetrating β-emitters as well as 
γ emitters) and standard film developing with liquid developing baths and appositions 
to phosphor screen and digital laser acquisition of the image from the screens using a 
Cyclone Plus Phosphor Imager.  From brain extraction to film/phosphor screen 
cassette sealing, no more than two half-lives passed.  Screens or films were developed 
the following day.  
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8.2.3.2.  Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.8.4.  [
11
C]Carfentanil assessment in rat brain sections – Phosphor Imager 
acquisition 
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Figure A.8.5.  [
11
C]Carfentanil assessment in rat brain sections – Hyperfilm acquisition 
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8.2.4.  [
3
H]Diprenorphine ex vivo autoradiography 
 
Figure A.8.6.  Representative images of [
3
H]diprenorphine binding 
Images from saline, amphetamine and methadone captured using an MCID image analyser, 
depicted with their corresponding cresyl violet stained section image. N = 3 for saline, 
amphetamine and methadone treated groups; 
 
 
8.2.5.  Amphetamine affinity at [
11
C]carfentanil or [
3
H]diprenorphine labelled sites 
The affinity of amphetamine was determined at [
11
C]carfentanil and 
[
3
H]diprenorphine sites (in both brain homogenates and CHO cells stably expressing 
the µ-opioid receptor).  Cocaine’s affinity profile was also determined since its 
monoamine transporter affinity profile is similar to that displayed by amphetamine.  
Naloxone was included as a positive control. 
 
8.2.5.1.  Methods – Ki determination 
Male Sprague Dawley rat whole brain minus cerebellum membrane homogenates and 
growth/membrane preparation from µ-expressing CHO cells were generated as 
described previously (Section 3.3.).  Membranes were generated and diluted to a 
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protein concentration of 0.5 mg/ml for tissues or 300,000 cells/well in assay buffer 
(50 mM Tris HCl, 140 mM NaCl, 5 mM KCl, 1.5 mM MgCl2, 1.5 mM CaCl2, pH 7.4, 
37 
o
C).  A range of amphetamine (300 μM – 10 pM), cocaine (100 μM – 10 pM) and 
naloxone (300 μM – 10 pM) concentrations were used to displace a fixed 
concentration of [
11
C]carfentanil and [
3
H]diprenorphine.  Specific binding was 
determined using naloxone (10 μM).  The final volume for each assay was 500 μl.  
Each data point was performed in triplicate.  Following incubation (30 minutes, 
37°C), the assay was terminated by filtration through Whatman glass fibre (GF/B; 
Piscataway, NJ) filters pre-soaked in 0.05% polyethyleneimine with ice-cold wash 
buffer (50 mM Tris HCl, 1.4 mM MgCl2, pH 7.4 at 4°C). KD values, previously 
determined with [
11
C]carfentanil and [
3
H]diprenorphine in the extracellular condition, 
were used to generate Ki values (affinity constants) using the method of Cheng and 
Prusoff (1973). 
 
8.2.5.2.  Results  
The affinity of cocaine, amphetamine and naloxone at [
3
H]diprenorphine labelled 
sites is shown in Table A.8.4. 
 
Table A.8.4.  Ki’s for [
3
H]diprenorphine labelled sites determined using GraphPad 
Prism 5.0.; mean ± s.e.mean. (n = 3). 
 
Receptor Source 
Amphetamine Ki 
(µM) 
Cocaine Ki (µM) Naloxone Ki (nM) 
WB  
(minus cerebellum) 
> 300 > 100 17.64 ± 0.46 
µ-CHO cells > 300 > 100 17.60 ± 0.43 
 
The affinity of amphetamine alone was determined in whole brain homogenates using 
[
11
C]carfentanil due to a limited numbers of radiosyntheses for this ligand.  No 
significant reduction in specific binding was observed within the concentration range 
tested, therefore Ki values of > 100 µM have to be assumed. 
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8.3.  Chapter 4 appendices 
 
8.3.1.  DAB opioid receptor immunohistochemical staining 
8.3.1.1.  Antibody Specificity 
8.3.1.1.1.  µ Receptor 
The specificity of the primary antibody for µ receptor imaging (UMB-3) has 
previously been demonstrated (Lupp et al., 2011). Lupp et al (2011) show a dark µ 
receptor band at ~72kDa in brain lysates using Western blotting techniques, 
furthermore, no µ receptor expression in µ
-/-
 receptor animals (Lupp et al., 2011). No 
staining is observed in tissue slices from these animals also. UMB-3 has also been 
shown to label internalised receptors in HEK-293 cells expressing the µ receptor gene 
following agonist stimulation (Lupp et al., 2011). Lastly, regional specificity of 
UMB-3 was demonstrated by high levels of patchy staining in rat nucleus accumbens 
and throughout the striatum, the hippocampus and in human enteric ganglion cells 
(Lupp et al., 2011). 
 
8.3.1.1.2.  δ Receptor 
The δ receptor antibody used has previously been used elsewhere both in tissue and 
cell preparations (Karlsson et al., 2012b, Byun et al., 2012).  No primary in these 
studies and in the data presented here demonstrate that binding is specific and 
regional cell distribution specificity suggests selective δ staining.  However, this 
antibody is yet to be tested in δ-/- receptor tissues. 
 
8.3.1.1.3.  κ Receptor 
The ĸ receptor antibody used has previously been implemented elsewhere in cardiac 
myocytes (Karlsson et al., 2012a).  No primary in the Karlsson et al (2012b) study 
and the data presented here demonstrate that binding is specific and regional, cell 
distribution specificity suggests selective ĸ receptor staining.  However, this antibody 
has also not been tested in ĸ-/- receptor tissues. 
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8.3.2.  Methods 
Brain sections were thawed and dried thoroughly for three hours before use.  Sections 
were pre-incubated in 0.3% hydrogen peroxide solution for thirty minutes to quench 
endogenous peroxidise activity.  The following conditions were used for 
Immunolabeling of opioid receptors (Table A.8.5.): 
 
Table A.8.5.  Assay conditions for chromogenic staining of opioid receptors 
 
Receptor Fix Block 1° Incubation 2° 
µ
1 
5 minutes, 4% 
PFA
$ 
30 minutes, 
10% FCS
%
, 
0.1% triton-X 
µ: 1:100, 2% FCS, 
0.02% triton-X 
µ: 1:400 biotinylated 
anti-rabbit, 2% FCS, 
0.02% triton-X 
δ2 
5 minutes, 
ice-cold 
acetone 
15 minutes, 
5% FCS, 
0.01% tween 
δ: 1:100 in 1% FCS, 
0.01% tween 
δ: 1:400 biotinylated 
anti-rabbit, 2% FCS, 
0.01% tween 
ĸ3 
5 minutes, 4% 
PFA 
15 minutes, 
5% FCS, 
0.01% tween 
ĸ: 1:100, 1% FCS, 
0.01% tween 
ĸ: 1:400 biotinylated 
anti-rabbit, 2% FCS, 
0.01% tween 
 
1
Supplied from Novus Biologicals, NBP1-96656, ‘UMB3’. Rabbit monoclonal anti-µ. 
2
Supplied by AbCam, ab66318. Rabbit polyclonal anti-δ. 
3
Supplied by AbCam, ab83293. Rabbit polyclonal anti-ĸ. 
$
Paraformaldehyde. 
%
Foetal calf serum. 
 
Following each step (fixation, blocking or antibody incubations) sections were 
extensively washed with phosphate buffered saline (five times with 2-3 mls; pH 7.4). 
Primary antibody incubations were conducted over night at 4⁰C to avoid evaporation.  
Secondary antibodies were incubated for thirty minutes at room temperature.  For 
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μ - sagittal 
δ - sagittal 
κ - sagittal 
secondary antibody substrate preparation, two drops of Vectastain® reagent A 
(avidin) were mixed with two drops of reagent B (biotin) in 10 mls of phosphate 
buffered saline and allowed to stand for thirty minutes at room temperature.  Substrate 
was incubated with rinsed sections at room temperature until the desired level of 
staining was achieved.  
 
8.3.3.  Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.8.7.  Low magnification sagittal regional opioid receptor staining. 
µ, δ and κ receptor staining in control male rat Sprague Dawley brain sections.  
Representative images from n = 2. Magnification = x1. 
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μ - coronal 
δ - coronal 
κ - coronal 
Striatum Hippo/Thalamus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.8.8.  Low magnification coronal regional opioid receptor staining. 
 µ, δ and κ receptor staining in control male rat Sprague Dawley brain sections. 
Representative images from n = 2. Magnification = x1. 
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μ  
Striatum (10x) 
Locus  
Coeruleus (10x) 
δ  
Hippo (10x) Hippo (20x) 
VM Hypothal (10x) 
κ 
Hippo (20x)  
Striatum (10x) 
Striatum (10x) 
Striatum (20x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.8.9.  High magnification regional opioid receptor staining. 
µ, δ and κ receptor staining in control male rat Sprague Dawley brain sections.  
Representative images from n = 2.  Images captured at x10 and x20 magnification. 
 
8.3.4.  DAB conclusions 
Good chromogenic staining was observed in both coronal and sagittal sections for all 
three receptor antibodies in regions with previously reported receptor expression at 
low and higher (x10 and x20) levels of optical magnification.  
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